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Abstract
Diagnostic strategies using DNA testing for hereditary 
haemochromatosis in at-risk populations: a systematic 
review and economic evaluation
J Bryant,* K Cooper, J Picot, A Clegg, P Roderick, W Rosenberg 
and C Patch
Southampton Health Technology Assessments Centre (SHTAC), Wessex Institute for Health Research 
and Development, University of Southampton, UK
*Corresponding author
Objective: To evaluate DNA testing for detecting 
hereditary haemochromatosis (HHC) in subgroups of 
patients suspected of having the disorder and in family 
members of those diagnosed with HHC.
Data sources: Major electronic databases, searched 
from inception to April 2007.
Review methods: A systematic review was undertaken 
using a priori methods and a de novo model developed 
to assess costs and consequences of DNA testing.
Results: Eleven studies were identified for estimating 
the clinical validity of genotyping for the C282Y 
mutation for the diagnosis of HHC. No clinical 
effectiveness studies meeting the inclusion criteria were 
identified. Two North American cost-effectiveness 
studies of reasonable quality were identified but their 
generalisability to the UK is not clear. Three cohort 
studies met the inclusion criteria for the review of 
psychosocial aspects. All had methodological limitations 
and their generalisability is difficult to determine. The 
clinical sensitivity of C282Y homozygosity for HHC 
ranged from 28.4% to 100%, or from 91.3% to 92.4% 
when considering only the most relevant studies. Clinical 
specificity ranged from 98.8% to 100%. One study 
found that gene testing was a cost-effective method of 
screening relatives of patients with haemochromatosis, 
whereas the other found that genotyping the spouse 
of a homozygote was the most cost-efficient strategy. 
Genetic testing for haemochromatosis appears to 
be well accepted, is accompanied by few negative 
psychosocial outcomes and may lead to reduced 
anxiety. The de novo economic model showed that, 
in people suspected of having haemochromatosis, 
the DNA strategy is cost saving compared with the 
baseline strategy using liver biopsy (cost saved per case 
detected £123), largely because of the reduction in liver 
biopsies. For family testing of siblings the DNA strategy 
is not cost saving because of the costs of the DNA test 
(additional cost per case detected £200). If the cost of 
the test were to reduce from £100 to £60, the DNA 
strategy would be the cheaper one. For family testing 
of offspring the DNA test strategy is cheaper than the 
baseline biochemical testing strategy (cost saved per 
case detected £7982). Sensitivity analyses showed 
that the conclusions in each case are robust across all 
reasonable parameter values. 
Conclusions: The preferred strategy in practice is 
DNA testing in conjunction with testing iron parameters 
when there is clear clinical indication of risk for 
haemochromatosis because of biochemical criteria or 
when there is familial risk for HHC. Access to genetic 
testing and centralisation of test provision in expert 
laboratories would lower the cost of testing, improve 
the cost-effectiveness of the strategy and improve the 
quality of information provided to clinicians and patients.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Glossary and list of abbreviations
ACCE  A model process for evaluating data on 
emerging genetic tests. It takes its name from 
the four components of evaluation – Analytical 
validity, Clinical validity, Clinical utility and 
associated Ethical, legal and social implications.
C282Y  Mutation in the HFE protein that results 
from a G to A transition at nucleotide 845 of 
the HFE gene, which produces a substitution 
of cysteine (C) for tyrosine (Y) at amino acid 
position 282 in the protein product.
H63D  Mutation in the HFE protein that results 
from a C to G transition at nucleotide 187 of the 
HFE gene causing an aspartate (D) to substitute 
for histidine (H) at position 63 in the HFE 
protein.
HFE  Haemochromatosis gene [found in region 
21.3 on the short (p) arm of human chromosome 
6] or the protein encoded by the gene (‘high Fe’).
HLA-A3  Human histocompatibility (HLA) 
surface antigen encoded by the A locus on 
chromosome 6.
HLA-H  Alternative symbol for HFE gene.
S65C  Mutation in the HFE protein that results 
from an A to T transition at nucleotide 193 of 
the HFE gene which produces a substitution of 
serine (S) for cysteine (C) at amino acid position 
65 in the protein product.
YD  Compound heterozygous, C282Y/H63D
YY  Homozygous, C282Y/C282Y
Glossary
mg Fe/g micrograms of iron per gram of 
tissue
BSH British Society for Haematology
DARE Database of Abstracts of Reviews 
of Effectiveness
DMT1 divalent metal transporter 1 
protein
ECG electrocardiogram
HC haemochromatosis (phenotype)
HHC hereditary haemochromatosis (due 
to mutation of HFE gene)
HI (mg/
year)
hepatic iron, micrograms per year
HII hepatic iron index
HLA human leucocyte antigen
HTA Health Technology Assessment
IES Impact of Event Scale
LIC liver iron content
LYS life-years saved
MCS mental component score of SF-36
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viii
MEDION Meta-analyses von Diagnostisch 
Onderzoek
NHS EED NHS Economic Evaluations 
Database
NICE National Institute for Health and 
Clinical Excellence
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NR not reported
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PPV positive predictive value
PSA probabilistic sensitivity analysis
QUADAS Quality Assessment of Diagnostic 
Accuracy Studies
RCT randomised controlled trial
RFLP restriction fragment length 
polymorphism
SCI Science Citation Index
SD standard deviation
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SF serum ferritin
SF-36 Short-Form 36 Health Survey
SHTAC Southampton Health Technology 
Assessments Centre
SSCP single-strand conformation 
polymorphism
SSCP-CE single-strand conformation 
polymorphism analysis for 
capillary electrophoresis
STAI-State Spielberger State–Trait Anxiety 
Inventory
TS transferrin saturation
UKGTN UK Genetic Testing Network
wt wild type
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known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used only in 
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notes at the end of the table.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
ix
Executive summary 
Background 
Hereditary haemochromatosis is an autosomal 
recessive disorder of iron metabolism that leads to 
excessive iron absorption and progressive abnormal 
deposition of iron in vital organs. A common 
causative mutation has been identified but not all 
homozygotes for the mutation will develop the 
phenotypic expression of the condition. Treatment 
by phlebotomy is simple and effective. The best 
diagnostic strategy for detecting hereditary 
haemochromatosis using DNA testing is unclear. 
Objective 
The main aim of this study was to evaluate the 
use of DNA testing for detecting hereditary 
haemochromatosis in subgroups of patients 
suspected of having the disorder on the basis 
of clinical presentation and disturbed iron 
parameters, and in family members of those 
diagnosed with haemochromatosis.
Methods 
A systematic review of the evidence was undertaken 
using a priori methods. A de novo model was 
developed to assess costs and consequences of DNA 
testing.
Data sources
Fifteen electronic databases were searched from 
inception to April 2007. Bibliographies of related 
papers were assessed for relevant studies and 
experts contacted to identify additional published 
references. 
Study selection
Studies were included if they fulfilled the following 
criteria:
•	 Intervention:
  – DNA tests.
•	 Participants: 
  – clinical validity – Caucasians with signs and 
symptoms suggestive of haemochromatosis
  – clinical utility – Caucasians with signs and 
symptoms suggestive of haemochromatosis 
and/or relatives of suspected cases
  – psychosocial aspects – diagnosed and at-
risk individuals.
•	 Comparator: 
  – clinical validity – control population
  – clinical utility – any case identification 
strategy not involving DNA testing.
•	 Outcomes: 
  – clinical validity – sensitivity and specificity
  – clinical utility – treatment, morbidity, 
mortality, quality of life, psychosocial 
aspects, cost per case detected, cost-
effectiveness or cost–utility
  – psychosocial aspects – treatment 
compliance, psychological outcomes, legal 
implications, quality of life, discrimination/
stigmatisation.
•	 Design: 
  – clinical validity – controlled cohort or case–
control
  – clinical utility – randomised controlled 
trials, cohorts with controls, case–control, 
economic evaluations, modelling studies
  – psychosocial aspects – any quantitative or 
qualitative primary research.
Studies identified were assessed for inclusion 
through two stages with titles and abstracts and full 
papers of retrieved studies assessed independently 
by two reviewers, with differences in decisions 
resolved through discussion or through recourse to 
a third independent reviewer. 
Data extraction and 
quality assessment
Data were extracted by two reviewers using a 
data extraction form developed a priori. Any 
disagreements were resolved through discussion 
or through recourse to independent assessment 
by a third reviewer. The methodological quality of 
the studies included in the systematic review was 
assessed using modified quality assessment tools 
using individual components of methodological Executive summary
x
quality rather than relying on summary scores. The 
quality criteria were applied by two reviewers, with 
any disagreements resolved through discussion or 
through recourse to a third independent reviewer. 
Data synthesis
Studies were synthesised using a narrative 
approach with full tabulation of results from all 
included studies. 
Economic model
The economic evaluation developed two decision-
analytic models to compare the costs and 
consequences of diagnostic strategies with and 
without DNA testing: one for people suspected 
of having haemochromatosis and the second 
for family members of patients diagnosed with 
haemochromatosis. Structure and data inputs of 
the decision trees were informed by systematic 
reviews and systematic searches of the literature 
and discussion with experts. Costs were derived 
from published primary data and from national 
and local NHS unit costs. The outcome reported is 
cost per case detected. 
Results 
Number and quality of studies
Eleven studies were identified that could be used 
to estimate the clinical validity of genotyping for 
the C282Y mutation for the diagnosis of hereditary 
haemochromatosis. The quality of the studies was 
variable and a range of definitions for the clinical 
phenotype was used. No clinical effectiveness 
studies meeting the inclusion criteria for the review 
were identified. Two cost-effectiveness studies 
(one cost–utility model and one cost-minimisation 
model) conducted in North America were 
identified. Both were of reasonable quality but their 
generalisability to the UK is not clear. Three cohort 
studies met the inclusion criteria for the review 
of psychosocial aspects. Each study assessed and 
reported on the psychosocial outcomes of genetic 
testing in a different way. All had methodological 
limitations and the generalisability of these studies 
is difficult to determine.
Summary of clinical validity 
and clinical utility
The clinical sensitivity of C282Y homozygosity for 
hereditary haemochromatosis ranged from 28.4% 
to 100% in the eleven studies; when considering 
only the most relevant studies, sensitivity ranged 
from 91.3% to 92.4%. Clinical specificity ranged 
from 98.8% to 100%. One cost-effectiveness 
study found that gene testing was a cost-effective 
method of screening relatives of patients with 
haemochromatosis, whereas the other study found 
that genotyping the spouse of a homozygote was 
the most cost-efficient strategy in family testing. 
Summary of psychosocial 
aspects of DNA testing
Generally the results suggest that genetic testing 
in the case of haemochromatosis is well accepted, 
is accompanied by few negative psychosocial 
outcomes and may lead to reduced anxiety. Control 
subjects in the one study that had a control group 
anticipated greater anxiety, depression, anger 
and difficulty in affording the genetic test than 
was reported by patients. In one study clinically 
affected participants had significantly lower 
health-related quality of life, as measured by the 
Short-Form 36 Health Survey (SF-36) physical 
component summary, before genetic testing 
than unaffected participants but this was no 
longer significantly different at 12 months post 
consultation. Another study reported significant 
improvements in the vitality subscale of the SF-
36 health measure and the physical composite 
score after participants were informed of their 
genetic test result. For generalised anxiety scores 
or intrusive thoughts, one study reported no 
statistically significant differences between clinically 
affected and unaffected participants before and 
after genetic testing; another study reported that 
anxiety fell significantly in C282Y homozygotes 
and heterozygotes once they received their genetic 
testing results. 
Summary of economic evaluation 
The de novo economic model demonstrated that, 
for people suspected of having haemochromatosis, 
the DNA strategy is cost saving compared with 
the baseline strategy using liver biopsy (cost saved 
per case detected £123). This is largely because 
of cost savings from the reduced number of liver 
biopsies being performed. For family testing, 
the DNA strategy is not cost saving in the case of 
siblings because of the extra costs of the DNA test 
(additional cost per case detected £200). If the cost 
of the DNA test were to fall from £100 to £60, the 
DNA strategy would be the cheaper one. For family 
testing of offspring of people with hereditary 
haemochromatosis, the DNA test strategy is 
cheaper than the baseline biochemical testing DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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strategy (cost saved per case detected £7982). 
Sensitivity analyses show that the conclusions 
in each case are robust across all reasonable 
parameter values. 
Results suggest that using a diagnostic strategy 
that incorporates DNA testing is cost saving 
in case identification and in testing offspring 
of haemochromatosis patients. The results for 
siblings suggest that DNA testing is not cost saving. 
However, this study considered cost per case 
detected and it was not possible to incorporate the 
benefit of reassurance and reduction in anxiety 
resulting from DNA testing, which could have an 
impact on the long-term cost-effectiveness of DNA 
testing in siblings. 
Conclusions
Implications for service provision
The preferred strategy in practice is DNA testing 
in conjunction with testing iron parameters when 
there is a clear clinical indication of suspicion of 
risk for haemochromatosis because of biochemical 
criteria or when there is a familial risk for 
hereditary haemochromatosis. Although clinical 
practice among those expert and interested in 
the management of the condition is already 
thought to follow this strategy, the development 
and dissemination of guidelines to physicians in 
both primary and secondary care is advisable. 
Access to genetic testing and centralisation of test 
provision in expert laboratories would lower the 
cost of testing, improve the cost-effectiveness of the 
strategy and improve the quality of information 
provided to clinicians and patients.
Suggested research priorities
The limited evidence base for assessing the use of 
DNA testing for haemochromatosis suggests that 
further primary research in the form of prospective 
long-term follow-up studies is required. However, 
an area of research more likely to be of practical 
value is epidemiological research, using national 
databases, on the environmental and other genetic 
factors that affect the penetrance of the genetic 
mutation to identify those people homozygous 
for the mutation who are likely to develop iron 
overload. Further research into psychosocial aspects 
of the use of DNA testing for haemochromatosis 
might be required after other factors that influence 
the expression of the phenotype have been 
identified. DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Chapter 1  
Background 
Description of the 
health problem 
Hereditary haemochromatosis (HHC) results from 
a genetic disorder of iron metabolism that leads 
to excessive intestinal absorption of iron and a 
progressive abnormal deposition of iron in the 
liver, heart, pancreas and other vital organs. Iron 
levels in the body are usually carefully regulated. 
Iron is absorbed from dietary sources to maintain 
iron stores and replace iron that is lost daily, mostly 
because of the loss of iron-containing red blood 
cells into the gut. In younger women, menstruation 
also makes an important contribution to iron 
loss. Haemochromatosis (the clinical condition of 
iron overload) occurs when this careful regulation 
of iron is gradually lost. In HHC absorption of 
iron from the gastrointestinal tract continues to 
occur when bodily iron stores and blood iron 
levels have reached and then exceeded normal 
levels, and iron therefore continues to accumulate 
within cells. Treatment by removing excess iron 
with phlebotomy is effective and, if started before 
irreversible end-organ damage, restores normal life 
expectancy.1,2
Haemochromatosis was first identified in the late 
nineteenth century as the classic clinical triad 
of diabetes, bronze skin pigmentation and liver 
cirrhosis (cited in Sheldon3). The condition was 
recognised as an inborn error of iron metabolism 
with a possible familial component in the 1930s.3,4 
In 1976 the demonstration of an excess of human 
leucocyte antigen (HLA)-A3 alleles in individuals 
with haemochromatosis compared with the 
normal population led to the conclusion that 
haemochromatosis was caused by an undefined 
gene that was tightly linked to the HLA locus 
on chromosome 6.5 Despite this relatively early 
success of linkage methods for suggesting the 
chromosomal location of a disease gene, it took a 
further 20 years before, in 1996, the causative gene 
was identified through classic positional cloning 
techniques.6,7 It is now recognised that HHC is 
an autosomal recessive disorder resulting from 
mutations of the HFE gene, usually manifesting in 
adults in their 40s and 50s.6 
Genetic studies have shown that the mutations 
associated with a risk of HHC are common 
(see section on epidemiology). However, 
there is debate in the clinical literature about 
the clinical expression of the condition.6,8 Of 
particular importance is the penetrance of the 
gene mutations, that is, the probability that a 
person with the gene mutations will develop 
clinical consequences (disease). Penetrance has 
been reported to be less than 1%9 or as high as 
40% in male relatives of affected individuals.10 
It is now clear that the at-risk genotype is a 
necessary but not sufficient cause of disease and 
that a range of factors determine the extent to 
which the phenotype is observed in a particular 
individual. Although the frequency of the genetic 
predisposition is the same in men and women, 
women have a lower incidence of the clinical 
phenotype. The explanation is probably that 
women lose iron through physiological blood 
loss (menstruation, childbirth) until they are 
postmenopausal. Phenotypic expression of 
haemochromatosis is variable and appears to 
depend on a complex interplay of the status of 
the HFE gene, other genetic factors, age, sex and 
such environmental influences as dietary iron, the 
extent of iron losses from other processes and the 
presence of other diseases or toxins (e.g. alcohol). 
There is agreement that the clinical condition 
of haemochromatosis is the end result of a 
combination of genetic and environmental factors, 
not all of which have been described. 
The discovery of the HFE gene in 19966 has led 
to increasing interest in haemochromatosis and 
the possibility of using DNA-based predisposition 
testing as a tool for diagnosis and family testing. 
The purpose of testing is case identification and 
the identification of children and siblings who 
are at increased risk for the disease, as early 
identification of iron overload and initiation of 
treatment is considered to be effective.11 Although 
the mutations associated with a risk of HHC 
are a good diagnostic indicator in those already 
suspected of having haemochromatosis or in 
the context of family testing, they are not useful 
for screening at the population level. The high 
prevalence of the genetic predisposition, the 
preventable serious consequences of progressive 
iron overload and the availability of effective 
treatment have been put forward as arguments for 
population screening in line with the World Health Background
2
Organization criteria,12 but recent guidelines have 
suggested that the natural history and penetrance 
of the condition is not clearly enough understood 
to recommend screening programmes based on 
genotype or phenotype.13,14 
Iron metabolism
Iron is vital for all living organisms as it is an 
essential component of a wide variety of metabolic 
reactions including transport of oxygen, DNA 
synthesis and electron transport. However, iron 
concentrations in the tissue need to be tightly 
regulated as excessive iron is toxic as a result of 
the formation of free radicals. The control of iron 
uptake and storage is therefore complex.
The majority of total body iron (60–70%) is 
present in haemoglobin in the erythrocyte pool. 
Another 10% is present in the form of myoglobins, 
cytochromes and iron-containing enzymes and, in 
a healthy individual, the remaining storage iron 
is sequestered by ferritin and haemosiderin in the 
liver, spleen and bone marrow. There is a constant 
turnover of iron for haemoglobin synthesis by 
erythroid precursor cells in the bone marrow; 
the majority of iron for this is recovered from the 
destruction of red blood cells. Iron is transported 
in the blood tightly bound to transferrin and, 
although this is less than 1% of the total body iron 
store, because of its high turnover it is the most 
significant body iron pool.15–18
A constant balance between uptake, transport, 
utilisation and storage of iron is needed to 
maintain cellular iron homeostasis both at the level 
of the cell and at the level of the whole organism. 
Identification of the gene for HHC has led to 
increased understanding of the biological pathways 
underpinning this process. This tight regulation 
depends upon the constant movement of iron 
bound to transferrin in the plasma between the 
functional iron pool and the storage iron pool. 
Because of its low solubility iron is not excreted, 
although iron is lost through menstruation, other 
blood loss and shedding of epithelial cells from 
the gastrointestinal and urogenital systems and the 
skin. The primary level at which body iron content 
is controlled is by variation in the amount of iron 
absorbed from the diet at the level of the small 
intestine. 
Iron is transported across the apical cell membrane 
of duodenal epithelial cells by the divalent metal 
transporter 1 (DMT1) protein. It is then either 
stored as ferritin or exported by ferroportin across 
the basolateral membrane where it enters the 
circulation bound by transferrin. Both DMT1 and 
ferroportin expression are dependent on cellular 
iron stores. In haemochromatosis duodenal DMT1 
and ferroportin expression are raised, leading to 
excess iron absorption and gradual accumulation of 
iron.18–20
The recently identified protein hepcidin is central 
to the pathophysiology of haemochromatosis. 
Hepcidin is a circulating hormone synthesised in 
the liver and levels of expression are regulated 
by iron stores and inflammation. Hepcidin is 
upregulated in the presence of iron and acts on 
ferroportin to inhibit iron transport, presumably 
resulting in decreased iron absorption.21 In HHC 
hepcidin levels are inappropriately low.
Clinical features of 
haemochromatosis
Symptoms of disease
In the early stages HHC is usually asymptomatic 
but as excess iron continues to be deposited 
damage begins to occur in a wide range of 
organs. Initial symptoms such as fatigue, joint 
pain, abdominal pain or sexual dysfunction22,23 
are non-specific and may often be ignored or 
misdiagnosed. Clinical findings include abnormal 
liver function tests, diabetes and electrocardiogram 
(ECG) abnormalities. In men, clinical signs 
of haemochromatosis usually become overt in 
the fourth or fifth decade of life. Women may 
present later in life, because the loss of iron 
during menstruation and pregnancy confers some 
degree of protection against the process of iron 
accumulation over time. A comparison of male and 
female patients with diagnosed haemochromatosis, 
however, suggests that in women full phenotypic 
expression can be seen.24 The non-specific 
nature of the early signs and symptoms of 
haemochromatosis leads to problems in diagnosis. 
As many of these early signs and symptoms are 
common they have low positive predictive value 
(PPV) for a diagnosis of haemochromatosis, which 
is a condition of low clinical prevalence. 
Liver
The liver is one of the most common organs to 
be affected and hepatomegaly (enlargement) 
is one of the most frequent findings at clinical 
presentation.25 It is assumed that progressive iron 
overload leads to liver fibrosis and ultimately 
cirrhosis. The percentage of patients who 
are reported to have cirrhosis at the time of 
presentation varies but there is a suggestion that it DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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is reducing over time, possibly because of earlier 
referral and diagnosis. The presence of cirrhosis at 
diagnosis is predictive of poorer survival.1,26,27
There is up to a 200-fold increased risk of 
hepatocellular carcinoma in patients with 
haemochromatosis.26,28 Studies of patients having 
liver transplants suggest that undiagnosed 
haemochromatosis is not infrequent, that the 
occurrence of unsuspected hepatocellular 
carcinoma in this group is increased, and that 
life expectancy post transplant for patients with 
undiagnosed haemochromatosis is significantly 
reduced.29,30
In addition to hepatocellular carcinoma the fibrosis 
and cirrhosis caused by progressive iron overload 
will be a cause of progressive liver disease with the 
attendant morbidity and mortality. 
Arthropathy
Arthropathy presents with bony swellings of 
the joints and may resemble osteoarthritis. 
Characteristically the second and third metacarpal 
joints are affected but all joints may be involved, 
particularly the wrists, ankles and knees. 
The pathophysiology of the arthropathy of 
haemochromatosis is not characterised,31 although 
there is evidence of iron deposition in the articular 
cartilage of patients with haemochromatosis.32 
Arthropathies are found in 40–75% of patients,22 
but the occurrence may be overestimated as 
arthritis is a common symptom; estimates are 
usually based on patient information, and the 
actual site and severity of the arthropathy is often 
not characterised. Arthritis as a symptom of 
haemochromatosis appears to be associated with a 
reduced quality of life33 and unfortunately is one 
of the symptoms that is probably not improved 
by venesection therapy and which may in fact 
deteriorate in some patients.1,34 
Endocrine 
Diabetes mellitus is the major endocrine disorder 
associated with haemochromatosis. There are 
probably two distinct mechanisms: first, iron 
accumulation in the pancreatic β-cells leading to 
decreased insulin production and, second, iron 
accumulation in other tissues, which impairs 
insulin sensitivity.26 The same issues regarding the 
prevalence of cirrhosis at diagnosis apply to the 
changing prevalence of diabetes over time. The 
changing testing and referral patterns may result in 
the diagnosis and treatment of a group of patients 
who would not develop serious disease, rather than 
reducing the incidence of serious disease by early 
treatment. 
Hypogonadism also occurs and is caused primarily 
by gonadotropin deficiency resulting from iron 
deposition in the pituitary or hypothalamus. Other 
endocrine disorders including impairment of the 
thyroid, parathyroid or adrenal glands have been 
reported.
Heart
Cardiac manifestations of haemochromatosis are 
thought to be associated with iron deposition in 
the myocardium. Congestive heart failure and 
arrhythmias have been seen in 2–35% and 7–36% 
of HHC patients respectively.35 ECG abnormalities 
have been reported to be more common in patients 
than in control subjects and it is suggested that 
abnormalities of cardiac conduction precede the 
development of cardiomyopathy and may be 
reversible by treatment.36 
Genetics of 
haemochromatosis
Two missense mutations of the HFE gene 
were identified in 19966 and the relationship 
between these two common mutations and 
haemochromatosis has been subsequently 
confirmed in prevalence studies (see section 
on epidemiology). The major mutation is 
characterised by a G to A transition at nucleotide 
845 causing tyrosine to substitute for cysteine at 
position 282 in the HFE protein (C282Y). The 
second mutation is a C to G transition at nucleotide 
187 causing a histidine to aspartate substitution at 
position 63 (H63D). 
The majority of patients are homozygous 
for the C282Y mutation, with a smaller 
minority compound heterozygotes for both 
mutations.6,37–39 The significance of the H63D 
mutation is unclear.6,40 Although the H63D 
mutation does increase transferrin saturation 
(TS) and ferritin levels in population samples, 
it is thought that compound heterozygosity is 
not sufficient for the development of clinically 
diagnosed haemochromatosis in isolation, 
although it may confer excess risk in the 
presence of other contributory factors such 
as alcoholic liver disease.41–43 The frequency 
of compound heterozygosity is no higher in 
cases of haemochromatosis than in the general 
population.38,44 Background
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The discovery of the HFE gene has facilitated 
understanding of the basic mechanisms 
underpinning the development of 
haemochromatosis as well as pushing forward the 
understanding of iron metabolism in general. 
Since the discovery of the HFE gene a number of 
mutations of other genes have been discovered that 
also cause haemochromatosis.45–48 However, these 
are individually rare and mutation testing is not 
routinely undertaken outside of research settings. 
This report will focus on the commonest (classic) 
form of HHC, linked to mutations in the HFE gene 
(HHC type 1), and specifically homozygosity for 
the C282Y mutation. 
Laboratory testing for iron
Serum iron, total iron 
binding capacity and 
transferrin saturation
Measurement of serum iron alone is of little clinical 
use as there is considerable variation from hour to 
hour in normal individuals. More information is 
obtained by measuring serum iron concentration 
and total iron-binding capacity (serum iron plus 
unbound iron-binding capacity) as a surrogate for 
percentage saturation of transferrin. Transferrin 
may also be measured by immunological methods 
and TS calculated directly {TS = [serum iron/total 
iron-binding capacity] × 100 or [serum iron/(serum 
iron × unsaturated iron-binding capacity )] × 100}. 
TS is considered the ‘gold standard’ for assessment 
of iron overload; however, there remain issues 
relating to test standards and quality control, 
whichever technique is used, and problems with 
standardisation of these assays are recognised.17,49 
TS can also be decreased in inflammatory states, 
can be increased by alcohol consumption and can 
be artefactually changed by recent ingestion of iron 
or vitamins.
Serum ferritin (SF) is considered to correlate 
with the total amount of storage iron in normal 
individuals. Iron overload is correlated with a high 
SF; however, SF may also be high in other forms of 
liver disease, cancer, infection, inflammation and 
chronic disease.17
Quantitative phlebotomy 
This is used to measure iron stores. It provides a 
direct measurement of the amount of iron available 
for haemoglobin synthesis. Blood is removed 
weekly and after a number of venesections the 
patient is unable to maintain his or her normal 
haemoglobin level. At this point it is assumed 
that the available iron stores have been used and 
the amount of iron removed can be calculated, 
although there is no gold standard against which 
this can be evaluated. Individuals with normal iron 
stores become iron deficient after the removal of 
approximately 1.5–2 g of iron (i.e. four 500-ml 
units of blood).17 Individuals with iron overload will 
require more venesections to deplete their storage 
iron.50 
Liver biopsy 
Liver biopsy was the definitive test for a diagnosis 
of haemochromatosis and allows histochemical 
estimation of tissue iron, assessment of the extent 
of fibrosis or cirrhosis and chemical measurement 
of hepatic iron concentration. The degree of 
stainable liver iron is usually graded and the 
consensus is that grades 0–1 are normal and grades 
2–4 represent increased parenchymal iron stores. 
Iron deposition in the liver may be increased in 
various forms of liver disease including alcoholic 
cirrhosis. 
It has been accepted that a hepatic iron index 
(hepatic iron concentration divided by age) greater 
than 1.9 discriminates between hepatic iron 
overload caused by HHC and hepatic iron overload 
caused by other liver diseases. This is based on the 
concept that iron overload increases with age in 
haemochromatosis but is stable in other chronic 
liver diseases. A hepatic iron index greater than 
1.9 was considered to be the gold standard test for 
haemochromatosis.50,51 The identification of the 
genetic basis of haemochromatosis now means that 
the role of liver biopsy in the diagnostic pathway is 
being reduced.52
Non-invasive imaging, such as magnetic resonance 
imaging or computerised tomography scans, are 
not widely recommended for diagnostic purposes.
Treatment of 
haemochromatosis
Venesection as a therapy for haemochromatosis is 
considered to be safe, inexpensive and effective. 
Practice guidelines suggest removal of iron by 
weekly or twice-weekly phlebotomy until the 
patient is marginally iron deficient. Subsequently 
the frequency of phlebotomy is adjusted according 
to serum TS and SF levels.53DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Evidence for the benefits of treatment comes from 
observational studies, including a small study 
that compared a series of treated patients with 
current and historical control subjects untreated 
either because they refused treatment or because 
they were diagnosed before venesection was a 
recognised treatment.54 This study indicated a 
benefit of treatment with prolonged survival and 
a reduction in signs and symptoms in the treated 
group. As there was no random allocation of 
treatment, these results may be confounded by 
systematic differences between the treated and 
untreated groups. 
The most widely reported evidence for the benefits 
of treatment comes from a cohort of patients 
referred to a specialist German centre together 
with family members identified through family 
screening.1 Analysis of the outcomes in these 
patients suggests that if treatment is initiated 
before the development of irreversible cirrhosis, 
diabetes or cardiomyopathy, then mortality in 
the treated group is no different from mortality 
in the population from which they are derived, 
when making comparisons using population 
mortality data. However, although this study uses 
age- and sex-matched data as a control, there is no 
concurrent control group and it cannot be assumed 
that 100% of the group who were diagnosed 
without symptoms would have developed serious 
complications of the condition. Similar findings of 
the benefit of treatment have been reported from 
other studies.2,26,27 It would now be unethical to 
conduct a randomised controlled trial (RCT) of 
treatment versus non-treatment as the evidence is 
strongly suggestive of the benefit of treatment in 
individuals diagnosed clinically and patients report 
symptomatic improvement. 
In a postal survey of diagnosed patients 86% 
reported that some or all of their symptoms 
improved with therapy.34 In patients with 
established iron overload and symptomatic disease, 
liver function, weakness, fatigue, loss of libido, 
cardiomyopathy and skin pigmentation usually 
improve.55 As discussed previously, the response 
to treatment for arthritis is variable. Removal of 
excess iron does not reverse cirrhosis or diabetes 
but the latter can be stabilised and insulin 
requirements reduced.1,54
Although venesection as a therapy for preventing 
the complications of haemochromatosis is 
considered to be simple, the patient perspective 
has not been evaluated. One anecdotal report 
suggests that the adverse effects of treatment may 
not be as trivial as is usually assumed.56,57 In a 
postal survey 12% of patients expressed a negative 
attitude towards phlebotomy, citing problems 
with venous access and the time involved and 
also dissatisfaction that the blood was discarded.34 
Initial compliance with therapy appears to be 
good; however, over the long term compliance may 
decline.58 
Some questions remain around when to start 
treatment, for instance should C282Y homozygotes 
with raised TS and a normal SF be given 
treatment? The British Society for Haematology 
(BSH) guidelines on haemochromatosis state that 
treatment would not normally be given at that 
stage of iron accumulation. For those with normal 
values of TS and SF concentration no treatment is 
necessary. The guidelines suggest that it would be 
reasonable to monitor iron status at yearly intervals 
to detect when SF becomes raised, indicating the 
onset of tissue iron accumulation.
Epidemiology 
Hereditary haemochromatosis is a common 
inherited metabolic disorder that predominantly 
affects Caucasian populations of north European 
descent, particularly those of Celtic origin.59 
Although several genetic and environmental 
factors are thought to affect the development of 
haemochromatosis, the existence of the C282Y 
and H63D mutations on the HFE gene underlie 
the disease.59–61 However, as previously discussed, 
the significance of the H63D mutation is not 
clear. As early treatment through phlebotomy 
may prevent premature illness and death,60 it is 
important to identify the most effective strategies 
for diagnosing the condition as early as possible. 
Given the apparent significance of the genetic 
component of haemochromatosis, it is necessary 
to assess the prevalence of the genetic mutations, 
the penetrance of the condition and the prevalence 
of the condition itself to adequately assess the 
effectiveness of different diagnostic strategies; 
however, difficulties exist in identifying reliable 
data. Assessment has tended to rely on the use 
of cohort studies of different population groups. 
These may be affected by certain limitations. 
Several studies use information from registers 
of particular health service users, which may not 
be representative of the general population (e.g. 
healthy blood donors).61 Studies focusing on 
people with haemochromatosis may be affected Background
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by the differing definitions and diagnostic 
criteria used to identify the condition and its 
sufferers.13,38,62 Other studies have focused on 
populations with differing ethnic groups, which 
considering the genetic nature of this condition 
may affect any epidemiological data.61 Similarly, 
demographic and environmental factors may 
influence the development of haemochromatosis 
and so any variations in these factors may limit 
the comparability of studies. Notwithstanding 
these difficulties, several studies have been 
undertaken within the UK and Ireland that provide 
an indication of the prevalence of the genetic 
mutation and the disease, as well as the penetrance 
of the condition. The following sections discuss 
these studies, outlining their key characteristics and 
their findings. 
TABLE 1  Characteristics of included prevalence studies
Study  Design
Populations
General population cohorts Control group
Byrnes et al. 
2001; 63 Ireland
Prospective cohort 
study
Randomly selected cohort from register of 
newborn children with Irish native surnames 
(n = 800)
None
Jackson et al. 
2001;65 Wales
Prospective cohort 
study
People (mean age 37.8 years men/35.7 years 
women) attending a blood donation service 
(n = 10,556)
None
Merryweather-
Clarke et al. 
1998;67 Jersey
Prospective cohort 
study
Volunteer blood donors (n = 411) None
Specific non-HHC patient groups Control group
O’Hara et al. 
2003;66 Ireland
Prospective cohort 
study
A cohort of inpatients, outpatients and general 
practice referrals providing fasting blood specimens 
to laboratory for routine screening (n = 330; mean 
age 56.5 years men/61.8 years women)
None
Campbell et al. 
2003;64 Scotland
Cross-sectional 
case–control study
Patients aged 25–64 on the MONICA heart attack 
register who had survived a first myocardial 
infarction (n = 924)
Patients aged 55–74 
years chosen at random 
from general practitioner 
registers (n = 1009)
HHC patient groups Control group
UK HHC 
Consortium 
1997;38 England 
and Wales
Prospective cohort 
and control study
Multicentre cohort of people from England and 
Wales with HHC diagnosed through hepatic 
iron index > 1.9 or > 5 g mobilisable iron from 
quantitative phlebotomy in absence of other cause 
of iron overload (n = 115)
Healthy blood donors 
from Wales (n = 101)
Murphy et al. 
1998;62 Northern 
Ireland
Prospective cohort 
and control study
A selected cohort of people diagnosed with HHC 
through pathology and liver biopsy (n = 30)
People on bone marrow 
register (n = 404)
McCune et al. 
2002;13 Wales
Retrospective 
cohort study
People (mean age 49.1 years men/51.3 years 
women) diagnosed and treated for HHC. 
Diagnosed on iron indices above normal range for 
hospital on two occasions and no other causes 
(n = 81)
None
MONICA, Multinational Monitoring of Trends and Determinants in Cardiovascular Disease.
UK epidemiology studies
Eight studies have been included in the assessment 
of the prevalence of the key genetic mutations 
within the general population and among those 
with haemochromatosis in the UK, Jersey and 
Ireland (Table 1 and see Chapter 3).13,38,62–67 Six 
studies were prospective cohort studies,38,62,63,65–67 
with two including a control group.38,62 The other 
two studies were a retrospective cohort study13 
and a cross-sectional case–control study.64 The 
participants in the studies varied depending 
upon the rationale for the study, including people 
diagnosed with haemochromatosis,13,38,62 people 
attending a blood donation service,65,67 those on 
registers of newborn children63 or heart attack 
sufferers,64 and those attending for routine blood 
screening.66 Control groups included healthy DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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blood donors,38 people registered with general 
practitioners64 and people on bone marrow 
registers.62
Prevalence of the genetic mutations 
in the general population
The prevalence of the genetic mutations in the 
general population appears to vary, with rates 
differing depending on the specific mutation, 
whether homozygous, heterozygous, wild type or 
compound heterozygous and the characteristics of 
the study and its population (Table 2). Prevalence 
data for the general population originated 
from several cohorts including healthy blood 
donors,38,65,67 a register of newborn children,63 
general practitioner populations,64 people on bone 
TABLE 2  Prevalence of the C282Y and H63D genetic mutations in UK and Ireland populations 
Genotype General population  Patients with HHC
C282Y homozygous 0.9%64
0.68%65
0.97%67
0.99%38 91.3%38
1.0%63
0.93%66
1.24%62 90%62
72.8%13a
C282Y heterozygous 15.3%64
12.7%65
11.4%67
5.9%38 0.87%38
19%63
2.5%13a
H63D homozygous 2.1%64
2.4%65
2.9%67
2.97%38 0.87%38
1.0%63
1.2%13a
H63D heterozygous 25.2%64
23.6%65
20.9%67
21.8%38 038
28%63
Compound heterozygous (C282Y/H63D) 2.4%64
2.4%65
3.2%67
3.96%38 2.6%38
4.0%63
7.4%13a
Wild type 58.3%65
60.6%67
64.4%38 4.4%38
a  16.1% of the study population not genotyped.Background
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marrow registers62 and people providing blood 
specimens for routine screening.66 Inevitably the 
variations in these groups may have some effect 
on the prevalence rates reported. In the UK 
studies identified, the prevalence of the C282Y 
homozygous mutation in the general population 
ranged from 0.68%65 to 1.24%,62 with five studies 
identifying prevalence rates between 0.9% and 1% 
(median prevalence 0.97%).38,63,64,66,67 Prevalence 
rates in the UK for the C282Y heterozygous 
mutation were higher and had a wider range. The 
prevalence in the five studies ranged from 5.9% 
in a cohort of healthy blood donors38 to 19% in a 
cohort of newborn Irish children.63 The median 
prevalence for the C282Y heterozygous mutation 
was 12.7%, reported in a cohort attending a blood 
donation service.65 The prevalence of the H63D 
mutation was higher than the prevalence of the 
C282Y mutation in the general population of the 
UK, although rates also varied among the studies. 
In the five studies assessing the general population, 
prevalence of the H63D homozygous mutation in 
cohorts in the UK and Ireland rates ranged from 
1.0%63 to 2.97%38 (median prevalence of 2.4%65). 
Prevalence rates for the H63D heterozygous 
mutation ranged from 20.9%67 to 28%63 in studies 
examining cohorts in the general population 
(median prevalence 23.2%64). The compound 
heterozygous mutation (C282Y/H63D) was less 
prevalent in the general population than the 
C282Y heterozygous and H63D heterozygous 
mutations with rates varying from 2.4%64,65 to 
4.0%63 (median prevalence 3.2%67). The prevalence 
of the wild-type genotype in the general population 
cohorts ranged from 58.3%65 to 64.4%38 (median 
60.6%67).
Prevalence of the genetic mutations 
in people with haemochromatosis
Three studies assessed the prevalence of the 
different genetic mutations in people with 
haemochromatosis in the UK and Ireland.13,38,62 
Inevitably variation in the prevalence of the 
genetic mutations may encompass some of the 
differences in the diagnostic criteria used by the 
studies to identify people with haemochromatosis. 
Unsurprisingly, the prevalence of these mutations 
varied considerably from the prevalence in 
the general population. The prevalence of the 
C282Y homozygous mutation was higher among 
those people with haemochromatosis than in 
the general population, with rates varying from 
72.8%13 to 91.3%.38 The prevalence reported 
by McCune and colleagues13 was considerably 
lower than the median prevalence for the three 
studies of 90%.13,38,62 This may reflect the fact 
that 16% of patients in the study by McCune 
and colleagues were not genotyped.13 The 
comparatively high prevalence of the C282Y 
homozygous mutation among those people 
with haemochromatosis reflects the underlying 
importance of this mutation in people developing 
the phenotype. In contrast, the prevalence of the 
C282Y heterozygous mutation was lower than 
that for the general population. The prevalence 
was reported by two studies with rates ranging 
from 0.87%38 to 2.5%.13 For the H63D genetic 
mutation the prevalence was lower than that in the 
general population and for the C282Y mutation 
in people with haemochromatosis. Some 0.87%38 
to 1.2%13 of people with haemochromatosis had 
the H63D homozygous mutation and 0% had 
the heterozygous mutation.38 As only two studies 
assessed the prevalence of the H63D mutation, 
some caution should be taken in interpreting 
these results. Similarly, only two studies examined 
the prevalence of the compound heterozygous 
mutation (C282Y/H63D) in the haemochromatosis 
population; one reported a rate of 2.6%,38 which is 
similar to the frequency in the general population, 
and the other, which did not genotype the whole 
sample, reported a rate of 7.4%.13 The wild-type 
genotype was evident in 4.4% of people with 
haemochromatosis.38
Penetrance of the gene mutation
As discussed in the section on description of the 
health problem, people with the genetic mutation 
for haemochromatosis may or may not develop 
the phenotypic condition. Studies assessing the 
penetrance of the gene mutation within the UK 
and Ireland were limited. Only McCune and 
colleagues13 provided a rate for the penetrance 
of the gene mutation, identifying a penetrance of 
1.2% in the general population. 
Prevalence of haemochromatosis
No studies were identified that presented the 
prevalence of haemochromatosis in the general 
population in the UK. Merryweather-Clarke and 
colleagues67 reported a population prevalence 
for haemochromatosis of 1 in 4700 in Jersey. 
Other studies have presented prevalence rates for 
specific groups who have presented with different 
signs and symptoms characteristic of increased 
iron. Emery and colleagues68 found that 4.2% of 
people presenting with signs and symptoms of 
increased iron or who had undergone iron studies 
and then underwent liver biopsy had confirmed 
haemochromatosis. Given that this group was 
a cohort with an increased likelihood of having 
the condition, it is not surprising that the rate DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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was considerably higher than that identified by 
Merryweather-Clarke and colleagues67 and hence it 
should be used with caution.
Current service provision 
Patients with haemochromatosis are diagnosed, 
treated and managed by a variety of clinical 
specialists, mostly in secondary care, including 
gastroenterologists, haematologists and 
hepatologists. This may lead to fragmented care, 
which means that it is difficult to establish standard 
clinical pathways. It is suggested that the diagnosis 
should be considered in patients presenting 
with the early features of haemochromatosis: 
unexplained weakness or fatigue, abnormal liver 
function tests, arthralgia/arthritis, impotence, 
late-onset diabetes, cardiomyopathy and raised 
ferritin.52,69,70 Assessment of iron status, particularly 
TS and SF, can be followed by genotyping. 
Unpublished data from the UK Haemochromatosis 
Society suggests that the majority of their members 
with a diagnosis of haemochromatosis (70%) are 
identified as a result of being investigated for 
symptoms related to iron overload such as joint 
pain and liver disease. Approximately 20% are 
identified as a result of having an affected family 
member. Some patients are found incidentally as 
SF may be performed as part of the investigation 
of a diverse range of medical conditions (e.g. 
possible anaemia). There also appears to be a 
delay of some years between reporting of the first 
symptom and diagnosis (an average of 9 years 
in men and 12 years in women). An analysis of 
hospital admission data for England for the years 
2000–3 suggests that 14% of patients at their 
first episode of care for haemochromatosis also 
had a diagnosis of liver disease.71 This supports 
anecdotal data that patients are still presenting 
with preventable complications of this treatable 
disease. The non-specific nature of early symptoms 
makes diagnosis difficult and, in the absence of 
screening programmes, diagnosis depends on 
clinical awareness in the relevant specialties.
In many centres haemochromatosis is often 
managed by a dedicated team consisting of a 
clinician supported by a nurse specialist and 
possibly junior medical staff who will do most 
of the phlebotomy and provide a day-to-day 
contact point for the patients. Haematologists, 
gastroenterologists and hepatologists provide 
the medical input, with care pathways following 
the BSH guidelines.69 Genetic advice may also be 
provided by the same teams, with some having 
in-house genotyping services and others using 
regional centres. Regional genetics centres also 
provide a service offering advice and family 
investigation, with referral of patients to the local 
haematologist/gastroenterologist for phlebotomy 
and clinical assessment.
Aspects of the diagnosis 
of haemochromatosis 
considered in this assessment 
The discovery of the gene for haemochromatosis 
has modified diagnostic and screening approaches 
to identifying cases that would benefit from 
treatment. However, there is no consensus as to 
which factors define a case. Most testing strategies 
include a combination of biochemical and genetic 
tests and liver biopsy together with modifying 
information such as age and gender.52,72 The most 
appropriate diagnostic strategy is not clear. 
Biochemical testing 
and liver biopsy
Before the discovery of the common gene 
mutations, diagnosis of haemochromatosis was 
based on clinical suspicion including persistently 
raised TS with no other explanation followed by 
liver biopsy. Both the BSH69 and the US College 
of American Pathologists35 recommend the TS 
test as the initial diagnostic test for HHC. This 
test should be carried out on a fasting sample. 
Elevated fasting TS indicates iron accumulation 
and, if this has been demonstrated, the BSH 
guidelines recommend that the SF concentration 
is measured. SF concentrations are not usually 
abnormal in the early stages of iron accumulation 
but once liver iron concentrations are elevated 
they rise disproportionately with the degree of 
liver damage. Liver biopsy with assessment of 
iron deposition, although previously considered 
to be the gold standard for diagnosis, is no 
longer used as a diagnostic tool; however, it is still 
widely used to confirm cirrhosis and as the only 
way of determining fibrosis. It is worth noting 
that biochemical tests are unable to discriminate 
between different possible causes of iron overload, 
so although iron overload may suggest a diagnosis 
of HHC other possible diagnoses will need to be 
ruled out.
Genetic testing
DNA-based testing can identify people who are 
homozygous for mutations in the HFE gene 
before symptoms of iron overload become 
apparent. Although this test identifies people at Background
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risk of developing the symptoms of iron overload, 
because of the low penetrance of the disorder, 
only a proportion will go on to exhibit the HHC 
phenotype. This means that both the sensitivity for 
detecting phenotypic HHC and the PPV of genetic 
testing are low in the general population. 
A wide range of DNA-based tests to identify the 
C282Y and H63D mutations have been described, 
most commonly polymerase chain reaction (PCR) 
followed by restriction enzyme digest, amplification 
refractory mutation system PCR, and PCR with 
single-strand conformation polymorphism (SSCP) 
analysis.73
Family screening
Hereditary haemochromatosis is an autosomal 
recessive condition and, as such, children and 
siblings are at increased risk for inheriting 
susceptibility to the disease, with probabilities of 
at least 1 in 20 and at least 1 in 4 respectively. 
The purpose of testing family members is to 
detect those individuals at risk who would benefit 
from treatment, and to detect those at risk who 
do not currently require treatment but who will 
be monitored for a suitable period of time until 
the need for future treatment can be ascertained. 
Testing can also identify those not at risk who 
can be excluded from further investigations and 
reassured. Penetrance may be higher in families 
as they share other genetic and environmental 
factors, although the main risk factor appears to be 
possession of the at-risk genotype.13
Psychosocial aspects 
of genetic testing
Concern about genetic testing and screening is 
evidenced by a number of reports that focus on 
issues of potential stigmatisation, discrimination, 
family implications and the possible psychological 
consequences.74,75 However, the rationale 
for genetic exceptionalism may not be well 
established.76 In addition, concerns relating to 
unfair discrimination will be influenced by the legal 
framework and welfare provision of the country 
of residence. For example, the situation regarding 
coverage and reimbursement for health care is 
very different in North America to that in the 
UK. In haemochromatosis the purpose of using 
the genetic test is to identify individuals who will 
benefit from treatment and to rule out disease 
in family members. Studies have investigated 
the psychosocial consequences of using DNA 
tests for population and targeted screening 
for haemochromatosis and found few adverse 
effects.77–79
Rationale for this study
There is broad agreement that early diagnosis of 
haemochromatosis and treatment with venesection 
is effective at reducing the risk of complications.1,19 
It is important therefore to identify (1) the best 
diagnostic strategy for those suspected of having 
haemochromatosis and (2) the best testing strategy 
for family members to identify those who need 
treatment or monitoring and those not at risk of 
haemochromatosis. Biochemical tests will identify 
the presence of raised iron levels requiring 
treatment but do not confirm a diagnosis of HHC 
and diagnostic thresholds are still debated. The 
additional value of a DNA test is unclear. 
From the perspective of the patients and their 
families the pressing clinical issues are to effectively 
and efficiently diagnose people early enough so 
that they may benefit from treatment and to rule 
out HHC in family members. The wider NHS 
perspective is to make the most efficient and cost-
effective use of the tests available. DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Chapter 2  
Aim and objectives
Overall aim and objectives 
of assessment 
The aim of this project is to evaluate the use of 
DNA tests for detecting HHC in subgroups of 
patients suspected of having the disorder on 
the basis of clinical presentation and disturbed 
iron parameters, and in family members of 
those diagnosed with haemochromatosis. 
A clear distinction will be drawn between 
diagnostic strategies in those suspected of having 
haemochromatosis and testing strategies in family 
members, as the consequences are different. 
The objectives are:
•	 to determine the clinical validity of DNA tests 
to diagnose HHC
•	 to summarise the evidence on the clinical 
utility of diagnostic strategies using DNA tests 
to detect cases for treatment or monitoring 
in terms of clinical effectiveness and cost-
effectiveness
•	 to compare the costs and consequences by 
decision-analysis modelling of diagnostic 
algorithms for HHC and family testing 
strategies with and without DNA testing in 
terms of cost per case detected
•	 to review the psychosocial literature and 
compare the psychosocial benefits and harms 
of adding DNA testing to diagnostic algorithms
•	 to identify priorities for future primary 
research.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Chapter 3  
Methods for systematic review
T
he a priori methods used for the review are 
outlined in the research protocol (Appendix 
1). This was sent to members of the advisory 
group for the review for expert comments (see 
Acknowledgements). Helpful comments were 
received relating to the general content of the 
research protocol; no specific problems with the 
proposed methods of the review were identified. 
The research methods for the systematic review 
are summarised in the following sections. The 
search strategy and inclusion and data extraction 
process also apply to the systematic searches used 
to identify information for the economic evaluation 
(see Appendix 1, Table 28, for details of systematic 
searches on epidemiology, biochemical tests and 
liver biopsy). Some points of clarification regarding 
the methods adopted are discussed later in this 
chapter (see Clarification of methods).
Search strategy
The following databases were searched for 
published studies and ongoing research, from 
inception to April 2007: the Cochrane Library 
(Database of Systematic Reviews and Controlled 
Trials Register), MEDLINE (Ovid), EMBASE 
(Ovid), PubMed, Science Citation Index (SCI), 
BIOSIS, PsychLit, MEDION, NHS Economic 
Evaluations Database (NHS EED), NHS Health 
Technology Assessment database (NHS HTA), NHS 
Database of Abstracts of Reviews of Effectiveness 
(NHS DARE), EconLit, NRR (National Research 
Register), Current Controlled Trials and 
ClinicalTrials. Grey literature and conference 
proceedings were also searched. Searches were 
restricted to the English language and to human 
studies, and for literature on DNA tests for C282Y 
mutations to 1996 onwards. Bibliographies of 
related papers were assessed for relevant studies. 
Investigators of studies were not contacted because 
of time constraints. Further details, including key 
search terms, can be found in Appendix 2. 
Inclusion and data 
extraction process
Titles and abstracts of studies identified by the 
search strategy were screened independently 
for inclusion by two reviewers. The full text of 
potentially eligible studies was obtained and 
examined independently for inclusion by two 
reviewers. Data were extracted by two reviewers on 
standard data extraction forms. Any disagreements 
were resolved by consensus or arbitration by a third 
reviewer if necessary. 
The process for identifying and including studies 
is illustrated in Figure 1. The primary reason for 
excluding studies was that they did not meet the 
inclusion criteria. For clinical validity and utility 
this was because they concerned population 
or targeted screening, analytical validity, non-
European populations, phenotype/genotype 
correlations or subgroups (such as diabetics or 
the elderly). A list of studies excluded at various 
stages of the process can be found in Appendix 3. 
Ongoing research is shown in Appendix 4. 
Quality assessment
The methodological quality of included studies 
was assessed using modified formal tools specific 
to the design of the study and focusing on possible 
sources of bias, which is discussed in the relevant 
sections throughout the report. Clinical validity 
studies were assessed using relevant questions 
from QUADAS (Quality Assessment of Diagnostic 
Accuracy Studies, Appendix 5)80 combined with 
relevant questions from criteria developed by 
Spitzer and colleagues81 Aspects considered for 
quality assessment included adequate description 
of haemochromatosis patients; appropriate 
definition of the disease; representative sampling 
of patients; adequately described control group; 
whether groups were comparable; description of 
the tests used and outcomes fully reported; whether Methods for systematic review
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there were missing data; and generalisability of 
results. Other observational studies were assessed 
for quality using the criteria developed by Spitzer 
and colleagues81 (Appendix 6). Quality assessment 
of economic evaluations was conducted using 
a checklist adapted from those developed by 
Drummond and Jefferson82 and Philips and 
colleagues.83
Quality criteria were applied by two reviewers. At 
each stage, any differences in opinion were resolved 
through discussion or if necessary by arbitration by 
a third reviewer. 
Inclusion criteria 
Inclusion criteria for studies on clinical validity, 
clinical utility and psychosocial aspects of DNA 
testing are shown below. 
Clinical validity
•	 Intervention: DNA tests.
•	 Population: Caucasians with iron overload 
suggestive of haemochromatosis (north 
European populations).
•	 Comparator: control population (Caucasian). 
•	 Outcomes: sensitivity and specificity (reported 
or calculable). 
•	 Study type: controlled cohort or case–control.
Clinical utility
Clinical effectiveness of 
diagnostic strategies
•	 Intervention: DNA tests.
•	 Population: Caucasians with iron overload 
suggestive of haemochromatosis; relatives of 
suspected cases.
•	 Comparator: any case identification strategy 
not involving DNA testing.
FIGURE 1  Flow chart of identification of studies for the systematic reviews and searches.
Epidemiology
n =135
Full papers retrieved
n = 120
Assessed for inclusion
in systematic reviews
Assessed systematically
for model input data
Clinical utility and/or
clinical validity
n = 52
Include validity
n = 11
Exclude validity
n = 41
Include
n = 2
Exclude
n = 6
Epidemiology
n = 35
Cost-effectiveness
n = 8
Liver biopsy
n = 22
Biochemistry
n = 12
Include
n = 3
Exclude
n = 16
Include
n = 19
Exclude
n = 16
Include
n = 2
Exclude
n = 20
Include
n = 3
Exclude
n = 9
Psychosocial
n = 19
Reference database
titles and abstracts screened
n = 2052
+ update search
n = 101
Total references screened
n = 2153DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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•	 Outcomes: treatment, morbidity, mortality, 
quality of life, psychosocial aspects.
•	 Study type: RCTs, cohorts with controls, case–
control (highest level only).
Cost-effectiveness of diagnostic strategies
•	 Intervention: DNA tests.
•	 Population: Caucasian, clinical suspects, 
defined; relatives of suspected cases. 
•	 Comparator: any case identification strategy, 
e.g. liver biopsy, phlebotomy or other iron 
studies.
•	 Outcomes: cost-effectiveness/utility, costs.
•	 Study type: economic evaluations, modelling 
studies.
Psychosocial aspects 
of DNA testing
•	 Intervention: DNA tests.
•	 Population: diagnosed and at-risk individuals 
(people with suspected HHC and first-degree 
relatives).
•	 Outcomes: psychosocial aspects (treatment 
compliance, psychological outcomes, legal 
implications, quality of life, discrimination/
stigmatisation).
•	 Study type: any quantitative or qualitative 
primary research.
Data synthesis
Synthesis of data was through narrative review with 
full tabulation of results of all included studies. Full 
data extraction forms are shown in Appendices 7, 
8 and 9. Meta-analysis was not possible because of 
the heterogeneous nature of the studies identified. 
Clarification of methods
Some changes, additions or points of clarification 
were made to the methods discussed in the original 
protocol. These are presented below:
•	 There is a large literature relating to 
haemochromatosis, mostly concerning 
population screening and epidemiology. 
Therefore, to identify the most relevant studies 
and to exclude population screening studies, 
different inclusion criteria were developed for 
the different systematic review elements. 
•	 Various authors have raised issues concerning 
the methods for assessing diagnostic tests and 
there is a consensus that explicit frameworks 
should be developed analogous to those used 
in studies of clinical effectiveness.84,85 The 
ACCE model has been developed by the Office 
of Genomics and Disease Prevention (Center 
for Disease Control, Atlanta, USA), working 
with the Foundation for Blood Research to 
evaluate DNA-based genetic tests,53 based on 
original methodology by Wald and Cuckle.86 
This model takes its name from the four 
components of the evaluation: Analytic validity, 
Clinical validity, Clinical utility and associated 
Ethical, legal and social issues. Although still 
at the development stage it provides a useful 
framework to inform the evaluation of genetic 
tests and was the methodology adopted for 
this review (see also Chapter 8, Other relevant 
factors, and Appendix 1). 
•	 Analytical validity is the ability of the test to 
accurately and reliably measure the genotype 
of interest. It is concerned with assessing test 
performance in the laboratory and is closely 
related to quality assurance of the laboratory 
processes surrounding the test. This is outside 
the remit of this report.
•	 Clinical validity refers to the accuracy with 
which a test predicts the presence or absence of 
a clinical condition. This involves establishing 
the probability that the test will be positive in 
people with the disease (clinical sensitivity) and 
the probability that the test will be negative in 
people without the disease (clinical specificity). 
Clinical sensitivity here refers to the proportion 
of individuals who have, or who may be 
destined to develop, the primary iron overload 
phenotype and who have a positive test result 
for C282Y homozygosity.
•	 Traditional diagnostic test assessment is 
difficult in the case of genetic testing and no 
studies conforming to the usual format for 
evaluating clinical validity are available for 
genetic testing for haemochromatosis. As 
such, a pragmatic approach was taken to assess 
clinical validity, which is discussed in more 
detail in Chapter 8 (Other relevant factors).
•	 Studies for assessing clinical validity were 
limited to those involving north European 
Caucasian populations as these were deemed 
most relevant to the UK.
•	 Clinical utility is defined as the likelihood that 
the test will lead to an improved outcome, 
and incorporates assessment of the risk and 
benefits of genetic testing, as well as economic 
evaluation. This is perhaps the most important 
aspect of the evaluation in that it assesses 
whether testing will alter clinical management 
or benefit those tested and at what cost. Methods for systematic review
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For assessing the clinical utility (i.e. clinical 
effectiveness and cost-effectiveness) of DNA 
testing, studies had to compare a strategy 
incorporating DNA tests with a strategy 
that did not in people suspected of having 
haemochromatosis or relatives of patients with 
haemochromatosis. For clinical effectiveness, 
studies had to report patient-based outcomes 
and, for cost-effectiveness, studies had to 
report some measure of cost and benefit.
•	 The last component of the ACCE framework 
was covered by considering psychosocial 
aspects of using genetic testing for 
haemochromatosis in terms of psychological 
issues, quality of life and discrimination 
and stigmatisation implications. For the 
psychosocial review, any study type in 
diagnosed and at-risk populations reporting 
primary data on psychosocial outcomes of the 
use of DNA tests in haemochromatosis was 
included. DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Chapter 4  
Assessment of clinical validity 
Quantity and quality of 
research available 
Eleven controlled cohort studies38,62,87–95 met the 
inclusion criteria for the review of clinical validity 
and are shown in Table 3 and Appendix 7. Two 
studies were conducted in the UK,38,95 two in 
Ireland,63,93 three in France,90,91,94 two in Sweden,87,89 
and two in Germany.88,92
Details of the participants in both 
haemochromatosis and control cohorts, the 
methodology used to genotype participants, the 
reported outcomes, the comparability of groups 
and the generalisability of the studies are presented 
in the following sections. Table 4 reports the quality 
assessment of the included studies. 
Haemochromatosis cohorts 
Eight of the 11 included studies reported 
clear selection criteria for the eligibility of 
haemochromatosis cases38,87–90,92,94,95 whereas the 
three remaining studies were unclear and did not 
report sufficient details.62,91,93 The criteria used to 
define haemochromatosis cases varied between 
studies but most required the presence of two or 
more diagnostic criteria. Six studies38,87,88,90,92,95 have 
used a definition that is likely to correctly classify 
HHC whereas the remainder are unclear from the 
description given. 
Seven studies87–89,91–94 included a requirement for 
both a high TS and a high SF concentration in 
their haemochromatosis patient definition. Five 
studies87–89,92,94 defined an elevated TS and this 
ranged from a cut-off of over 45% to a cut-off 
of over 62%. These five studies also defined an 
elevated SF and this ranged from a cut-off of over 
200 mg/l (women only) to a cut-off of over 400 mg/l 
(men only). Two91,93 of the seven studies did not 
state what values of TS or SF would be considered 
high. One additional study95 used a high TS 
concentration (greater than 60%) without mention 
of SF levels. Three studies did not use TS and SF 
values.38,62,90 
In six studies62,87,88,90,92,93 all members of the 
haemochromatosis cohort had results from liver 
biopsy that showed liver iron deposition, and four 
studies reported that haemochromatosis cohort 
members had a hepatic iron index (HII) greater 
than 1.938,88 or greater than 2.90,95 One study92 
used a value of iron from wet weight of liver and 
reported that haemochromatosis cohort members 
had an HII of over 30. Phlebotomy treatment for 
either some or all of the haemochromatosis cohort 
was a feature of seven studies.38,87–90,92,95 Only four 
studies38,87,88,90 reported that other causes of iron 
overload had been ruled out. One study62 provided 
few details about the diagnosis of the patients 
in the haemochromatosis cohort, reporting only 
that ‘haemochromatosis cases were both clinically 
assessed and pathologically diagnosed by liver 
biopsy’. 
In all studies it is not clear whether bias has 
been avoided in the sampling of participants in 
the haemochromatosis cohorts as the methods 
used have not been described. Most of the 
haemochromatosis patient cohorts comprised fewer 
than 100 individuals62,87,88,92,93,95 (range 18–92), 
three cohorts comprised 115–156 individuals,38,90,94 
there was one patient cohort of 29689 and the 
largest contained 478 haemochromatosis patients.91 
Individuals in five of the haemochromatosis 
cohorts38,87,88,90,92 were reported to be unrelated 
to one another, and in one study93 although the 
majority of the cohort consisted of unrelated 
individuals it is not clear whether this is true for 
the entire cohort. One haemochromatosis cohort 
is reported to include some related individuals.95 
Only three studies88,91,95 specifically state that 
the patients are Caucasian, with a further study 
cohort94 being predominantly Caucasian (96.2%).
Only two studies92,94 report some additional 
characteristics for their haemochromatosis cohort, 
and three studies87–89 report on the age and sex of 
the cohort.
Control cohorts
Control subjects were drawn from different 
sources in the included studies and may not 
be representative of the population that the 
haemochromatosis patients were drawn from 
and may not be free from selection bias. In four 
studies87,90,91,94 the control cohort was drawn Assessment of clinical validity
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TABLE 3  Studies used to assess clinical validity
Study details Haemochromatosis cohort Control cohort
Cardoso et al. 
1998;87 Sweden
Unrelated patients with high TS (> 60% in men and > 50% 
in women) and SF > 300 mg/l and LB with typical iron staining 
indicating primary HHC (n = 87)
Random healthy Swedish subjects 
(n = 117)
Hellerbrand et al. 
2001;88 Germany
Unrelated patients diagnosed on basis of clinical history and 
meeting following criteria: (1) increased TS (repeatedly > 50%) 
and elevated SF levels; (2) hepatocellular hemosiderin deposits 
of grade III–IV; (3) HII > 1.9 and/or total iron removed > 5g 
(men) and > 3g (women) (n = 36)
Healthy hospital employees (n = 126)
Holmstrom et al. 
2002;89 Sweden
SF > 300 mg/l (men) or > 200 mg/l (women) or TS > 50% (men) 
or > 45% (women) (n = 296)
Hospital staff and students and their 
relatives (no history of liver disease 
or multiple blood transfusions) 
(n = 250)
Jouanolle et al. 
1997;90 France
Unrelated participants diagnosed on basis of clinical and 
biological signs with at least one of increased stainable iron 
in at least 75% of hepatocytes; hepatic iron concentration >  
100 mmol/g dry weight; HII > 2; more than 5 g of iron removed 
by weekly phlebotomy (n = 132)
Random subjects from general 
population (not defined) (n = 139)
Mura  et al. 2005;91 
France
Diagnosis based on classic signs and symptoms: elevated 
TS and/or SF concentration; hepatic symptoms, such as 
unexplained elevation of serum liver enzymes, cirrhosis, liver 
failure, or diabetes mellitus; and non-specific compatible 
symptoms, e.g. fatigue, abdominal pain, joint pain, cardiac 
arrhythmia and hyperpigmentation (n = 478)
Randomly selected, Caucasian 
(n = 410)
Murphy et al. 
1998;62 Ireland
Clinically assessed and pathologically diagnosed by LB (n = 30) Normal volunteers (bone marrow 
registry) (n = 404)
Nielsen et al. 
1998;92 Germany
Unrelated patients diagnosed by the presence of at least three 
of the following criteria: (1) TS > 62%; SF > 300 mg/l; (2) LIC 
> 2000 mg Fe/g wet weight; (3) HII [HI (mg/year) = (LIC/age)] 
> 30; (4) grade III or IV stainable iron in liver; (5) > 4 g of iron 
removed by phlebotomy (n = 92)
Unrelated healthy volunteers of 
German ancestry (n = 157)
Ryan et al. 1998;93 
Ireland
Patients diagnosed on basis of clinical history, physical 
examination, persistently raised TS and SF and, for group 1, 
> 3+ hepatic iron deposition (n = 60) and, for group 2, < 3+ 
iron deposition on liver biopsy (n = 18)
Randomly selected individuals from 
hospital staff (not defined) (n = 109)
UK HHC 
Consortium 
1997;38 UK
Unrelated patients with, in the absence of any other cause 
of iron loading, either HII > 1.9 or > 5 g mobilisable iron by 
quantitative phlebotomy (n = 115)
Series of unrelated healthy blood 
donors (n = 101)
Vantyghem et al. 
2006;94 France
General symptoms (fatigue, weight loss, arthralgia), diabetes, 
hepatomegaly, disturbed liver enzymes or hypogonadism and 
abnormal iron markers (SF > 300 ng/ml or TS > 45%) (n = 156)
Healthy Caucasian subjects without 
family history of diabetes or iron 
overload (n = 106)
Willis et al. 1997;95 
UK
Patients being treated for HHC by phlebotomy. Criteria: fasting 
TS > 60% in two samples and HII > 2 where appropriate 
(n = 18)
Referred to hospital for reasons 
unrelated to known manifestations of 
HHC and representative of hospital 
population (different patient groups 
included) (n = 200)
HI, hepatic iron; HII,  hepatic iron index; LB, liver biopsy; LIC, liver iron content; SF, serum ferritin; TS, transferrin 
saturation.
from the general population; only two of these 
studies91,94 clearly state that the control group 
subjects are Caucasian. Three studies recruited 
the control cohort from amongst hospital 
employees88,93 or hospital employees and students 
and their relatives.89 Three studies38,62,92 recruited 
from particular groups of healthy persons, 
including blood donors38 and a bone marrow 
registry.62 The remaining study recruited the 
control cohort from amongst several other patient 
groups.95
Sampling of the control cohorts was described as 
random in four studies,87,90,91,93 with the sampling 
methods being unclear in five studies;38,88,89,94,95 the 
remaining studies involved volunteers.62,92 DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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All of the control cohorts comprised more than 
100 individuals. One cohort comprised 200 
individuals,95 one 250 individuals,89 and the two 
largest control cohorts contained 40462 and 41091 
subjects. Only two studies38,92 reported that the 
individuals in the control cohort were unrelated 
to one another, and in one study89 the inclusion 
criteria allowed for related individuals to be 
included. 
Only one study92 reported some additional 
characteristics for the control cohort, and one 
study89 reported age and sex of the cohort, noting 
that these parameters were significantly different 
from those of the haemochromatosis cohort.
Genotyping methodology
To analyse the HFE gene regions encompassing 
the C282Y and H63D mutation sites eight 
studies38,87,88,90–94 isolated genomic DNA and 
performed a PCR followed by restriction 
enzyme digest of the PCR products [restriction 
fragment length polymorphism (RFLP) analysis] 
to determine whether samples carried the two 
mutations of interest. One study95 used this method 
only for H63D mutation determination. The 
primers used for the PCR varied between studies. 
Six studies38,87,88,90–92 published the sequences of 
some or all of the primers used, two studies93,95 
cited a reference and one study94 provided no 
information at all about the PCR primers used. To 
identify wild-type and mutant C282Y PCR products 
by RFLP the restriction enzymes Rsa138,90,93,94 
or SnaB187,88,91,92 were used, and for H63D the 
restriction enzymes Bcl138,87,88,91,92,94,95 or Mbo190,93 
were used. Only two of the studies38,93 using the 
PCR-RFLP method specifically mention that 
primers had been modified to include an internal 
control restriction site. One study90 had analysed 
the C282Y and H63D loci in DNA samples 
from haemochromatosis and control cohorts by 
fluorescent sequencing before conducting the 
PCR-RFLP analysis. Another study,88 in addition 
to the PCR-RFLP analysis, also performed a PCR-
ELISA (enzyme-linked immunosorbent assay) to 
analyse the C282Y mutation, and a single-strand 
conformation polymorphism analysis for capillary 
electrophoresis (SSCP-CE) analysis for both C282Y 
and H63D mutations in the HFE gene.
Two studies performed a PCR and then 
immobilised the PCR products on membranes so 
that hybridisation with normal and mutant versions 
of C282Y62,95 and H63D62 could be carried out to 
identify whether samples carried the mutations of 
interest. One study62 published the sequences of 
the primers used for the PCR and the other study95 
cited a reference. Both studies published the 
sequences of the probes used in the hybridisation. 
One study62 also stated that a number of the PCR 
products had been sequenced to confirm that 
the correct region of the HFE gene had been 
amplified, and samples of known genotype were 
also included as a control in the hybridisations.
In the 10 studies described above samples from 
the haemochromatosis cohort and the control 
cohort were analysed in the same way. In one 
study89 different methods were used for the two 
cohorts. DNA samples from the haemochromatosis 
cohort were sequenced to identify the mutations 
of interest; details of the primers used in the 
sequencing reaction are not provided. DNA 
samples from the control cohort were analysed by 
PCR-RFLP (references are cited for this method) 
and all substitutions detected by RFLP were 
confirmed. For C282Y the RFLP was repeated, and 
for H63D samples were sequenced to confirm the 
result.
Outcomes
All studies reported on the prevalence 
of the HFE mutations C282Y and H63D 
in the haemochromatosis and control 
cohorts. Two studies89,91 also reported on 
the HFE mutation S65C. Other commonly 
reported outcomes included allele 
frequencies in haemochromatosis87,91,94 and/
or control cohorts,62,87,91,94,95 clinical data for 
haemochromatosis patients who were not C282Y 
homozygous,38,87,88,93 genotype–phenotype 
correlations for the haemochromatosis cohort89,94 
or both cohorts,92 and haplotype analysis.38,90 
Withdrawals and dropouts were not applicable to 
these studies but one study reported missing SF 
and TS data for the haemochromatosis group.89
Comparability of groups
In one study89 the haemochromatosis and control 
groups are not comparable in terms of age, sex and 
race/ethnicity and in all other studies it is not clear 
whether the groups are comparable. 
Generalisability
The results of six studies38,87,88,90,92,95 may be 
generalisable in terms of them being from 
representative samples of unrelated Caucasian 
haemochromatosis patients. It is unclear whether 
the results of the other studies are generalisable.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Results of the clinical 
validity studies
Estimates from the included studies of the clinical 
sensitivity, clinical specificity, PPV and negative 
predictive value (NPV) of the genetic mutation 
C282Y for the iron overload phenotype in 
northern European Caucasians are summarised in 
Table 5. 
Sensitivity
Clinical sensitivity ranges from 28.4% to 100% 
as determined from the included studies. The 
definitions of primary iron overload are variable, 
which may account for the wide range. When 
considering only the studies that are most likely to 
correctly define haemochromatosis,38,87,88,90,92,93,95 
clinical sensitivity ranges from 72.2% to 100%. If 
the studies are further limited to those that have 
reported that other causes of iron overload have 
been ruled out and that patients are unrelated, the 
range is 72.2–92.4%.38,87,88,90 The range is 91.3–
92.4% when the small study in southern Germany, 
which may be on the north–south European divide, 
is excluded.88 
TABLE 5  Clinical sensitivity, clinical specificity, positive predictive value (PPV) and negative predictive value (NPV) of DNA testing
Studya Country Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Cardoso et al. 199887 
(n = 87/117)
Sweden 92 100 100 94.4
Hellerbrand et al. 
200188 (n = 36/126)
Germany 72.2 100 100 92.7
Holmstrom et al. 
200289 (n = 296/250)
Sweden 28.4 99.6 98.8 54
Jouanolle et al. 199790 
(n = 132/139)
France 92.4 100 100 93.3
Mura et al. 200591 
(n = 478/410)
France 81.2 99.5 99.5 81.9
Murphy et al. 199862 
(n = 30/404)
Ireland 90 98.8 84.4 99.3
Nielsen et al. 199892 
(n = 92/157)
Germany 94.6 100 100 96.9
Ryan et al. 199893 
(n = 18/109)
Ireland 93.3 100 100 96.5
UK HHC Consortium 
199738 (n = 115/101)
UK 91.3 99 99 91
Vantyghem et al. 
200694 (n = 156/106)
France 21.2 100 100 46.3
Willis et al. 199795 
(n = 18/200)
UK 100 99.5 94.7 100
a  n = number in haemochromatosis group/number in control group.
From two studies the estimated clinical sensitivity 
is low at 28.4%89 and 21.1%.94 This may be 
explained in one study89 by the fact that HFE 
testing was carried out retrospectively in patients 
with clinical suspicion of iron overload based only 
on biochemical measurements, some of which 
were missing. The other study with low clinical 
sensitivity included patients referred to a hospital 
endocrinology and metabolism department with 
excessive alcohol intake and diabetes, in whom 
disturbed iron parameters may have been due to 
cirrhosis and insulin resistance, respectively, and 
not to genetic iron overload.94
Clinical sensitivity was 100% in one small study of 
18 patients, which included related subjects.95 
Specificity
Clinical specificity ranges from 98.8% to 100% 
from the included studies. In two38,89 of the five 
studies that give an estimate below 100%, the 
single individual homozygous for the C282Y 
mutation in the control group showed signs of 
evidence of iron overload. No details are given 
about the homozygous individuals in the control Assessment of clinical validity
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groups of the other three studies62,91,95 so it is 
not known if they showed signs of irregular iron 
loading or whether they would in the future. 
However, specificity may be less than 100% as 
some homozygotes in the control group may never 
exhibit symptoms. 
Positive predictive value and 
negative predictive value
The PPV ranges from 84.3% to 100% and the NPV 
from 46.3% to 100%. As expected these values 
reflect those of the clinical specificity and clinical 
sensitivity, respectively, and show a range of values 
for the reasons given above. Considering the most 
appropriate studies the PPV ranges from 99% to 
100% and the NPV from 91% to 94.4%.
Summary of clinical validity
•	 Eleven studies were identified that could 
be used to estimate the clinical validity of 
genotyping for the C282Y mutation for the 
diagnosis of genetic haemochromatosis.
•	 The quality of the studies using the criteria 
developed for this review is variable. 
•	 The studies used a range of definitions for 
the clinical phenotype. Six of the studies used 
criteria likely to correctly classify HHC, the 
results of which are likely to be generalisable.
•	 The clinical sensitivity of C282Y homozygosity 
for HHC ranged from 28.4% to 100% in 
the 11 studies. When using only the six 
studies most likely to have correctly defined 
haemochromatosis, sensitivity ranged from 
72.2% to 100%. By further limiting the 
studies to those that have reported ruling 
out other causes of iron overload and related 
patients, the range is 72.2–92.4%. The range 
is 91.3–92.4% when only the most northerly 
populations are included. 
•	 When strict inclusion criteria for phenotypic 
expression are used in relevant populations the 
clinical sensitivity increases.
•	 Clinical specificity ranged from 98.8% to 100%. DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Chapter 5  
Clinical utility
N
o clinical effectiveness studies meeting 
the inclusion criteria for the review were 
identified. Two cost-effectiveness studies were 
identified and are reported in Chapter 7 
(Systematic review of the literature).DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Chapter 6  
Psychosocial aspects of DNA testing
D
NA-based testing for mutations in the HFE 
gene can be conducted to confirm a diagnosis 
of HHC in those who already have clinically 
apparent symptoms of iron overload. The DNA 
test can also identify people who may be at risk of 
developing iron overload enabling them to benefit 
from early treatment. However, the low penetrance 
of this disorder means that only a proportion of 
those identified as ‘at risk’ will progress to exhibit 
the HHC phenotype. In common with other 
predictive tests (including non-genetic tests) the 
potential harms of testing must also be taken 
into account. Concerns have been raised among 
academics, policy-makers, the media and the public 
that genetic testing may lead to stigmatisation, 
discrimination, family conflict and psychological 
harm.
In this section of the report the literature on 
the psychosocial aspects of DNA testing for 
haemochromatosis in diagnosed and at-risk 
individuals (people with suspected HHC and their 
first-degree relatives) is reviewed to assess the 
psychosocial benefits and harms of adding DNA 
testing to the existing diagnostic algorithms.
Quantity and quality of 
research available 
Three cohort studies met the inclusion criteria 
for the review. One study was a cohort study with 
a control group,96 one cohort study compared 
clinically affected with clinically unaffected 
patients97 and one study compared patients 
according to genotype for one outcome.98 The 
methodological quality of the included studies was 
assessed using the criteria developed by Spitzer 
and colleagues.81 None of the studies was carried 
out in the UK. A summary of the studies is shown 
in Table 6 and the quality assessment of the studies 
is shown in Table 7. Full data extractions are given 
in Appendix 8.
Sampling methods were not clearly reported 
or discussed in any of the cohort studies so it 
is not possible to determine whether sampling 
bias has been avoided. In the report of the 
controlled cohort study96 all patients who met 
the eligibility criteria were invited to take part in 
the study. However, the time frame over which 
patients were enrolled is not reported, and it is 
not clear how many eligible patients there were 
and what proportion of them agreed to enter 
the patient cohort. All eligible patients were also 
invited to participate in one of the uncontrolled 
cohort studies;97 patients were enrolled over a 
2-year period and all completed the baseline 
questionnaire. Power and Adams98 drew their 
participants from two sources. Most (n = 117) were 
patients referred for diagnostic evaluation for 
haemochromatosis, but a second group (n = 25) 
were all of those people identified by a population 
screening study as homozygotes (subsequently nine 
were found to be heterozygotes). The subgroup of 
25 people identified by population screening does 
not meet the inclusion criteria for our review and 
so the results for this group have not been reported 
on except when it has not been possible to separate 
out these results from those of the referred patient 
group. The time frame over which the referred 
patients were enrolled is not given, and again it 
is not clear whether all of the potentially eligible 
referred patients took part.
None of the studies reported whether their sample 
size was likely to be adequate. The control cohort 
in the only controlled study96 comprised 50 
individuals. Patient cohorts ranged in size from 
87 to 142, but two of the studies97,98 subdivided 
their patient cohort into smaller groups for 
some analyses according to genotype98 or clinical 
presentation.97 Only one study98 acknowledges that 
the small sample size for some of the outcomes 
means that there may not have been sufficient 
power to detect significant differences between the 
groups. 
All of the studies reported on objective outcomes 
but none of the studies reported on whether 
blinded assessment was carried out and so it is 
not possible to determine whether the studies 
are free from measurement bias. One study96 did 
report that two independent raters categorised the 
answers to short-answer questions using a coding 
system. Those studies employing the Impact of 
Event Scale (IES),97 the Spielberger State–Trait 
Anxiety Inventory (STAI-State),97,98 the Short-Form Psychosocial aspects of DNA testing
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TABLE 6  Summary of psychosocial studies
Study Design Outcomes Intervention details Age and sex
Hicken et al. 
2004;96 USA
Cohort with 
control
Participation in 
testing; emotional 
reactions; 
understanding 
and knowledge; 
perceived 
effects of testing; 
compliance with 
treatment
HHC cohort (n = 87): Structured 
interview for reporting attitudes about 
genetic testing and understanding 
of genetics and haemochromatosis; 
average delay between genotyping and 
interview was 3 years
Control cohort (n = 50): The 
same structured interview as 
haemochromatosis patients but control 
subjects estimated the reactions that 
they would have if they underwent 
genetic testing
Age: HHC cohort 
53.9 ± 12.5 years 
(range 25–82); control 
cohort 58.5 ± 13.7 
years (range 31–80)
Male (%): HHC 
cohort 55%; control 
cohort 56%
Meiser et 
al. 2005;97 
Australia
Cohort without 
control
STAI-State; SF-
36; Impact of 
Event Scale; 
understanding and 
knowledge
Self-administered questionnaires 
including standardised measures 
of psychological and quality of life 
outcomes (Impact of Event Scale, 
STAI-State short version and SF-36). 
Participants assessed just before clinic 
visit, 2 weeks after clinic visit and 12 
months after clinic visit (n = 101)
Mean age: 45 years 
(range 18–69)
Male (%): 61.6%
Power and 
Adams 2001;98 
Canada
Cohort without 
control
STAI-State; 
Feelings About 
Test Result 
Measure
SF-36 and STAI. Participants completed 
the questionnaires before learning about 
their test results and immediately after 
learning of their test results (n = 117; 
outcomes for which results could not 
be separated include an additional 25 
participants recruited from a screening 
programme)
Age: 46 ± 13 years
Male (%): not 
reported
SF-36, Short-Form 36 Health Survey; STAI-State, Spielberger State–Trait Anxiety Inventory.
TABLE 7  Summary of the quality assessment of the psychosocial outcomes studies81 
Criteria Hicken et al. 200496 Meiser et al. 200597 Power and Adams 200198
Proper random assignment n/a n/a n/a
Proper sampling NR NR NR
Adequate sample size 87 patients, 50 control 
subjects
101 (62 at 12 months) 117 
Objective outcomes Y Y Y
Blind assessment NR NR NR
Objective eligibility criteria Y U U
Reported attrition Y I NR
Comparability of groups N n/a n/a
Generalisability U U U
Y, yes; N, no; U, uncertain; I, incomplete; NR, not reported; n/a, not applicable.
36 Health Survey (SF-36)97,98 and the Feelings 
About Test Result Measure98 commented that these 
instruments had been validated or used in similar 
studies. The validity of the other methods used 
in the studies to assess other outcomes (several of 
which used either a 5-point or a 4-point Likert-type 
scale) was not generally commented on, except in 
one instance when it was acknowledged that the DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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measure of knowledge about haemochromatosis 
had not been validated and therefore its reliability 
and validity characteristics were unknown.97
Eligibility criteria were clearly reported by only 
one study;96 they were unclear in the other two 
studies.97,98 Where the eligibility criteria are 
unclear it is difficult to ascertain whether the 
participants were correctly classified as having, or 
being at risk of, haemochromatosis. In the cohort 
study with a control group96 all participants had 
to be Caucasians over 18 years of age. Those in 
the haemochromatosis cohort also had to have 
haemochromatosis with iron overload, to have 
undergone phlebotomy to reduce or maintain 
ferritin levels at the study centre between January 
1990 and May 2000, and to have been genotyped 
at least 1 year before chart review. Those in the 
control cohort had to report that they did not 
have haemochromatosis and had not undergone 
HFE genotyping. All of the control subjects were 
people with hypertension who were enrolled in a 
hypertension clinical trial. One study97 reported 
only exclusion criteria. Patients were ineligible 
for the study if they were unable to give informed 
consent or if they had limited literacy in English. 
It is not stated explicitly whether all other patients 
were eligible to participate. In the study in which 
participants were drawn from two sources,98 the 
eligibility criteria for the group of participants 
referred to the haemochromatosis clinic were 
unclear. Participants had suspicious symptoms, a 
family history or abnormal iron blood tests, but 
the exact clinical criteria (e.g. what constituted an 
abnormal iron blood test result) are not reported. 
Hicken and colleagues96 clearly report participant 
attrition and the reasons for this. In total, 12% 
of their patient outcome data (interviews with 10 
patients) were pilot data and were included only 
in the analyses of outcomes and attitudes about 
genetic testing. In addition, 34% of patients could 
not recall undergoing HFE genotyping and so were 
not able to contribute data on the psychosocial 
outcomes of genetic testing. The participants 
who could not recall undergoing HFE genotyping 
were not significantly different to those who did 
remember undergoing HFE genotyping in terms 
of age, time since HFE genotyping or knowledge 
about haemochromatosis. The other two studies 
either have incomplete reporting of participant 
attrition97 or do not report or comment on 
participant attrition at all.98 All participants in 
the Meiser and colleagues study97 are reported 
as having completed a baseline questionnaire; 
however, it is apparent from the tables of patient 
characteristics and the results tables that some 
baseline data are missing and this is not discussed 
by the authors. Loss to follow-up at both the 2-week 
and 12-month post-consultation time points 
is reported together with an assessment of the 
differences between participants who were retained 
and those who were lost to the 12-month follow 
up. Participants lost at the 12-month follow-up 
were more likely not to have post-school education 
(p = 0.021) and had significantly worse mental 
health (p = 0.031). Participant attrition is not 
reported or discussed in the remaining study but 
it is clear from the results presented that data are 
not available for all participants.98 In this study 
there is doubt about how many participants have 
contributed to some of the reported outcomes, 
whereas for other outcomes the number of 
participants contributing data is clearly stated.
Only one of the cohort studies included a control 
group.96 The characteristics of both groups 
are provided and it is acknowledged that for 
the characteristics of marital status and health 
insurance there are significant differences between 
the groups with more patients being married in the 
HHC cohort than in the control cohort (82% versus 
58%, p < 0.001) and more patients having health 
insurance in the HHC cohort than in the control 
cohort (98% versus 84%, p < 0.01). The studies 
that did not have a control group subdivided their 
patient cohort in reporting some outcomes. These 
studies did not report on the characteristics of their 
subgroups and whether they were comparable.97,98
Generalisability to the UK population being 
considered in the context of this Health 
Technology Assessment (HTA) report is difficult to 
determine for all of the included studies. Eligibility 
criteria are clearly reported in only one study,96 
although the other two studies97,98 do provide some 
details on the characteristics of the participants. 
One issue not yet discussed, which may also impact 
on the generalisability of the results, is the timing 
of data collection in relation to the execution 
of the genetic test. Only one study assessed all 
participants before they had been informed of their 
genetic testing results.98 However, only the subset of 
25 participants (all homozygotes or heterozygotes) 
was followed up after 1 year and reassessed and 
these participants do not meet the inclusion criteria 
for this review and so their results are not reported 
on here. In the only other study that assessed 
participants before their attendance at the study 
centre,97 genetic testing results were available for 
only 95 of the 101 participants; however, of these 
95 participants, 80 (84.2%) had already learnt of Psychosocial aspects of DNA testing
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their genetic testing result before clinic attendance 
and it is not clear whether they knew of their test 
result when they completed the baseline (preclinic) 
assessment. Only 15.8% learnt their genetic testing 
result when they attended the clinic. This study also 
followed up participants at the later time points of 
2 weeks and 1 year after clinic attendance; however, 
there was substantial loss to follow-up. The length 
of time between genotypic testing and interviewing 
participants is an important issue in the controlled 
cohort study in which the average delay between 
HFE genotyping and study assessment was 3 
years, which may lead to recall bias.96 In this study 
participants were not asked about their feelings at 
the time of the test but they were asked to recall 
details about the information they received before 
HFE genotyping.
Assessment of psychosocial 
aspects of DNA testing
Tables 8–12 summarise the psychosocial aspects of 
DNA testing for haemochromatosis. The outcomes 
are detailed in the following sections; not every 
study reported on each of these outcomes.
Participating in testing
Only one study96 reported outcomes of 
participating in testing (Table 8). Most patients 
who could recall having the genetic test stated that 
they were satisfied with the information they had 
received before the test, had wanted to receive the 
test and had understood the rationale for being 
tested. People who could not recall having the 
genetic test (34%, n = 30) did not contribute to this 
outcome measure. 
Emotional reactions
All three studies reported on the emotional 
reactions experienced by people in response to 
receiving the HFE genetic test (Table 9). However, 
the only common outcome measures among the 
TABLE 8  Summary of outcomes of participating in testing (n = 57)
Participating in testing, Hicken et al. 200496 Mean ± SD (range)a
Satisfaction with information received 3.39 ± 0.59 (2–4)
Wanted to undergo HFE genotyping 3.38 ± 0.56 (2–4)
Understood rationale for testing 3.38 ± 0.59 (2–4)
a  Agreement rated 1–4 (1 = strongly disagree; 4 = strongly agree).
studies were the STAI and the SF-36, which were 
both reported by two studies.97,98 
Spielberger State–Trait Anxiety Inventory
Meiser and colleagues97 surveyed a sample of 
101 patients who attended a haemochromatosis 
clinic and report the mean STAI-State scores for 
both clinically unaffected and clinically affected 
participants (participants were categorised as 
‘affected’ by the study clinician based on published 
criteria, which included the presence of diabetes, 
cardiac involvement, endocrine dysfunction, 
stigmata of the liver and cirrhosis), and the groups 
combined at three time points: baseline, 2 weeks 
post consultation and 12 months post consultation. 
There were no significant differences in the mean 
STAI-State scores of clinically unaffected and 
clinically affected individuals at baseline (p = 0.89). 
Similarly there were no significant differences 
between the clinically unaffected and the clinically 
affected individuals at the two other time points. 
In addition, changes across time points were not 
suggested by the data and Meiser and colleagues 
state that this was confirmed by statistical analyses 
although no details are provided. It was noted, 
however, that the STAI-State scores were high, 
indicating increased levels of generalised anxiety. 
Meiser and colleagues report that there were no 
statistically significant associations between baseline 
generalised anxiety and age, sex, educational level, 
marital status or ferritin levels.
Power and Adams98 used the STAI to assess 
change in emotional reaction before and after 
genetic testing. Participants’ anxiety scores were 
recorded before genotyping was carried out and a 
year after genotyping. As there was no significant 
difference between the mean STAI scores of the 
two patient groups the data were pooled for 
analysis. The combined data are reported here 
although it should be remembered that this 
outcome includes data from the 25 participants 
identified by population screening who do not 
meet the inclusion criteria of this review. When 
all participants were considered as one group the DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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TABLE 9  Summary of outcomes of emotional reactions
STAI-State short version, Meiser et al. 200597
Unaffected mean 
(SD) Affected mean (SD) Total mean (SD) p-value
Baseline 45.8 (7.6), n = 59 45.5 (8.6), n = 26 45.8 (7.7), n = 89 0.89a
2 weeks post consultation 44.6 (7.1), n = 38 46.5 (7.1), n = 18 45.1 (7.0), n = 58 0.37a
12 months post consultation 43.2 (5.9), n = 21 44.6 (5.1), n = 16 43.8 (5.6), n = 37 0.45a
STAI-State, Power and Adams 200198
wt (n = 35) HET (n = 23) HOM (n = 27)
p-value Pre Post Pre Post Pre Post
Pretest and post-test change 
in mean STAI (values read 
from chart)
40.4 38.8 37.2 32.2b 39.7 34.0b < 0.05b
SF-36, Meiser et al. 200597
Unaffected mean 
(SD) Affected mean (SD) Total mean (SD) p-value
PCS at baseline 49.0 (7.7), n = 59 42.9 (10.7), n = 28 46.9 (9.4), n = 91 0.02a,c
PCS at 2 weeks post 
consultation
47.8 (9.4), n = 42 43.6 (10.0), n = 20 46.4 (9.7), n = 65 0.06a
PCS at 12 months post 
consultation
45.1 (11.5), n = 23 41.1 (14.0), n = 17 43.4 (12.6), n = 40 0.50a
MCS at baseline 46.7 (9.7), n = 59 42.3 (10.5), n = 28 45.3 (10.0), n = 91 0.06a
MCS at 2 weeks post 
consultation
47.2 (9.8), n = 42 42.5 (12.0), n = 20 45.6 (10.6), n = 65 0.17a
MCS at 12 months post 
consultation
51.0 (8.5), n = 23 45.7 (9.6), n = 17 48.7 (9.3), n = 40 0.08a
Emotional reactions summary measures, Hicken et al. 200496
Control subjects (anticipated), 
mean rating Patients (actual), mean rating p-value
Positive outcomes 13.14 12.44 > 0.5
Negative outcomes 17.56 13.39 < 0.0001
Emotional reactions individual negative measures (values from graph), Hicken et al. 200496
Control subjects (anticipated), 
mean rating Patients (actual), mean rating p-value
Anxious 3.1 ± 0.6 1.8 ± 0.8 < 0.0001
Sad 2.4 ± 0.7 1.8 ± 0.6 < 0.0001
Angry 1.9 ± 0.7 1.5 ± 0.6 < 0.005
Cost 2.8 ± 0.8 1.7 ± 0.7 < 0.0001
Family conflict 1.7 ± 0.6 1.6 ± 0.6
Job or insurance loss 2.0 ± 0.7 1.9 ± 0.8
Discrimination 2.0 ± 0.6 1.8 ± 0.8
Confidentiality 2.2 ± 0.8 1.9 ± 0.7
continuedPsychosocial aspects of DNA testing
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Impact of Event scale, Meiser et al. 200597
Unaffected mean 
(SD) Affected mean (SD) Total mean (SD) p-value
2 weeks post consultation 4.0 (5.8), n = 44 5.6 (6.8), n = 21 4.6 (6.2), n = 68 0.48a
wt, wild type; HET, heterozygotes; HOM, homozygotes.
a  p-value for comparison between clinically affected and unaffected participants.
b  p-value for comparison with pretest value. These results include data from the 25 participants identified by population 
screening who do not meet the inclusion criteria of this review.
c  Significant at p < 0.05.
TABLE 9  Summary of outcomes of emotional reactions (continued)
mean (± SD) STAI state anxiety score significantly 
decreased from 39.15 (± 11.45) before testing to 
35.54 (± 11.46) after testing (n = 142, p < 0.01). The 
authors also analysed these results according to 
subjects’ genotype (results presented in a figure for 
85 of the 142 participants; reasons for missing data 
not given). This analysis showed that it was only in 
those who discovered that they were homozygotes 
or heterozygotes that anxiety significantly 
decreased (p < 0.05). Those participants who tested 
negative for the C282Y mutation had an anxiety 
level that remained constant before and after the 
test. None of the mean STAI scores lay outside the 
normal range of 25–45.
Short-Form 36
Meiser and colleagues97 used the SF-36 to assess 
health-related quality of life. For all indices of the 
SF-36 subscales, clinically unaffected individuals 
had higher scores (indicating better health or 
well-being) than affected individuals and these 
differences were statistically significant for most 
subscales: role–physical (p < 0.001), bodily pain 
(p = 0.039), general health (p = 0.01), vitality 
(p = 0.01), social functioning (p = 0.017) and mental 
health (p = 0.02). A trend for differences between 
clinically unaffected and affected participants was 
observed for role–emotional (p = 0.092), and no 
statistically significant differences were found for 
physical functioning (p = 0.02). The two summary 
indices of the SF-36 are also reported. Before 
the clinic visit (baseline) affected individuals had 
a statistically significantly lower mean physical 
component score (PCS) than the clinically 
unaffected individuals (p = 0.02). This was the 
only time point at which there was a statistically 
significant difference between the mean PCS of the 
clinically unaffected and clinically affected groups. 
There were no statistically significant differences 
in the mean mental component scores (MCS) of 
the clinically unaffected and affected participants 
at any of the time points. Statistical analyses also 
confirmed that there were no statistically significant 
differences across the time points in the PCS 
for the combined group of clinically unaffected 
and affected participants. There was, however, a 
statistically significant increase in the MCS score 
(that is, better mental health) at the 12-month 
follow-up compared with baseline (no p-value 
reported). There were no statistically significant 
associations between baseline PCS or baseline MCS 
and age, sex, educational level, marital status or 
ferritin levels.
Power and Adams98 report the changes in the 
scores of the SF-36 subscales. As the results for the 
two patient groups were not significantly different 
the groups were analysed together. Once again, 
the combined data are reported here, which 
includes data from the 25 participants identified 
by population screening who do not meet the 
inclusion criteria of this review. The vitality scale of 
the SF-36 significantly improved after participants 
were informed of their genetic test result (p < 0.05). 
The PCS also significantly improved with no 
significant difference in the general health score or 
MCS. There were no significant changes across any 
of the SF-36 subscales according to genetic testing 
result (no numerical results reported in paper and 
it was not possible to read values from the figure).
Study-specific outcomes used in 
reporting emotional reactions
Hicken and colleagues96 report on the emotional 
reactions of patients after the test had been 
carried out. Summary scores for the outcomes of 
genetic testing were created by summing positive 
outcomes (to give a score range of 4–16) and 
negative outcomes (score range 8–32). Patients 
reported HFE genotyping to be as beneficial as the 
control subjects anticipated it would be (patient 
group mean 12.44 versus control group mean 
13.14, p > 0.05), and patients found it to be less 
detrimental than anticipated by control subjects 
(patient group mean 17.56 versus control group 
mean 13.39, p < 0.001). These results are presented 
in a bar chart, which includes error bars to give 
an indication of uncertainty about the mean, and DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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TABLE 10  Summary of outcomes of understanding of the test result
Individual knowledge questions, Hicken et al. 200496
Patients (n = 87) 
correct recall
Control 
subjects 
(n = 50) 
correct recall p-value
Overall recall 65% ± 26% 59% ± 30% > 0.05
Define genetic test 48% 56%
Interpret positive HFE genotype 59% 62%
Immutability of genetic test result 65% 64%
Phlebotomy changes iron levels 81% 86%
Test predicts symptoms 51% 42%
Test indicates current illness 45% 36%
Test predicts when symptoms begin 75% 76%
Children and siblings will have same mutation 49% 52%
Short-answer questions, Hicken et al. 200496
Correct answer
Purpose of phlebotomy 85%
Purpose of annual serum ferritin measurement 79%
Definition of genetic 90%
Difference between HFE genotyping and transferrin saturation test 25%
True–false questions, Hicken et al. 200496
Correct answer
In haemochromatosis the body tends to store too much iron 98%
There is no effective treatment for haemochromatosis 92%
Haemochromatosis is treated by drawing blood to lower iron levels 98%
It is not necessary to treat haemochromatosis unless the person has organ damage 96%
Possible to have haemochromatosis and not know it 99%
About 1 out of every 200 people has haemochromatosis 60%
People with haemochromatosis get sick because too much iron damages organs 97%
Untreated haemochromatosis may lead to early death 97%
There is no cure for haemochromatosis 86%
Haemochromatosis is less common in women 42%
continued
the numerical values have been estimated from 
the chart. The paper does not indicate which 
measure of uncertainty [SD or standard error of 
the mean (SEM)] is indicated by the error bars. In 
addition to the summary measure for positive and 
negative outcomes the individual negative elements 
are also reported in a bar chart (from which the 
numerical values in Table 8 and Appendix 8 have 
been estimated) with some p-values reported in 
the text. Control subjects expected more anxiety 
(p < 0.0001), sadness (p < 0.0001) and anger 
(p < 0.005) and expected to have more difficulty 
paying for genetic testing (p < 0.0001) than was 
reported by patients. There were no significant 
differences between patients and control subjects 
for the other negative outcomes of family 
conflict, job or insurance loss, discrimination and 
confidentiality.Psychosocial aspects of DNA testing
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True–false questions, Meiser et al. 200597
Correct 
answer 
2-week 
follow-up
Correct 
answer 
12-month 
follow-upa
Regular removal of blood will avoid or reduce many of the symptoms of 
haemochromatosis (True)
93.2% 98.7%
A person who has two copies of the gene change for haemochromatosis is likely to 
develop haemochromatosis (True)
87.3% 87.2%
Hereditary haemochromatosis is uncommon (False) 85.3%a 75.6%
A person who has just one copy of the gene change for haemochromatosis usually will be 
perfectly healthy (True)
76.1% 70.5%
To be at risk of developing haemochromatosis you need to inherit one copy of the gene 
change from each of your parents (True)
71.2%a 69.9%
If a person carries two copies of the haemochromatosis gene change they have a 100% 
chance of passing on the two gene changes to a son or daughter (False)
54.5%a 67.9%
The gene change C282Y is found in most people with haemochromatosis (True) 45.2% 59.6%
Understanding of gene changes, Meiser et al. 200597
Homozygous for 
C282Y or H63D
Heterozygous for 
C282Y or H63D
Compound 
heterozygotes
One gene change, n (%) 7 (16.7) 12 (63.2) 4 (23.5)
Two gene changes, n (%) 28 (66.7) 3 (15.8) 10 (58.8)
Unable to remember, n (%) 7 (16.7) 4 (21.1)  2 (17.6)
a  Three values for the 2-week follow-up and all values for the 12-month follow-up were estimated from a figure in the 
paper.
TABLE 10  Summary of outcomes of understanding of the test result (continued)
TABLE 11  Summary of outcomes of benefits and problems of testing
Common perceived benefits of testing, Hicken et al. 200496
Improved health and prevention of future health problems 40%
Learning risk to self and family 19%
Improved understanding of health 11%
Improved psychological well-being 12%
No benefits identified 19% (n = 11)
Perceived detrimental effects of testing, Hicken et al. 200496
No problems with genetic testing identified 88% (n = 49)
Decreased psychological well-being 2% (n = 1)
Denied health insurance because of HFE genotype 2% (n = 1)
At the 2-week post-consultation time point 
Meiser and colleagues97 administered the 7-item 
intrusion subscale of the IES to measure the 
frequency and severity of intrusive thoughts about 
haemochromatosis. A score of 20 or higher on the 
intrusion subscale of the IES is considered to be 
strongly predictive of a significant stress response 
syndrome. However, only one participant scored 
over 20 when this instrument was administered. 
There was no statistically significant difference 
between the responses of unaffected and affected 
individuals. DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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TABLE 12  Summary of outcomes of compliance with treatment
Compliance with treatment, Hicken et al. 200496
Iron depletion was achieved in 99% of patients
Adherence to maintenance therapy in the first year was 94%
Maintenance therapy dropped by 8% each year in subsequent years
Adherence to maintenance was not associated with demographic factors, barriers to compliance or knowledge of 
haemochromatosis (p > 0.05)
The majority of patients (88%) reported few difficulties with obtaining annual serum measurements
Understanding of test result
Two studies96,97 report outcomes related to 
participants' understanding of their test result 
(Table 10). This information is often embedded 
within, and difficult to separate from, the reporting 
of outcomes on participants' knowledge about 
haemochromatosis. 
The overall recall of information by patients 
reported by Hicken and colleagues96 was not 
significantly different from that of control subjects 
(patients 65% ± 26% versus control subjects 
59% ± 30%, p > 0.5). The percentage of participants 
providing the correct answer to each of the 
individual questions that made up this outcome 
are also reported but if any statistical comparisons 
were made between patients and control subjects 
these are not reported. Hicken and colleagues also 
asked the patient cohort some short-answer and 
true–false questions. The short-answer questions 
were correctly answered by 70% of patients 
(range 25–90%) and the true–false questions were 
answered correctly by 87% (range 42–99%). Only 
25% of patients could correctly answer the short-
answer question about the difference between HFE 
genotyping and the TS test. Unsurprisingly the 
patients who could not recall undergoing an HFE 
genotyping test were less likely to understand the 
difference between HFE genotyping and the TS 
test (p < 0.0001).
In total, 101 participants in the study reported by 
Meiser and colleagues97 answered seven true–false 
questions 2 weeks after their consultation. Two 
of the questions assessed their understanding 
of the significance of carrying one or two 
mutations, respectively, for haemochromatosis. 
Most participants responded correctly to these 
two questions (76.1% and 87.3%). In total, 93% 
of participants knew that regular removal of 
blood will avoid or reduce many of the symptoms 
of haemochromatosis. The question that fewest 
participants answered correctly assessed whether 
participants knew that the C282Y mutation is 
found in most people with haemochromatosis. 
Only 45.2% of participants knew that this was 
the case. Participants were asked these questions 
again at the 12-month follow-up. The results are 
presented in a figure but the study authors do not 
comment on whether these differed in any way 
to the results obtained at the 2-week follow-up. 
Genetic testing results were available for 95 of 
the 101 participants in the Meiser and colleagues 
study. Of the 95 participants with a genetic testing 
result, 80 (84.2%) had learnt of the outcome 
of their test before their first attendance at the 
clinic and entry into the study. Homozygotes 
and heterozygotes for C282Y and H63D, plus 
compound heterozygotes, were asked at the 2-week 
consultation whether they believed that they had 
one or two gene mutations, or if they could not 
remember. The results for 77 of these participants 
are reported: 69.3% were able to correctly state the 
number of mutations that they carried. There was 
no association between education level and having 
an accurate understanding of the number of gene 
changes associated with one’s particular genetic 
testing result (p = 0.29), and similarly there was 
no association between the presence of a family 
history of haemochromatosis and understanding 
of the number of gene changes associated with the 
genetic testing result (p = 0.53).
Benefits and problems of testing 
perceived after test carried out
The patients in the study by Hicken96 reported 
the positive benefits and negative detrimental 
outcomes that resulted from HFE genotyping on 
two short-answer questions (Table 11). The most 
commonly reported benefit of testing was improved 
health and prevention of future health problems 
(40% of patients). The other reported benefits 
were learning of the risk to self and family (19%), 
improved understanding of health (11%), and 
improved psychological well-being (12%). Eleven 
participants (19%) did not identify any benefit 
of testing. The majority of participants did not 
report any problems from genetic testing (88%). 
Decreased psychological well-being was reported Psychosocial aspects of DNA testing
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by one woman, and one man reported that he had 
been denied health insurance because of his HFE 
genotype.
Compliance with treatment
Hicken and colleagues96 reported on patient 
compliance with treatment recommendations 
(Table 12). Compliance with therapy was defined 
as achieving an SF ≤ 20 ng/ml after undergoing 
serial phlebotomy for iron overload. Iron depletion 
was achieved in 99% of patients. However, 
after achieving iron depletion, adherence to 
maintenance therapy in the following years 
dropped. In the first year after achieving iron 
depletion 94% adhered to maintenance therapy but 
this dropped by 8% each year in subsequent years. 
Adherence to maintenance was not associated with 
demographic factors, barriers to compliance or 
knowledge of haemochromatosis (p > 0.05). The 
majority of patients (88%) reported few difficulties 
with obtaining annual serum measurements.
Meiser and colleagues97 reported that, at the 
12-month follow-up, all participants for whom 
iron studies are recommended (homozygotes and 
compound heterozygotes) reported having ever 
had iron studies, and 96% reported having had 
iron studies in the past year. At the 12-month 
follow-up 62% of those participants who had 
increased SF at baseline reported ever having had 
a venesection, and 57% reported having undergone 
a venesection in the past year, which included 
any that may have been carried out at the actual 
clinic visit. However, it is important to note that 39 
participants (38.6%) had been lost to follow-up by 
the 12-month time point.
Summary of psychosocial 
aspects of DNA testing
•	 Evidence on the psychosocial aspects of DNA 
testing is limited in quality and quantity. Only 
three cohort studies met the inclusion criteria 
for the review and each study assessed and 
reported on the psychosocial outcomes of 
genetic testing for HFE in a different way.
•	 All of the studies had methodological 
limitations. Sampling and blind assessment 
were not discussed or reported in any of 
the studies. Only one study clearly reported 
objective eligibility criteria and sample 
attrition; in the other two studies eligibility 
criteria were unclear and reporting of sample 
attrition was incomplete, therefore the studies 
may have sampling and measurement bias. The 
studies were small and the generalisability of 
these studies to the UK population is difficult 
to determine. 
•	 Generally the results suggest that genetic 
testing in the case of haemochromatosis is 
viewed positively and is well accepted. Genetic 
testing is accompanied by few negative 
psychosocial outcomes and may lead to 
reduced anxiety. 
•	 One cohort study96 with a control group 
sought opinions from people who had been 
HFE genotyped on average 3 years before the 
study took place. Control subjects expected 
to experience statistically significantly more 
anxiety, depression and anger related to a 
positive genetic test than was reported by 
patients.
•	 One study97 assessed psychological distress 
levels in participants before and after 
attendance at a haemochromatosis clinic 
and compared patients clinically affected 
by haemochromatosis with those clinically 
unaffected. No statistically significant 
differences were seen between clinically 
affected and clinically unaffected participants 
at any time point for generalised anxiety 
scores (STAI) or intrusive thoughts. Clinically 
affected participants had significantly lower 
scores on the SF-36 PCS at baseline than 
unaffected participants but scores were no 
longer significantly different at 12 months 
post consultation. STAI-State and PCS did not 
change across time points for both clinically 
affected and clinically unaffected participants 
combined, although a statistically significant 
increase in the SF-36 MCS (i.e. better mental 
health) was observed at the 12-month follow-
up. The mean IES scores suggest only 
moderately high levels of intrusive thoughts 
after genetic testing. 
•	 One study98 assessed psychological effects 
before and after genetic testing using the 
STAI and SF-36. There were significant 
improvements in the vitality subscale of 
the SF-36 and the PCS after participants 
were informed of their genetic test result. 
There were no significant differences in 
the general health score or the MCS before 
and after participants had received their 
genetic test result. No significant deleterious 
psychological effects were found on anxiety; 
anxiety significantly decreased in homozygotes 
and heterozygotes after genetic testing and 
remained constant in C282Y mutation-negative 
cases (possibly because no explanation had 
been found for their presenting symptoms).DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Chapter 7  
Economic evaluation
Introduction
The aim of this chapter is to evaluate adding 
DNA testing to existing diagnostic strategies for 
detecting HHC in groups of patients suspected 
of having the disorder and family members of 
patients with haemochromatosis. A systematic 
review of the literature was conducted to identify 
economic evaluations on the use of genotypic tests 
for the detection of HHC. An economic model 
was developed to compare diagnostic algorithms 
and family testing strategies with and without 
DNA testing. Sections in this chapter will report 
the results of the systematic review and outline the 
components of the economic evaluations, including 
the structure of the economic model, the sources of 
information for costs and benefits and the results of 
the analysis.
Systematic review 
of the literature
A systematic review of the literature was undertaken 
to identify economic evaluations on the use of 
genotypic tests for the detection of HHC. The 
methods for the systematic review are described 
in Chapter 3. The details of the inclusion and 
exclusion criteria are shown in Appendix 1 and the 
search strategies are shown in Appendix 2.
Titles and abstracts of studies identified by 
the search strategy were assessed for potential 
eligibility by two reviewers. The full text of relevant 
papers was obtained and inclusion criteria were 
applied by a health economist and a reviewer. 
Differences in opinion were resolved through 
discussion or by arbitration by a third reviewer if 
necessary.
Economic evaluations were eligible for inclusion 
if they reported on the cost or cost-effectiveness 
of comparing DNA tests with other diagnostic 
strategies including quantitative phlebotomy or 
other iron studies and liver biopsy for Caucasians 
with clinical suspicion of iron overload or relatives 
of suspected cases (Appendix 1). Specialist clinic-
based patient groups (e.g. diabetic clinics) and 
population screening studies were excluded. 
Quantity and quality of research
The literature search identified two published 
economic evaluations that met the inclusion 
criteria.99,100 Studies that were assessed and 
excluded are shown in Appendix 3 with their 
reasons for exclusion. El-Serag and colleagues99 
estimated the cost-effectiveness of screening for 
HHC in family members using genotypic tests 
compared with phenotypic tests and no screening 
in the USA. Adams100 investigated the likely cost of 
genotyping spouses and whether this would reduce 
the number of investigations of children in Canada. 
The quality of these economic evaluations has been 
assessed using a standard checklist adapted from 
Drummond and Jefferson82 (Table 13) and the two 
studies are discussed in more detail below. 
Both studies clearly defined the study question and 
explained the competing alternatives. They each 
used the correct comparator and the patient group 
of interest was clearly stated and appropriate. 
Furthermore the study type appeared reasonable: 
Adams100 used a cost-minimisation model and El-
Serag and colleagues99 used a cost–utility model. 
Both studies were conducted in North America and 
so it is unclear how these studies relate to the UK 
NHS.
Adams100 did not consider long-term costs and 
consequences. El-Serag and colleagues100 used a 
lifetime horizon and estimated incremental cost-
effectiveness with appropriate discounting rates. 
They also presented sensitivity analyses of the key 
parameters. It is unclear whether the studies valued 
the costs and consequences appropriately. Adams100 
does not report the source of costs used in the 
study or how these costs were derived. El-Serag and 
colleagues100 seem to have included all of the costs 
relevant to HHC and screening; however, these 
have been taken from earlier studies and have 
not been adjusted for time. The data used in the 
model have not been discussed and in many cases 
the sources of the data have not been given. The Economic evaluation
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TABLE 13  Methodological quality of reporting of the cost-effectiveness studies
Quality criteria
El-Serag et al. 
200099 Adams 1998100
Is there a well-defined question? Y Y
Is there a clear description of alternatives (i.e. who did what to whom, where and 
how often)?
Y Y
Has the correct patient group/population of interest been clearly stated? Y Y
Is the correct comparator used? Y Y
Is the study type reasonable? Y Y
Is the perspective of the analysis clearly stated? Y U
Is the perspective employed appropriate? U U
Is the effectiveness of the intervention established? Y Y
Has a lifetime horizon been used for analysis and if not has a shorter time horizon 
been justified?
Y n/a
Are the costs and consequences valued credibly?  U U
Is differential timing considered? Y N
Is incremental analysis performed? Y N
Is sensitivity analysis undertaken and presented clearly?  Y N
Were credible conclusions drawn from the results Y Y
Y, yes; N, no; U, unclear; n/a, not applicable.
conclusions in both of the studies appear credible 
from the results presented.
Results of the published 
economic evaluations
A summary of the results of the published 
economic evaluations is shown in Table 14.
Adams100 estimated the costs of genotyping 
spouses of homozygotes to reduce the number of 
investigations of children. Costs were estimated for 
genotyping all children of homozygotes compared 
with genotyping spouses and then genotyping 
children if the spouse was a heterozygote or 
homozygote. If the spouse was not a homozygote 
or heterozygote, investigations in the children 
would be unnecessary.
A total of 291 children of homozygotes were 
investigated using TS, SF and genetic tests. 
Costs incurred in the phenotypic strategy were 
CDN$58,200. In total, 13 of these children were 
found to be homozygotes in 116 families with 
the C282Y mutation. In the spousal strategy 
116 spouses were genotyped with subsequent 
investigation of 22 children at a total cost of 
CDN$35,600. Therefore the genotyping of the 
spouses reduced the number of investigations in 
children from 291 to 22 with a cost saving of 39%.
El-Serag and colleagues99 developed a decision 
tree model to evaluate screening strategies 
for HHC in siblings and children of affected 
patients. They assumed that a proband had been 
confirmed to have HHC on the basis of standard 
phenotypic criteria. It was estimated that 5% of 
the children would be homozygous, assuming 
that the proband was homozygous and 25% of 
siblings were homozygous. The model estimated 
the life expectancy, qualify of life and costs for 
various screening strategies, and incremental 
cost-effectiveness ratios were calculated compared 
with no screening. For the no screening strategy, 
life expectancy was estimated based on previous 
studies, including that of Adams and colleagues.11 
The serum iron studies strategy entailed measuring 
TS and SF levels in relatives of the proband. 
Screening of children was assumed to start at 10 
years of age and continue until 40 years of age or 
until an abnormal test result was found. Siblings 
were screened once with repeated testing in people 
with elevated values.
There were three strategies for genetic testing. In 
the first genetic testing strategy, the proband was 
tested first and, if found to be homozygous, the 
spouse was tested. Children were gene tested if the 
spouse was heterozygous. Children homozygous for 
C282Y underwent iron studies. If a child was found 
not to be homozygous no further screening was DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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TABLE 14  Summary of cost-effectiveness studies
Adams 1998100  El-Serag et al. 200099
Location Canada USA
Strategy Genotyping spouse of proband homozygote 
with HHC and if homozygous or 
heterozygous gene testing children compared 
with genotyping all children of homozygous 
proband (phenotypic strategy)
No screening among siblings and children
Screening using serum iron studies
Gene testing proband followed by gene testing spouse
Gene testing proband followed by gene testing siblings 
and children
Gene testing siblings and children before the proband
Study type Cost-minimisation model Cost-effectiveness decision tree model
Study group Children and spouses of an affected proband 
with HHC; 291 children of 121 homozygotes
Hypothetical cohort of siblings and children of an affected 
proband with HHC
Results  Phenotypic strategy: 291 children 
investigated; costs incurred CDN$58,200
Genotyping spouse strategy: 116 spouses 
and 22 children genotyped; costs incurred 
CDN$35,600
Cost saving 39% by genotyping spouse
Screening children: screening using iron studies ICER 
US$7934/LYS; gene testing proband followed by spouse 
(for two or more children) ICER US$3665/LYS; gene 
testing proband followed by one child ICER US$508/LYS; 
gene testing children before proband ICER US$12,277/
LYS
Screening siblings: all screening strategies were dominant 
compared with no screening; screening with iron studies 
was the most expensive; gene testing of siblings first had 
lower costs when only one sibling was tested; for two or 
more siblings, gene testing proband first was less costly
Conclusion Genotyping the spouse of a homozygote is 
the most cost-efficient strategy in pedigree 
studies because it leads to more selective 
investigation of children for the HHC gene
Gene testing is a cost-effective method of screening 
relatives of patients with HHC
CDN$, Canadian dollars; ICER, incremental cost-effectiveness ratio; LYS, life-years saved
performed. If the proband was not homozygous the 
child would undergo iron studies.
The next strategy was similar to the first one 
except that the spouse was not gene tested. The 
proband was gene tested followed by gene testing 
of the children or siblings if the proband was 
homozygous. Relatives who were homozygous then 
underwent iron studies. As before, if the proband 
was not homozygous the relative would undergo 
iron studies.
In the final genetic testing strategy the relatives 
were gene tested before the proband. Those 
relatives who were homozygous underwent iron 
testing. If the relative was not homozygous, then 
the proband was gene tested and the relative 
underwent iron studies if the proband was 
homozygous.
Strategies using gene testing were less costly than 
serum iron studies. Compared with no screening, 
gene testing the proband followed by testing of 
a child was the least expensive and most cost-
effective strategy for one child (incremental cost-
effectiveness ratio US$508 per life-year saved). For 
screening two or more children, gene testing the 
spouse if the proband was homozygous was the 
most cost-effective strategy. Compared with the no 
screening strategies for siblings, all strategies cost 
less and yielded greater benefits. 
El-Serag and colleagues99 performed sensitivity 
analyses for the costs of the tests, screening 
frequency and proportions of probands with HFE 
gene mutations. For all sensitivity analyses, HFE 
gene testing remained cost-effective.
SHTAC economic model
The economic evaluations identified in the 
systematic review were of reasonable quality but, 
as discussed above, were not able to answer the 
current research question. In particular there 
were concerns about the generalisability of the Economic evaluation
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evaluations to the UK and incomplete description 
of data sources. The strategy of testing the spouse 
of the proband as outlined in one of the studies 
has the consequence of identifying carriers from 
the general population and therefore merges into 
population screening. In addition, this strategy 
was most efficient when there were more than 
two offspring but the UK current birth rate is less 
than two (see Chapter 8, Other relevant factors). 
As a consequence it was decided to develop a 
de novo economic model to evaluate diagnostic 
testing strategies for HHC in the UK. The models 
identified in the systematic review provided a useful 
background and basis for developing this model, 
although other sources of data/information were 
required.
A comparison of the costs and consequences 
of testing strategies for the diagnosis of 
haemochromatosis was made using decision-
analytic models. Models were constructed in 
Microsoft excel for diagnosing HHC in people 
suspected of having haemochromatosis and 
in family members of patients diagnosed with 
haemochromatosis. The models were constructed 
according to standard modelling methods.101
Costs were derived from primary data from 
previous studies and from national and local NHS 
unit costs. Only direct NHS costs were included 
and hence the model was from the perspective 
of the NHS. The time horizon chosen for the 
model was for the testing and treatment period 
only. It was decided not to model lifelong costs 
and consequences of the diagnostic decision 
because (1) long-term data on the natural history, 
prognosis and quality of life of patients with 
haemochromatosis is poor and (2) the strategies 
chosen detect the same numbers of patients with 
haemochromatosis and so a cost-minimisation 
model is appropriate. 
The economic evaluation focused on estimating the 
number of cases detected by the diagnostic strategy, 
the number of cases treated and the resources used. 
The outcome is reported as cost per case detected 
as this outcome is of most interest to the NHS. 
Differences in costs between the strategies are also 
reported. 
The structure and data inputs of all of the decision 
trees were informed by systematic literature reviews 
(Chapter 4), clinical guidelines and the results of 
systematic searches (Appendices 1 and 10) and 
discussion with clinical experts. 
Economic model structure
The addition of DNA testing to 
diagnostic algorithms in people 
suspected of having haemochromatosis
Before the discovery of the common gene 
mutations, diagnosis of HHC was based on 
clinical suspicion, including persistently raised 
TS and SF with no other diagnosis followed by 
liver biopsy. Since the identification of the gene it 
has been possible to use DNA testing to confirm 
the diagnosis in those in whom it is suspected. 
Liver biopsy then becomes a prognostic test in 
those suspected of having liver damage and can 
be avoided in those with raised iron levels and no 
biochemical evidence of liver damage. 
Decision models were constructed to compare 
the costs and consequences of two diagnostic 
algorithms in people suspected of having HHC 
on the basis of persistently raised TS > 45% and 
SF > 300 mg/l.72 The algorithms for people with 
suspected HHC are liver biopsy for all people and 
genetic testing for all people. The end point of 
both algorithms is detection of a case requiring 
treatment according to current clinical guidelines 
and the reported outcome will be cost per case 
detected. The goal of a diagnostic strategy is to 
improve patient management and ultimately 
patient outcomes. The advantage of the genetic 
testing strategy is that it avoids the use of liver 
biopsy.
The decision tree is shown in Figure 2. For the 
liver biopsy strategy all patients have liver biopsy 
and are either confirmed positive or negative 
phenotypic haemochromatosis. Those who are 
positive will be treated for haemochromatosis and 
those who are negative will not.
For the DNA testing strategy all people receive 
a DNA test, which will be either positive (YY, 
C282Y homozygous) or negative. Those who are 
YD compound heterozygous (C282Y/H63D) will 
be treated in the same way as those who have a 
negative DNA test. This assumption was made 
based on clinical guidelines and expert clinical 
opinion and was a pragmatic approach in view of 
the limited data on the long-term prognosis and 
treatment of YD compound heterozygous patients. 
All patients with raised SF (> 1000 mg/l) receive a 
liver biopsy to check for liver cirrhosis. All patients 
with a positive DNA test will be treated as they are 
assumed to have HHC. Patients with a negative 
DNA test and SF < 1000 mg/l are monitored and 
receive a repeat SF test. If their SF is stable or DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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decreasing then they are not treated, whereas 
those with increasing SF have a liver biopsy to 
confirm haemochromatosis. Those with confirmed 
haemochromatosis will be treated. 
The model can be run for different strategies 
for different TS and SF levels. For the purpose 
of the model a ‘typical’ patient is defined who is 
representative of all patients. For the baseline run 
it is assumed that a typical patient is a 45-year-old 
man because clinical HHC is more common in men 
and raised iron levels will typically appear during 
the middle of the fourth decade of life. The effect 
of patient age or gender is investigated in the 
model through the use of sensitivity analyses.
DNA testing for family members of people 
diagnosed with haemochromatosis
Separate decision models were constructed to 
compare the costs and consequences of two 
testing algorithms in family members of people 
diagnosed with HHC. The algorithms for testing 
family members are biochemical testing for all 
versus genetic testing for all. The end points of 
the algorithms are detection of a case requiring 
treatment according to current clinical guidelines, 
identification of family members at risk for HHC 
who need to be monitored and identification of 
family members who are not at risk for HHC. 
These outcomes will be incorporated into the 
model by considering unnecessary investigation 
of those with false-positive diagnoses and missed 
diagnoses.
The decision tree is shown in Figure 3. For the 
biochemical test strategy relatives have SF and 
TS tests. If they have raised iron levels (positive 
biochemical tests results, i.e. TS > 45% and SF 
> 300 mg/l) according to clinical guidelines,72 they 
are treated; if not they will be monitored to see if 
their iron levels increase. If the iron levels increase, 
they will be treated for HHC.
For the DNA test strategy relatives have a DNA 
test. Those with a positive result (YY, homozygous 
C282Y) have biochemical tests and those with 
raised iron levels (positive biochemical tests results, 
i.e. TS > 45% and SF > 300 mg/l) are treated.72 
Those who do not have raised iron levels (negative 
TS and SF results) are monitored to see if their 
iron levels increase; if they do increase they will 
be treated for HHC, and if they do not they will 
not be treated. Those without a positive DNA test 
for C282Y will not need treatment or any further 
medical investigation for HHC.
For the purpose of the model a typical patient 
is defined who is representative of all patients. 
Siblings will be assumed to be over 45 years of age 
because most new probands will be over 45 years 
of age at diagnosis. Those who are monitored 
will be retested once according to clinical advice. 
Similarly, a typical child will be aged 25 years as 
there is a presumption against testing children 
for conditions that do not directly affect them 
during childhood.102 At this age most will not have 
manifestations of iron overload but we assume that 
FIGURE 2  Decision tree for DNA testing in people suspected of having haemochromatosis. HC, haemochromatosis; LB, liver biopsy; SF, 
serum ferritin; YD, compound heterozygous C282Y/H63D.
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those who develop symptoms of iron overload will 
do so within 20 years and that the proportion of 
children with increased iron levels will rise linearly 
over this time period. The children will be tested 
every 5 years until iron overload is detected, i.e. a 
maximum of five times. 
Data sources used in the models
This section describes the inputs to the models, 
provides justification for their use, details their 
respective sources and explains their role in the 
models. The data used in the models have been 
collected from systematic reviews and systematic 
searches discussed in more detail in Chapter 4 
and Appendix 1. Data sources were chosen for 
the models on the basis of appropriateness to the 
UK and the quality of the data as assessed by the 
reviewers and in consultation with clinical experts.
The literature shows that a range of thresholds is 
used for the diagnostic tests, and there is a wide 
range of results in the accuracy of these tests. Table 
15 shows the data used in the models and also 
the ranges of other data found in the systematic 
searches (Appendix 10). These ranges were used to 
inform appropriate sensitivity analysis ranges. The 
thresholds used here for modelling are TS > 45% 
and SF > 300 mg/l, as used in clinical guidelines.72 
The effect of using different thresholds has been 
shown as a sensitivity analysis below (see Table 
22). The sensitivity and specificity for TS was also 
taken from the clinical guidelines.72 The sensitivity 
and specificity of SF was taken from Moodie and 
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FIGURE 3  Decision tree for the use of DNA testing in family members. SF , serum ferritin; TS, transferrin saturation.
colleagues61 as this UK study reported values for 
different thresholds of SF separately for men and 
women. Liver biopsy is used as the gold standard 
for confirming diagnosis from SF and TS tests and 
so the model assumed that liver biopsy was 100% 
accurate in diagnosing HHC.
Table 16 shows the key inputs to the SHTAC 
decision tree models and the ranges of these 
parameter values found in the data searches. 
The decision tree for people suspected of having 
haemochromatosis required an estimate of the 
prevalence of HHC in those who are referred with 
symptoms of HHC. The data for prevalence for this 
population was scarce with only one relevant study 
found.61 The prevalence of HHC in a population 
with suspected iron overload was estimated from 
this study of 427 patients referred for investigation 
of liver disease from an ethnically mixed 
population in south London.61 The prevalence was 
estimated by excluding those of Afro-Caribbean, 
African, Asian or Mediterranean origin, including 
only those with northern European or Celtic 
origins. The prevalence of HHC in relatives is 
estimated using simple genetic theory.
Although liver biopsy was associated with a small 
risk of death and other complications, for the 
base case we assumed that there were no deaths 
or major events from liver biopsy as in other 
modelling studies.104
Vantyghem and colleagues94 described the makeup 
of 156 subjects recruited in the Endocrinology and DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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TABLE 15  Sensitivity and specificity of diagnostic tests for haemochromatosis
Sensitivity (range) Specificity (range) Source
TS > 45%a 94% (64–100%) 94% (73–100%) Olynyk et al. 1999103
SF > 300 mg/la 73% (50–96%) 85% (85–87%) Moodie et al. 200261
SF > 200 mg/la 73% (70–97%) 70% (70–94%) Moodie et al. 200261
Liver biopsyb 100% 100% Assumption
a  Accuracy of biochemical tests for detecting haemochromatosis.
b  Accuracy of liver biopsy for detecting haemochromatosis.
TABLE 16  Key inputs to SHTAC economic model 
Input valuea Reference/comment
Prevalence of HHC
Population with suspected iron overload 0.038 Moodie et al. 200261 from liver clinic
Siblings 0.25 Mendelian 
Children 0.05 0.5 × 1 in 10 
Among patients with HHC 91.3% (range 90–100%) UK HHC Consortium 199738
Among the general population 0.99% (range 0–1.24%) UK HHC Consortium 199738
Liver biopsy
Death 0 Assumption 
Bleeding requiring transfusion 0 Assumption 
For diagnostic pathways tree
Proportion with raised SF > 1000 mg/l (DNA positive) 39% (range 48%) Vantyghem et al. 200694
Proportion with raised SF > 300 mg/l and < 1000 mg/l 
(DNA positive)
61% (range 48%) Vantyghem et al. 200694
Proportion with raised SF > 1000 mg/l (DNA negative) 24% Vantyghem et al. 200694
Proportion with raised SF > 300 mg/l and < 1000 mg/l 
(DNA negative) 
76% Vantyghem et al. 200694
For family testing tree
Penetrance of HHC men 76% McCune et al. 200660
Penetrance of HHC women 32% McCune et al. 200660
Proportion of offspring with HHC who initially have 
iron overload
20% Assumption
SF, serum ferritin.
a  Range shows the range of alternative data sources found for the parameter.
Metabolism Department of Lille University who 
were referred because of general symptoms of iron 
overload and abnormal iron levels (SF > 300  mg/l 
or TS > 45%). Amongst other data they reported 
the numbers who were homozygous for the C282Y 
mutation with high SF (> 1000  mg/l).
Penetrance is the proportion of people 
homozygous for C282Y who go on to develop 
manifestations of the disease. The penetrance 
depends on the definition of disease (biochemical 
variables or fibrosis, etc.) and hence the value for 
the penetrance varies widely. Economic evaluation
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Costs
As the analysis reflects an NHS perspective, UK-
specific resource use and costing data have been 
used when available. Cost data were obtained from 
a number of primary and secondary sources (Table 
17).
The UK Genetic Testing Network (UKGTN; www.
ukgtn.org) provides information on genetic testing 
in the UK, including information on costing for 
DNA tests from different UK laboratories for 
different diseases and genes. Seven laboratories on 
the GTN website provide information on the cost 
of the genetic test for HHC, with the average cost 
approximately £100 (range £23.60–£140). Based 
on advice from clinicians we assumed that patients’ 
consultations with a nurse or consultant would last 
15 and 30 minutes respectively, and that patients 
would have one consultation with the nurse and 
consultant for the DNA test, liver biopsy or iron 
test. Furthermore we assumed that patients with 
clinical manifestations of disease would require 
approximately 20 venesections to remove iron 
from the blood and then maintain iron levels and 
that they would be seen about seven times by a 
consultant over a 5-year period.105,106 The time 
taken to correct a false diagnosis will vary and such 
patients often receive a liver biopsy to confirm 
diagnosis. For this reason we assumed that people 
incorrectly diagnosed with HHC will have similar 
treatment costs to those correctly diagnosed. We 
further assumed that adults who are monitored 
will receive further iron tests and appointments 
with the nurse and consultant. The day-case cost 
for liver biopsy was derived from the Southampton 
General Hospital Trust and included costs for the 
procedure and accompanying blood tests.107 
TABLE 17  Cost data used in the haemochromatosis decision tree models (price year 2006)
Description Cost  Source
DNA test laboratorya £100 UKGTN108
Iron test laboratorya £11.70b Shepherd et al. 2006107
Venesection treatment (15 minutes)a £8.75 Curtis and Netten 2006109 (Band 5)
Liver biopsy day casea £388.05 Shepherd et al. 2006107
Nurse appointment (15 minutes) £8.75 Curtis and Netten 2006109 (Band 5)
Surgical consultant appointment (30 minutes) £39.00 Curtis and Netten 2006109
Number of treatments 20 Assumption – clinical opinion
Number of monitoring, children 5 Assumption – clinical opinion
Number of monitoring, sibling 1 Assumption – clinical opinion
a  Cost does not include consultant and nurse appointment costs.
b  Cost for serum ferritin or transferrin saturation test.
Results
Each of the decision tree models shown in Figures 
2 and 3 were run with the parameters discussed 
in the sections above. The models estimated the 
number of patients detected with HHC and the 
numbers treated and monitored as appropriate. 
Cost data were used to estimate the total resource 
costs for each strategy and the strategies were 
compared according to cost per case of HHC 
detected. 
Diagnostic tests in people suspected 
of having haemochromatosis
The results for the diagnostic test decision tree 
are for an average man of 45 years of age (as it is 
assumed that HHC will have become manifest by 
this age). The flow diagram (Figure 4) illustrates 
the diagnostic process and shows the numbers of 
people that are treated. The results in this section 
are presented per 100 people who have a positive 
TS and SF result (shown in dotted lines in the 
flow diagram). Based on the chosen accuracy of 
the diagnostic tests, there will be 100 positive 
test results for TS and SF for every 2880 people 
tested for suspected iron overload. Out of these 
2880 people, 109 actually have HHC. Of those 
100 people with positive test results, 75.1 are true 
positives (i.e. the PPV of the combined test is 
75.1%). A total of 2780 people have a negative test 
result. Of these, 34.3 actually have the disease and 
are missed by the biochemical tests. 
Table 18 shows the results for the diagnostic tests 
decision tree, comparing liver biopsy with DNA 
testing for 100 people with signs and symptoms of 
iron overload and a positive test result for TS and 
SF. Each strategy detects a similar number of cases 
(75.1) and misses 1.2 per 100 tested with the initial DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
43
FIGURE 4  Flow diagram of diagnostic tests (based on TS sensitivity = 94%, TS specificity = 94%, SF sensitivity = 73%, SF 
specificity = 85%, prevalence = 0.038, see Tables 15 and 16). SF, serum ferritin; TS, transferrin saturation.
Suspected iron overload tested with TS and SF:
2880 patients (prevalence = 0.038)
Positive TS and SF results:
100 patients
75.1
true positive
24.9
false positive
2745.7
true negative
34.3
false negative
Negative TS and SF results:
2780 patients
TABLE 18  Base-case results for the diagnostic pathways decision tree, per 100 people with a positive test
Liver 
biopsy, n
Cases 
detected, n Monitor, n
Total 
cost, £
Cost saving/
person tested, £
Cost saved/case 
detected, £
Liver biopsy 100.0 75.1 0 83,068
DNA strategy 41.1 75.1 22.9 73,823 92.45 123
TS and SF test as shown in Figure 4. Of those with 
a positive test result for TS and SF, 75.1% actually 
have HHC. In the liver biopsy strategy everyone 
receives a liver biopsy, whereas in the DNA strategy 
only those with a negative DNA test for HHC or 
high SF receive a liver biopsy. Some of those with 
a negative DNA test are monitored to see if their 
SF increases. Thus, the DNA strategy has fewer 
liver biopsies performed but more patients will be 
monitored than in the liver biopsy strategy. The 
extra costs for liver biopsy are more than the extra 
costs of monitoring patients and DNA tests and so 
the DNA strategy will be cost saving. 
The results vary according to the prevalence of 
the disease and the accuracy of the biochemical 
tests. This is illustrated by varying the PPV of the 
tests. PPV is the proportion of those with a positive 
biochemical test who have the disease, and it is 
dependent upon the prevalence of disease and the 
sensitivity and specificity of the tests:110 
PPV = (sensitivity)(prevalence)/[(sensitivity)
(prevalence) + (1 – specificity)(1 – prevalence)]
If the PPV increases, the number of cases detected 
increases and the number of cases monitored in 
the DNA strategy decreases, because there are 
fewer people with a negative DNA test. If the PPV 
decreases, the converse happens. The number of 
liver biopsies performed in the DNA strategy stays 
fairly constant irrespective of the PPV even though 
they may be in different arms of the decision tree 
shown in Figure 2. The total cost saving for both 
scenarios is similar at around £90 per person 
referred. Thus, the cost saving per case detected is 
higher when fewer cases are detected.
This is illustrated in Table 19 with a hypothetical 
PPV of 80%, for example through an increased 
prevalence of 0.05, in which case the cost saved per 
case detected is £115. With a hypothetical PPV of 
44%, for example through a prevalence of 0.01, 
the cost saved per case detected is £216 (Table 20). 
The results are not greatly influenced by changes in 
costs related to the other parameters.
Sensitivity analyses
The parameters in the diagnostic pathways 
decision tree were varied in a series of sensitivity 
analyses and the results are shown in Table 21 
and Figure 5. When possible the parameters were 
varied according to the ranges from the confidence 
intervals of these parameters, otherwise a suitable 
range was chosen after discussion with experts. The 
sensitivity analyses show that the conclusions from 
the decision tree are robust across all reasonable 
parameter ranges, that is, the DNA strategy is cost 
saving compared with the baseline strategy using 
liver biopsy. The results were most sensitive to the Economic evaluation
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TABLE 19  Base-case results for the diagnostic pathways decision tree with a positive predictive value of 0.8
Liver 
biopsy, n
Cases 
detected, n Monitor, n
Total 
cost, £
Cost saving/
person tested, £
Cost saved/case 
detected, £
Liver biopsy 100.0 80.1 0 85,687
DNA test 41.8 80.1 19.4 76,467 92.20 115
TABLE 20  Base-case results for the diagnostic pathways decision tree with a positive predictive value of 0.44
Liver 
biopsy, n
Cases 
detected, n Monitor, n
Total 
cost, £
Cost saving/
person tested, £
Cost saved/case 
detected, £
Liver biopsy  100.0 43.5 0 66,465
DNA test 37.1 43.5 45.2 57,060 94.05 216
TABLE 21  Sensitivity analyses for the diagnostic pathways decision tree
Variable Base case
Inputs Cost saved/case detected, £
Lowa Higha Lowa Higha Range
Proportion raised SF > 1000 mg/l, DNA +ve 0.39 0.22 0.56 190 57 133
TS specificity, % 94 75 99 224 97 127
Costs liver biopsy test, £ 388.05 310.44 465.66 62 184 122
Prevalence in suspected iron overload 0.038 0.016 0.06 169 111 58
Costs DNA test, £ 100 80 120 150 97 53
SF specificity, % 85 75 99 144 93 51
Prevalence of genetic mutation 91.3 90 100 119 150 31
SF sensitivity, % 73 50 99 151 122 29
Proportion raised SF > 1000 mg/l, DNA –ve 0.24 0.16 0.32 132 115 17
TS sensitivity, % 94 75 99 131 122 9
SF, serum ferritin; TS, transferrin saturation.
a  Results in the ‘low’ and ‘high’ columns use inputs from corresponding columns to give the range; the base-case results are 
shown in Table 18.
specificity of the TS test, the cost of the liver biopsy 
test and the proportion of people with a positive 
DNA test for the C282Y mutation and raised SF. 
Results were also estimated for cost per person 
tested. The cost saved per person tested varied 
between £47 and £138 for changes in the cost of 
the liver biopsy but it changed little for changes in 
TS specificity.
Changing the threshold for the biochemical tests
The threshold values for positive TS and SF tests in 
the decision tree were based upon those suggested 
in guidelines. However, other thresholds have been 
suggested in the literature. Therefore a sensitivity 
analysis was performed to investigate the effect of 
changing the threshold values for the biochemical 
tests. Adams and Chakrabarti111 reported the 
accuracy of the TS test for different thresholds 
of 40%, 46% and 55%. Table 22 shows the effect 
of using these different thresholds for TS. With 
a higher threshold there are fewer positive test 
results for TS, fewer people have SF tests and thus 
more people with the disease are missed. In fact, 
more of those with positive test results have the 
condition (PPV). For example, with a TS threshold 
of 55%, the PPV is 100% and the cost saved per 
case detected is £91. On the other hand, with a 
threshold of 40%, the PPV is 70% and the cost 
saved per case detected is £135.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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FIGURE 5  Tornado plot for sensitivity analyses for the diagnostic pathways decision tree. SF, serum ferritin; TS, transferrin sensitivity.
TABLE 22  Model results using different thresholds for transferrin saturationa
Threshold
Sensitivity 
of TS, %
Specificity 
of TS, %
Positive 
TS and 
SF, n
Negative 
TS and 
SF, n
True positive, 
n (PPV)
False 
negative
Cost 
saved/case 
detected, £
40% 92 92 37 963 26 (70%) 12 135
46% 89 95 32 968 25 (78%) 13 119
55% 77 100 21 979 21 (100%) 17 91
PPV, positive predictive value; SF, serum ferritin; TS, transferrin saturation.
a  For 1000 patients tested with TS and SF.
250
Cost saved per case detected (£)
Proportion raised SF > 1000 DNA +ve
200 150 100 50 0
TS specificity
Costs of liver biopsy test
Prevalence suspected iron overload
Costs of DNA test
SF specificity
Prevalence of genetic mutation
SF sensitivity
Proportion raised SF > 1000 DNA –ve
TS sensitivity
The decision tree model was run for 45-year-old 
women. In this group a threshold for SF of 200 mg/l 
has been suggested in the literature.72 Using this 
threshold with other parameters unchanged there 
were 60.1 cases detected and there was a cost saving 
per case detected for the DNA strategy of £155. 
Family testing
Siblings
Table 23 shows the results from the family testing 
decision tree model (Figure 3) for male siblings 
of 45 years of age. The biochemical strategy tests 
all siblings with biochemical tests whereas the 
alternative strategy uses DNA tests. Each strategy 
detects 19% and misses 6% of cases of HHC. More 
people without HHC are treated and monitored 
in the biochemical testing strategy than with the 
DNA test strategy because those with negative 
biochemical tests are monitored. In the DNA 
strategy, although fewer people are monitored, 
the cost is higher than the cost of the biochemical 
strategy because the cost of monitoring is much 
cheaper than the cost of the DNA test. If the cost 
of the DNA test were to fall from £100 to £60, the 
DNA strategy would be the cheaper one. If those 
who were monitored were tested twice (instead of 
only once), the DNA strategy becomes cost saving 
(£79 per case detected). 
An alternative strategy was run for the biochemical 
tests. In this case, if relatives have raised iron 
levels, i.e. TS > 45% and SF > 300 mg/l, they will 
be treated as before. If the SF is < 200 mg/l, they 
will be monitored for a number of months to see 
if their iron levels increase and, if the iron levels 
increase, they will be treated for HHC, otherwise 
they will be discharged. If the SF is between 200 
and 300 mg/l they will receive a DNA test. Those Economic evaluation
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TABLE 23  Base-case results for the family testing decision tree for male siblings, per 100 people tested
Cases 
detected, n
Cases 
treated, n Monitor, n
DNA 
test, n
Total 
cost, £
Additional 
cost/person 
tested, £
Additional cost/
case detected, £
Biochemical 19.0 19.7 86.2 0.0 23,628
DNA testing 19.0 19.1 11.9 100.0 27,423 37.95 200
with a positive DNA test will be treated and those 
with a negative DNA test will be monitored. This 
scenario is very similar to the baseline biochemical 
test strategy because there are few people with 
a SF between 200 and 300 mg/l; it cost an extra 
£3 per case detected compared with the baseline 
biochemical test strategy.
The parameters in the family testing decision 
tree for male siblings were varied in sensitivity 
analyses and the results are shown in Table 24. The 
sensitivity analyses show that the conclusions from 
the decision tree are robust across all reasonable 
parameter ranges, i.e. the DNA strategy is more 
expensive than the baseline biochemical strategy. 
The most sensitive parameters were the cost of the 
DNA test and the specificity of the TS test. Results 
were also estimated for cost per person tested, and 
show that the additional cost per person tested 
varied between £18 and £58 for changes in the 
price of the DNA test.
A sensitivity analysis was run for women of 45 
years of age with a threshold for SF of 200 mg/l and 
a penetrance of 0.32%.60 In this case there were 
eight cases detected and an additional cost per case 
detected for the DNA strategy of £436 compared 
with the biochemical strategy.
Offspring
Table 25 shows the results from the family testing 
decision tree model for offspring of 25 years of 
TABLE 24  Sensitivity analyses for the family testing decision tree for male siblings
Variable Base case
Inputs Additional cost per case detected, £
Lowa Higha Lowa Higha Range
Cost of DNA test, £ 100 80 120 94 305 211
Cost of monitoring, £ 71.15 56.92 85.38 256 144 112
Penetrance, % 76 60 93 253 163 90
TS specificity, % 94 75 99 149 211 62
SF specificity, % 85 75 99 189 215 26
SF, serum ferritin; TS, transferrin saturation.
a  Results in the ‘low’ and ‘high’ columns use inputs from corresponding columns to give range; base-case results are shown 
in Table 23.
age (Figure 3). The biochemical strategy tests 
all offspring with biochemical tests whereas the 
alternative strategy uses DNA tests. The DNA test 
strategy is cheaper than the baseline biochemical 
testing strategy and there are a similar number 
of HHC cases detected using both strategies. In 
the biochemical test strategy there are many more 
people monitored than in the DNA strategy. In this 
case, people are monitored five times, once every 5 
years, and thus the monitoring cost is higher than 
the DNA test cost and so there is a cost saving for 
using DNA tests. These results assumed that 20% of 
offspring with HHC showed manifestations of the 
disease at the time of testing. The results are not 
very sensitive to this assumption.
The parameters in the family testing decision tree 
for offspring were varied in sensitivity analyses and 
the results are shown in Table 26 and Figure 6. The 
sensitivity analyses show that the conclusions from 
the decision tree are valid across all reasonable 
parameter ranges, i.e. the DNA strategy is cost 
saving compared with the baseline strategy. The 
most sensitive parameters were the number of 
times that the offspring are monitored and the 
penetrance of HHC. Results were also estimated 
for cost per person tested and show that the cost 
saved per person tested varied between £139 and 
£423 for changes in the frequency of monitoring. 
A sensitivity analysis was run for women of age 
45 years with a threshold for SF of 200 mg/l and a DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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TABLE 25  Base-case results for the family testing decision tree for offspring, per 100 people tested
Cases 
detected, 
n
Cases 
treated, 
n Monitor, n
DNA 
test, n
Total 
cost, £
Cost saved/
person tested, £
Cost saved/case 
detected, £
Biochemical 3.5 4.4 98.6 0.0 46,753
DNA testing 3.5 3.6 4.4 100.0 18,638 281.15 7982
FIGURE 6  Tornado plot of sensitivity analyses for family testing decision tree for offspring.
14,000
Cost saved per case detected (£)
12,000 10,000 6000 2000 8000 4000 0
Number of monitorings
Penetrance
TS specificity
Cost of DNA test
SF specificity
Cost of monitoring
Initial proportion with iron overload
penetrance of 0.32%.60 In this case, there were 1.5 
cases detected and a cost saved per case detected 
for the DNA strategy of £18,958.
Probabilistic sensitivity analysis
A probabilistic sensitivity analysis (PSA)112 was 
conducted to investigate the uncertainty of the 
model. The probability distributions were fitted 
to each of the model parameters using the high 
and low values from the sensitivity analysis and are 
shown in Appendix 11. The model used Monte 
Carlo simulation to randomly sample values for 
the model inputs and was run for 1000 iterations. 
In the PSA the cost saved per case detected for the 
diagnostic pathways varied between £97 and £187 
for the 25th and 75th percentiles respectively. For 
the family testing decision tree the cost saved per 
case detected varied between £7323 and £9458 
for offspring for the 25th and 75th percentiles 
respectively. For siblings the extra cost per case 
detected varied between £234 and £145 for the 
TABLE 26  Sensitivity analyses for the family testing decision tree for offspring
Variable Base case
Inputs Cost saved per case detected, £
Lowa Higha Lowa Higha Range
Number of monitorings 5 3 7 4144 11,786 7642
Penetrance, % 76 60 93 10,111 6523 3588
TS specificity, % 94 75 99 9867 7430 2437
Cost of DNA test, £ 100 80 120 8550 7415 1135
SF specificity, % 85 75 99 8406 7365 1041
Cost of monitoring, £ 71.15 56.92 85.38 8366 7599 767
Initial proportion with iron overload 0.2 0 0.5 8141 7756 385
a  Results in the ‘low’ and ‘high’ columns use inputs from corresponding columns to give range; base-case results are shown 
in Table 25.Economic evaluation
48
25th and 75th percentiles respectively. More results 
are shown in Appendix 11. 
Summary of results
Systematic review of 
economic evaluations
•	 Two studies were identified that met the 
inclusion criteria for the review.
•	 One study estimated the cost-effectiveness of 
screening for HHC in family members using 
genetic tests compared with a phenotypic test 
and no screening using a cost–utility model.
•	 The other study investigated the likely cost of 
genotyping spouses using a cost-minimisation 
model and whether this would reduce the 
number of investigations of children.
•	 Both studies were of reasonable quality when 
assessed against standard criteria, but as both 
studies were conducted in North America their 
generalisability to the UK is not clear. 
•	 Gene testing was found to be a cost-effective 
method of screening relatives of patients with 
HHC in one study.
•	 In the other study genotyping the spouse of 
a homozygote was found to be the most cost-
efficient strategy in family testing because it 
leads to more selective investigation of children 
for the HFE gene. 
De novo model (SHTAC model)
Diagnostic strategies in people suspected 
of having haemochromatosis
•	 The DNA strategy is cost saving (because of 
the reduction in the number of liver biopsies 
performed). 
•	 The sensitivity analyses show that the 
conclusion that the DNA strategy is cost saving 
is robust across all reasonable parameter 
ranges. 
•	 The results were most sensitive to the specificity 
of the TS test, the cost of the liver biopsy test 
and the proportion of people with a positive 
DNA test for the C282Y mutation with raised 
SF. 
•	 The cost saved per case detected varied 
between £62 and £184 for changes in the cost 
of the liver biopsy. 
Family testing strategies (siblings)
•	 The DNA strategy is not cost saving (because of 
the extra costs of the DNA test). If the cost of 
the DNA test were to fall from £100 to £60, the 
DNA strategy would be the cheaper one.
•	 The sensitivity analyses show that the 
conclusion that the DNA strategy is more 
expensive is robust across all reasonable 
parameter ranges. 
•	 The most sensitive parameters were the cost of 
the DNA test and the specificity of the TS test. 
•	 The additional cost per case detected varied 
between £94 and £305 for changes in the price 
of the DNA test.
Family testing strategies (offspring)
•	 The DNA test strategy is cheaper than the 
baseline biochemical testing strategy.
•	 The sensitivity analyses show that the 
conclusions from the decision tree are valid 
across all reasonable parameter ranges. 
•	 The most sensitive parameters were the 
number of times that the offspring are 
monitored and the penetrance of HHC. 
•	 The cost saved per case detected varied 
between £4144 and £11,786 for changes in the 
frequency of monitoring. DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Chapter 8  
Discussion
Statement of 
principal findings
Clinical validity
Eleven studies were identified that could be used to 
estimate the clinical validity of genotyping for the 
C282Y mutation for the diagnosis of HHC. The 
quality of the studies using the criteria developed 
for this review was variable and the studies used 
a range of definitions for the clinical phenotype. 
The clinical sensitivity of C282Y homozygosity 
for HHC ranged from 28.4% to 100% in the 11 
studies. When using only the studies most likely to 
have correctly defined haemochromatosis, which 
reported ruling out other causes of iron overload 
and related patients and which included the most 
northerly populations, sensitivity ranged from 
91.3% to 92.4%. Clinical specificity ranged from 
98.8% to 100%.
Clinical utility
No clinical effectiveness studies meeting the 
inclusion criteria for the review were identified. 
Two cost-effectiveness studies were identified. One 
study estimated the cost-effectiveness of screening 
for HHC in family members using genetic tests 
compared with phenotypic tests and no screening 
using a cost–utility model. The other study 
investigated the likely cost of genotyping spouses 
using a cost-minimisation model. Both studies 
were of reasonable quality when assessed against 
standard criteria, but as they were conducted 
in North America their generalisability to the 
UK is not clear. Gene testing was found to be a 
cost-effective method of screening relatives of 
patients with HHC. Genotyping the spouse of a 
homozygote was the most cost-efficient strategy 
in family testing because it leads to more selective 
investigation of children for the HFE gene.
Psychosocial aspects 
of DNA testing
Three cohort studies met the inclusion criteria 
for the review. Each study assessed and reported 
on the psychosocial outcomes of genetic testing 
for HFE in a different way. All of the studies had 
methodological limitations and the generalisability 
of these studies is difficult to determine. Generally 
the results suggest that genetic testing in the 
case of haemochromatosis is well accepted, 
is accompanied by few negative psychosocial 
outcomes and may lead to reduced anxiety. Control 
subjects in the one study that had a control group 
anticipated greater anxiety, depression, anger 
and difficulty in affording the genetic test than 
was reported by patients. In one study, clinically 
affected participants had significantly lower 
health-related quality of life as measured by the 
SF-36 PCS before genetic testing than unaffected 
participants, but this was no longer significantly 
different at 12 months post consultation. Another 
study reported significant improvements in the 
vitality subscale of the SF-36 and the PCS after 
participants were informed of their genetic test 
result. For generalised anxiety scores or intrusive 
thoughts, one study reported no statistically 
significant differences between clinically affected 
and clinically unaffected participants before and 
after genetic testing; another study reported that 
anxiety fell significantly in C282Y homozygotes 
and heterozygotes once they received their genetic 
testing results. 
Economic evaluation 
The de novo economic model found that for 
people suspected of having haemochromatosis 
the DNA strategy is cost saving compared with 
the baseline strategy (cost saved per case detected 
£123). This is because the cost savings that result 
from the reduced number of liver biopsies being 
performed are greater than the increased costs of 
monitoring. For family testing the DNA strategy 
is not cost saving in the case of testing siblings as 
the DNA test costs are higher than the reduced 
monitoring costs (additional cost per case detected 
£200). If the cost of the DNA test were to fall 
from £100 to £60, the DNA strategy would be 
the cheaper one. For family testing in the case of 
offspring of people with haemochromatosis, the 
DNA test strategy is cheaper than the baseline 
biochemical testing strategy (cost saved per case 
detected £7982). Sensitivity analyses show that 
the conclusions in each case are robust across all 
reasonable parameter values. Discussion
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Strengths and limitations 
of the assessment 
The review has certain strengths:
•	 It is independent of any vested interest.
•	 The review brings together the evidence for the 
clinical validity, clinical utility and psychosocial 
aspects of DNA testing for haemochromatosis 
following recommendations for evaluating 
a genetic test and applying consistent 
methods of critical appraisal, presentation 
and transparency. In addition, a de novo 
economic model has been developed following 
recognised guidelines. 
•	 The review was guided by the principles 
for undertaking a systematic review. Before 
undertaking the review the methods were set 
out in a research protocol (Appendix 1) and 
this was commented on by an advisory group. 
The protocol defined the research question, 
inclusion criteria, quality criteria, data 
extraction process and methods employed to 
undertake the different stages of the review.
•	 An advisory group has informed the review 
from its initiation up to the development of the 
research protocol and completion of the report.
•	 Systematic searches were undertaken to identify 
data for the economic model and the main 
results summarised and presented.
•	 The quality of the clinical validity studies was 
assessed by criteria developed for the review, 
which combined relevant criteria from existing 
quality assessment tools. 
In contrast, there were certain limitations placed 
upon the review:
•	 The number and type of studies available for 
inclusion in the review were limited. No RCTs 
were identified. 
•	 Synthesis of the included studies was through 
narrative review. Because of the limitations of 
the literature, meta-analysis was deemed not 
appropriate. 
•	 The economic evaluation was limited to a 
cost-minimisation study because of the lack of 
available information on the natural history 
and prognosis of haemochromatosis and 
associated quality of life issues. 
Other relevant factors 
General 
•	 As mentioned in Chapter 3 the method used 
to evaluate DNA testing for HHC was largely 
based on the ACCE model developed by the 
Office of Genomics and Disease Prevention 
(Center for Disease Control, Atlanta, USA) and 
consists of systematic reviews of clinical validity, 
clinical utility and psychosocial aspects, with 
the development of a de novo economic model. 
The literature on the use of DNA testing for 
haemochromatosis is extensive; however, 
studies mostly consider gene frequencies 
in different populations, phenotypic and 
genotypic associations/correlations and 
population screening. The type of study 
employed is not always obvious from the title 
and abstract of publications. Finding studies 
that could be used for the different elements 
of the review was problematic, particularly 
for assessing the clinical validity of a genetic 
test. As such, a pragmatic approach was taken 
by developing different inclusion criteria for 
the different systematic reviews to ensure that 
relevant information was identified whilst 
retaining the focus of the review and allowing 
manageable synthesis of evidence.
Clinical validity
•	 The traditional diagnostic test assessment 
study that estimates the clinical sensitivity 
and clinical specificity of a test requires the 
new test to be compared with a reference 
standard (gold standard). However, this does 
not apply in the case of genetic tests for which  
the gold standard entails gene sequencing to 
detect mutations.113 Potential alternative gold 
standards in the case of haemochromatosis are 
no longer used for diagnostic purposes, such as 
liver biopsy, which is used mostly for prognosis, 
and haplotyping, which has been superseded 
since the discovery of the HFE gene. As such, 
traditional diagnostic test assessment studies 
are inappropriate and are not available or 
applicable in this case. 
•	 The ideal way to assess the clinical validity of 
DNA testing for haemochromatosis would be 
to follow a large group of individuals through 
to expression of phenotypic disease and 
perform genetic testing. No such population-
based cohort studies are available and such 
studies could be considered unethical and are 
therefore unlikely. As such, clinical validity 
has been assessed here by considering studies 
that identify a group of individuals who have 
the primary iron overload phenotype and 
then determining the proportion who are 
C282Y homozygous and by comparing them 
with a control group. The control subjects are 
individuals who do not have the phenotype DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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of interest according to the disease case 
definition.114 It is only through the use of such 
control subjects that an assessment of specificity 
can be made. The use of such studies has 
limitations though in that individuals in the 
control group who test positive may yet go on 
to develop the phenotypic disease. Although 
this risk is likely to be small because of the 
prevalence and penetrance of HHC, it must be 
acknowledged that calculation of the specificity 
of the genetic mutation (C282Y) for HHC from 
such studies may not be accurate. Specificity of 
100% for the homozygous C282Y mutation in 
patients with phenotypic expression has been 
reported.115 
•	 Studies that find the percentage of individuals 
who have the primary iron overload phenotype 
and who have a positive test result for C282Y 
homozygosity to give the clinical sensitivity 
of the mutation are in effect gene frequency 
studies. As such, there is some overlap between 
the epidemiology studies and those included in 
the clinical validity section. 
•	 An associated difficulty in the case of HHC 
is specifying the exact diagnostic criteria 
or reference standard used to define the 
condition. The disease may sometimes be 
defined phenotypically by the presence of 
certain signs and symptoms and at other times 
genotypically by reference to the mutations that 
give rise to the disease. It has been suggested 
that the definition of a genetic disease should 
require both the clinical manifestations and 
the presence of the mutation; however, it has 
also been suggested that the presence of either 
the clinical features or the mutation suffices 
for a definitive diagnosis. In assessing genetic 
testing, as in the case of haemochromatosis, 
the definition of the disease should be by 
reference to signs and symptoms or clinical 
features but not by reference to genotype.114 
The definition of cases may vary from signs 
and symptoms to confirmed iron overload 
with clinical manifestations and this can affect 
the characteristics of the genetic test and the 
reported clinical validity (see below). 
•	 Clinical sensitivity from the included studies 
ranges from 28% to 100%. It can be seen from 
these results that the reliability of estimating 
clinical sensitivity of C282Y homozygosity 
for HHC is particularly susceptible to the 
definition of the clinical phenotype used in the 
studies. When the definition is more rigorous 
and strict criteria for phenotypic expression are 
used, the clinical sensitivity increases.
•	 There are also difficulties associated with 
assessing a prognostic or predictive test when 
the genotype is more highly prevalent than 
the phenotype. In classic rare single gene 
disorders the genotype is an accurate predictor 
of the phenotype because both genotype and 
phenotype are sufficiently rare that if they 
occur together the predictive value is high. 
This is not the case for haemochromatosis 
and will not be the case for the other common 
complex genetic diseases. 
•	 Quality issues of diagnostic test studies are 
different from those in effectiveness studies 
and the quality assessment of clinical validity 
studies in the context of DNA are even further 
removed from the usual issues. Therefore, as 
the clinical validity studies did not conform 
to typical diagnostic accuracy studies or 
observational studies, a modified Spitzer 
assessment tool, incorporating elements from 
QUADAS, was used, which concentrated 
on the issues of particular relevance to 
the studies in question. That is, aspects 
considered for quality assessment included 
whether there was adequate description of 
the haemochromatosis group of patients; the 
likelihood that the definition of disease was 
an accurate reflection of the disease and that 
the patients were a representative sample; 
whether the control population was adequately 
described and appropriate; whether the groups 
were comparable in terms of factors such as 
age, sex and ancestry; whether the DNA tests 
were adequately described and appropriate; 
whether outcomes were fully reported; whether 
there was mention of missing data; and the 
generalisablity of results. 
Clinical utility
•	 The best evidence for the clinical utility of 
a diagnostic test is an RCT with patients 
randomly assigned to alternative diagnostic 
strategies with clinical or cost-effectiveness 
reported.85 In the absence of RCTs it was 
intended to assess the clinical effectiveness 
of DNA testing by using the highest level of 
evidence available that considered suspected 
cases of HHC (or relatives of cases) and 
comparative testing strategies and reported 
patient-based outcomes. No such studies with 
appropriate designs and outcomes were found. 
Some studies that purported to be clinical 
utility studies were problematic in that they 
reported gene frequency without any clinical or 
cost-effectiveness measure. Another example 
of difficulties associated with the literature 
was that some studies which initially appeared 
to be comparing diagnostic strategies in fact Discussion
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compared different groups of patients using 
biochemical and DNA testing algorithms 
rather than suspected HHC patients tested by 
different diagnostic algorithms with or without 
DNA tests to assess the utility of DNA testing. 
•	 Two cost-effectiveness studies were identified. 
Although these were conducted in North 
America and used different approaches from 
that used in the current project, they support 
the case that incorporating DNA testing in 
diagnostic algorithms is likely to be a cost-
saving strategy. 
Psychosocial aspects
•	 The aims of the psychosocial section of the 
review were very specific: to compare the 
psychosocial benefits and harms of adding 
DNA testing to diagnostic algorithms. 
However, there were few studies that could be 
included in the review. An ideal study might 
have randomised people with suspected 
HHC and first-degree relatives into a trial 
in which participants in one arm received 
standard biochemical tests to diagnose HHC 
and those in the second arm received DNA 
testing in addition to the standard biochemical 
tests. With data collection on psychosocial 
outcomes carried out both before and after 
the intervention and disclosure of test results, 
such a study could provide an indication of 
whether the prospect of DNA testing for HHC 
is any more stressful than that of biochemical 
testing. Additionally, such a study might also 
indicate whether receiving DNA test results 
has a greater positive or negative psychosocial 
impact than receiving biochemical test results. 
Longer-term follow-up would be essential to 
capture data for outcomes such as treatment 
compliance, discrimination and stigmatisation. 
•	 The three studies included in this report took 
place in the USA, Canada and Australia and 
therefore it is important to consider the nature 
of the health-care systems in these countries 
as this might impact on the transferability 
of the results to the UK setting. In the USA 
patients must either have health insurance or 
pay for their medical care directly themselves. 
Therefore, in the USA people might be 
expected to have more worries about financial 
and insurance issues in relation to a diagnosis 
of haemochromatosis than those in Canada 
and Australia, which have publicly funded 
health insurance plans, or those in the UK, 
where health care is provided by the NHS.
•	 The three included cohort studies employed 
different methods and reported results in 
different ways, which made it difficult to 
synthesise the evidence and draw any firm 
conclusions from the review. Nevertheless a 
common theme emerges. After people were 
informed of their test results anxiety levels fell 
or remained at pretest result levels and this 
was mirrored in the results for general health-
related quality of life, which either improved in 
some aspects or stayed constant with respect to 
pretest result values. This suggests that when 
the genetic test result confirms a diagnosis of 
HHC this does not have a negative impact 
in terms of anxiety or health-related quality 
of life, and indeed there is some evidence to 
suggest that once the test result is received 
anxiety levels may fall and health-related 
quality of life can improve.
•	 A second common theme that emerges from 
two of the included studies is that most patients 
are able to correctly recall the information that 
they have been given about haemochromatosis. 
However, there were areas in which recall and/
or understanding were poor, for example 
understanding the difference between HFE 
genotyping and the TS test result, and knowing 
that the C282Y mutation is found in most 
people with haemochromatosis. Of particular 
potential concern is the finding in one study 
that 34% of participants did not recall having 
received a genetic test result, and in the 
second study that between 16% and 21% of 
homozygotes, heterozygotes and compound 
heterozygotes were unable to remember 
their mutation status. This highlights the 
importance of comprehensive pretest and post-
test counselling to ensure that patients fully 
understand the test results that they receive.
•	 The limited evidence base in this area does 
not address whether there might be different 
psychosocial effects of testing, depending 
on whether an individual is referred for 
genetic testing because they have signs and 
symptoms suggestive of HHC or whether they 
are asymptomatic and have been referred for 
testing following diagnosis of HHC in a family 
member. 
•	 Population screening studies were not included 
in this review and a comprehensive search for 
such studies was not undertaken. However, 
those population screening studies that were 
excluded from this review (listed in Appendix 
3) report findings that are similar to those 
reported here. For instance, when phenotypic 
and genotypic screening strategies have been 
compared, both have been acceptable79,116 
and little psychological disturbance has 
been apparent in the short term with DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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either strategy.78,117 Negative psychosocial 
consequences have been reported to be rare.118
•	 Although the evidence shows that there are not 
likely to be detrimental psychological effects 
of genetic testing it has been suggested that 
patients would benefit from routine assessment 
of psychological distress and that referral to a 
mental health professional should be available 
for those whose levels suggest a need for 
clinical intervention.97 
Economic evaluation
Diagnostic strategies in people suspected 
of having haemochromatosis
•	 The analysis in this report shows that, in 
people suspected of having HHC, DNA testing 
is cost saving compared with testing using 
liver biopsy. The analysis did not consider 
complications from liver biopsy, such as 
bleeding. Gilmore and colleagues119 estimated 
a death rate of 0.13–0.33% and a bleeding rate 
requiring transfusion of 0.7% for people who 
have ultrasound-guided liver biopsy. These 
rates are for a different patient group with a 
higher risk of haemorrhage and as such were 
not used in the analysis. However, they do 
suggest that had complications been included 
results would have been even more favourable 
towards the DNA testing strategy.  In the DNA 
testing strategy there were less than half the 
number of liver biopsies performed than in 
the liver biopsy testing strategy and so there 
will be a similar reduction in liver biopsy 
complications.
•	 The sensitivity analyses show that the 
conclusions are unlikely to change, even with 
better data. There is some uncertainty about 
the prevalence of HHC in people presenting 
with symptoms of haemochromatosis. The data 
used in the model were taken from a study of 
a liver clinic in south London and may not be 
exactly representative of those with symptoms 
of HHC. However, the cost saved per case 
detected varied little when the prevalence was 
doubled or halved. Furthermore, the DNA test 
strategy remains cost saving for all possible 
values of prevalence.
•	 The results were most sensitive to the specificity 
of the TS test, the cost of the liver biopsy test 
and the proportion of people with a positive 
DNA test for C282Y homozygosity and raised 
SF. The cost saved per case detected varied 
between £62 and £184 for changes in the cost 
of the liver biopsy. 
•	 The results were reported as cost per case 
detected as this was deemed of most relevance 
to the NHS and clinicians. Cost saved per 
person tested for HHC was also investigated. 
These outcomes may produce results that 
are sensitive to the outcome measure used 
and there is a possibility that some results 
may be misleading. For example, the cost 
per case detected is affected by the number 
of cases detected (i.e. the sensitivity of the 
test). However, the sensitivity analyses showed 
similar results for cost saved per person tested 
as for cost per case detected except that the 
results for cost saved per person tested are not 
sensitive to TS specificity. 
•	 The decision tree model does not consider 
long-term costs and consequences of HHC. 
This is because the data on the long-term 
costs and consequences was considered of 
poor quality. Furthermore, the analyses in this 
project detected the same number of cases 
of HHC using both strategies and so a cost-
minimisation model is more appropriate. 
Family testing strategies (siblings)
•	 This analysis shows that DNA testing is not 
a cost-saving strategy compared with testing 
using biochemical tests for screening siblings 
of a patient with HHC. However, if the cost 
of the DNA test were to reduce from £100 to 
£60 the DNA strategy would be the cheaper 
one. Also, the model does not estimate the 
likely inconvenience and anxiety attached 
to monitoring and treating patients without 
HHC. As the DNA strategy monitored 
significantly fewer and treated fewer patients 
who did not have HHC than the biochemical 
strategy this could impact on the long-term 
cost-effectiveness of DNA testing in siblings. 
•	 The sensitivity analyses show that the 
conclusions are unlikely to change, even with 
better data. There is some uncertainty about 
the penetrance of HHC for people with the 
HHC genotype; however, the cost per case 
detected varied little when the penetrance was 
changed. Furthermore the DNA test strategy 
remains more costly for all possible values of 
penetrance. The most sensitive parameters 
were the costs of the DNA test and monitoring. 
The additional cost per case detected varied 
between £94 and £305 for changes in the price 
of the DNA test. 
•	 The additional cost per person tested was also 
investigated and shows similar results, varying 
between £18 and £58 for changes in the price 
of the DNA test. 
•	 A strategy of not screening relatives of patients 
with HHC would require comparing the long-
term costs and consequences of HHC and Discussion
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was not considered for the reasons discussed 
above. Previous studies have reported the 
appropriateness of screening first-degree 
relatives of affected patients.11,99 El-Serag and 
colleagues99 calculated the cost of screening a 
pedigree that consists of up to three siblings 
and found that the screening of family 
members was dominant for all screening 
strategies compared with no screening. In 
contrast to the results in this paper they found 
that screening with serum iron studies was 
more expensive than gene testing although it is 
unclear why from the results reported. 
Family testing strategies (offspring)
•	 This analysis shows that DNA testing is a cost-
saving strategy compared with testing using 
biochemical tests for screening offspring 
of a patient with HHC. The DNA strategy 
monitored significantly fewer patients and 
treated fewer patients who did not have 
HHC than the biochemical strategy. With the 
biochemical testing strategy most children of 
probands would have to undergo repeated 
testing until they reached 40 years of age. In 
the DNA test strategy 95% of these children 
will avoid further unnecessary investigations 
and the associated potential long-term 
uncertainty and anxiety.
•	 As for the other decision tree models the 
sensitivity analyses show that these conclusions 
are unlikely to change, even with better 
data. The most sensitive parameters were 
the number of times that the offspring are 
monitored and the penetrance of HHC. The 
cost saved per case detected varied between 
£4144 and £11,786 for changes in the 
frequency of monitoring. 
•	 The cost saved per person tested varied 
between £139 and £423 for changes in the 
frequency of monitoring.
•	 The model developed here did not include 
a strategy for testing the spouse first before 
testing the offspring. Adams100 recommended 
this strategy to avoid unnecessary investigation 
of offspring of probands. El-Serag and 
colleagues99 found that testing the spouse 
before children was the most cost-effective 
strategy when testing two or more children. 
The current fertility rate in the UK is 1.8 
liveborn children per woman and so such 
analyses are of limited relevance to the UK. 
Also, these previous analyses do not take 
into account the effect of identifying carriers 
of the gene and what further investigations 
might be required. The purpose of testing 
within families is to identify cases that might 
require treatment and those that will not. 
Testing spouses rather than directly testing 
the individual at-risk children is merging into 
population screening for haemochromatosis, 
which is not supported by evidence of 
effectiveness. An additional concern is the 
information and counselling requirements of 
those tested. Although there is little evidence 
that genetic testing for susceptibility to 
haemochromatosis leads to long-term adverse 
psychosocial consequences, mild negative 
effects on participants with indeterminate 
results from screening programmes have been 
noted.120 For these reasons the family testing 
strategy evaluated in the current project was to 
test the offspring directly.
Genetic exceptionalism and 
phenotype versus genotype
•	 It is sometimes argued that information 
derived from a genetic source has special 
properties over that derived from a phenotypic 
source. If this were the case it could be argued 
that the identification of genetic susceptibility 
in haemochromatosis – the ‘at-risk genotype’ – 
has different properties to the identification of 
the iron overload state by phenotypic means. 
However, the diagnosis of haemochromatosis 
is made by combining the genetic information 
with the phenotypic information. It is 
suggested that for clinical purposes the case 
definition should be homozygosity for the 
common C282Y mutation with a raised SF. 
The person with homozygosity and normal 
iron studies is at risk of developing HFE-
related iron overload but does not have 
haemochromatosis. The person who is a 
compound heterozygote with raised SF with 
no other explanation could be regarded as 
having HFE-related haemochromatosis. There 
will be a small group of patients who have 
iron overload with no other explanation who 
are negative for the common mutations in the 
HFE gene. These may be classified as atypical 
haemochromatosis and in a routine clinical 
setting further genetic analysis is impractical. 
Using this combination of genotypic and 
phenotypic information is probably the best 
scenario for clinical decision-making but does 
of course make it difficult to conduct classic 
studies comparing genotype and phenotype.121
•	 The special properties of information derived 
from DNA-based analysis are said to relate to 
issues such as concern for kin, potential for 
discrimination and stigmatisation, the potential 
for long-term storage and ease of access to DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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samples for future analysis, and predictive 
value. However, all of these characteristics can 
be applied to medical and health information 
derived from non-genetic sources. More 
careful analysis suggests that it is not the 
method by which the information is derived 
that gives it special status but the context in 
which that information is used.76 In the case 
of haemochromatosis, as outlined above, the 
clinical definition relies on both genotypic and 
phenotypic information. The context of the 
information is what defines the property of that 
information, not how it is derived. The results 
of the genetic analysis can be used to diagnose 
those who might benefit from treatment, 
to predict those at risk of developing iron 
overload and to rule it out in those not at risk.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Chapter 9  
Conclusions
of DNA testing through a molecular genetic 
laboratory network, which could rationalise 
the use of resources. Access to genetic testing 
and centralisation of test provision in expert 
laboratories in line with the Carter report122 
would lower the cost of testing, improve the cost-
effectiveness of the strategy and improve the 
quality of information provided to clinicians and 
patients.
Suggested research priorities 
It is apparent from this project that the evidence 
base for assessing the use of DNA testing for 
haemochromatosis is limited in quality and in 
quantity and that further primary research in the 
form of prospective long-term follow-up studies 
is required. However, the need for research must 
be tempered by the scale of the problem, which 
involves an inexpensive test, and the uncertainty 
around the added value of such costly research. 
An area of research more likely to be of practical 
value is epidemiological research into the factors, 
both other genetic factors and environmental 
factors, that affect the penetrance of the genetic 
mutation, to identify those people homozygous 
for the mutation who are likely to develop iron 
overload. Use could be made of databases, such 
as the UK Biobank, for case–control studies 
based on the accurate phenotype of proven 
haemochromatosis cases and a large control 
population. 
It is unlikely that further research into the 
psychosocial aspects of the use of DNA testing for 
haemochromatosis will be required as research 
has shown that such testing reduces anxiety and 
because treatment is simple and effective. However, 
this could change if other factors that influence the 
expression of the phenotype were identified.
DNA testing for 
haemochromatosis
The results suggest that using a diagnostic strategy 
that incorporates DNA testing is cost saving in case 
identification and testing of offspring of patients 
with haemochromatosis. The results for siblings 
are more surprising in that they suggest that DNA 
testing is not cost saving (because of DNA test 
costs being higher than the reduced monitoring 
costs). However, in this study, which considered 
cost per case detected, it was not possible to factor 
in the benefit of reassurance and reduction in 
anxiety resulting from DNA testing, which could be 
expected to have an impact on the long-term cost-
effectiveness of DNA testing in siblings. 
As such, the preferred strategy in practice would 
be using DNA testing for case identification and 
for both offspring and siblings of patients with 
haemochromatosis  as this can result in reduced 
anxiety with no adverse effects. 
Implications for 
service provision 
The conclusions drawn from this study suggest 
that DNA testing should be used in conjunction 
with testing iron parameters when there is a clear 
clinical indication of suspicion of being at risk 
for haemochromatosis because of biochemical 
criteria or when being at familial risk for 
haemochromatosis. Although clinical practice 
amongst those expert and interested in the 
management of the condition is already thought 
to follow this strategy, the development and 
dissemination of guidelines to physicians in both 
primary and secondary care is advisable.
There are implications for service delivery in 
that cost volume issues could reduce the cost DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Appendix 1  
Review methods from the research protocol
Methods for reviewing 
effectiveness
The a priori methods used for the review are 
outlined in the following sections. The sources of 
information used are outlined in Appendix 2.
Inclusion and exclusion criteria
Specific inclusion criteria will be defined and 
tailored to each of the systematic reviews and 
systematic searches undertaken. 
The planned inclusion/exclusion criteria for the 
systematic reviews are shown in Table 27.
In addition, the results of systematic literature 
searches to identify relevant studies in the areas 
of the epidemiology of haemochromatosis, 
performance of biochemical tests and 
complications of liver biopsy will be assessed 
against inclusion criteria and used to inform the 
decision models (Table 28). 
The full literature search results will be screened 
by one reviewer and checked by a second reviewer 
to identify all citations that may meet the inclusion 
criteria. Full manuscripts of all selected citations 
will be retrieved and assessed by two reviewers 
TABLE 27  Inclusion criteria for systematic reviews 
Systematic review: 
clinical validity  Systematic review: clinical utility Systematic review: 
psychosocial 
aspects of DNA 
testing  DNA tests
Clinical effectiveness of 
diagnostic strategies
Cost-effectiveness of 
diagnostic strategies
Patients Caucasian patients with 
iron overload, signs and 
symptoms suggestive of 
HHC (defined)
Emphasis to be UK 
populations/north 
European
Caucasian patients with 
iron overload, signs and 
symptoms suggestive of 
HHC (defined)
Relatives of suspected 
cases
Exclude specialist clinic-
based patient groups 
(e.g. diabetic clinics) and 
population screening
Caucasian patients with 
iron overload, signs and 
symptoms suggestive of 
HHC (defined)
Relatives of suspected 
cases
Exclude specialist clinic-
based patient groups 
(e.g. diabetic clinics) and 
population screening
At-risk individuals, 
i.e. suspected HHC 
cases and first-
degree relatives
Intervention DNA tests DNA tests DNA tests DNA tests 
Comparator Control population (e.g. 
healthy control subjects or 
comparator patient group 
attending clinic/hospital for 
non-HHC/iron overload 
reasons) 
Any case identification 
strategy. May include 
liver biopsy to give HII or 
quantitative phlebotomy or 
other iron studies 
Any case identification 
strategy. May include 
liver biopsy to give HII or 
quantitative phlebotomy 
or other iron studies
n/a 
Outcomes Sensitivity and specificity 
(reported or calculable)
Treatment, morbidity, 
mortality, QoL, 
psychosocial (patient-based 
outcomes)
Cost per case detected, 
cost-minimisation, cost-
effectiveness or cost–
utility
Psychosocial 
(treatment 
compliance, 
psychological, legal 
implications, QoL, 
discrimination/
stigmatisation)
Design Controlled cohort or 
case–control 
RCTs, controlled cohort, 
case–control (highest level 
of evidence only) 
Economic evaluations, 
modelling studies
Any primary 
research; 
quantitative and 
qualitative 
HII, hepatic iron index; n/a, not applicable; QoL, quality of life; RCT, randomised controlled trial.Appendix 1
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TABLE 28  Inclusion criteria for systematic searches 
Epidemiology  Biochemical tests  Complications of liver biopsy
Patients Caucasian patients with iron 
overload, signs and symptoms 
suggestive of HHC (defined)
Relatives of suspected cases
Emphasis to be UK populations/
north European
Caucasian patients with iron 
overload, signs and symptoms 
suggestive of HHC (defined)
Caucasian patients with iron 
overload, signs and symptoms 
suggestive of HHC (defined)
If no data, extend to other patients 
having elective biopsy without 
decompensated liver disease
Intervention n/a Transferrin saturation and serum 
ferritin reporting cut-off values
Ultrasound-guided liver biopsy
Comparator n/a Liver biopsy to give HII or 
quantitative phlebotomy or DNA 
(to confirm diagnosis)
Liver biopsy without ultrasound 
Outcomes Incidence, prevalence, natural 
history, penetrance
Sensitivity and specificity, PPV and 
NPV; reported and/or calculable 
Adverse events; complications 
reported as frequencies, 
probabilities
Design Observational studies  RCTs, cohorts, case–control 
(highest level of evidence only)
RCTs 
HII, hepatic iron index; NPV, negative predictive value; PPV, positive predictive index; RCT, randomised controlled trial.
against the inclusion criteria. An inclusion flow 
chart will be developed and used for each paper 
assessed. Disagreements over study inclusion 
will be resolved by consensus or if necessary by 
arbitration by a third reviewer.
Data extraction
The extraction of studies’ findings will be 
conducted by two reviewers using a predesigned 
and piloted data extraction form to avoid any 
errors. Any disagreements between reviewers 
will be resolved by consensus or if necessary by 
arbitration by a third reviewer.
Quality assessment strategy
The methodological quality of included studies will 
be assessed using formal tools specific to the design 
of the study and focusing on possible sources of 
bias. Quality assessment of RCTs will be conducted 
using criteria developed by the NHS Centre for 
Reviews and Dissemination123 and observational 
studies will be assessed using criteria developed 
by Spitzer and colleagues.81 For diagnostic test 
studies quality assessment will be conducted using 
a tool such as the QUADAS (Quality Assessment of 
Diagnostic Accuracy Studies) where appropriate.80 
Quality assessment of economic evaluations will 
be conducted using a checklist adapted from 
those developed by Drummond and Jefferson82 
and Philips and colleagues.83 Study quality will 
be assessed by two reviewers. Any disagreements 
between reviewers will be resolved by consensus 
or if necessary by arbitration involving a third 
reviewer.
Methods of analysis/synthesis
The methods of data synthesis will be determined 
by the nature of the studies identified through 
searches and included in the review. Quantitative 
synthesis of results, for example meta-analysis, 
will be considered if there are several high-
quality studies of the same design, and sources 
of heterogeneity will be investigated by subgroup 
analyses if applicable. The results of any included 
studies suitable for quantitative synthesis will also 
be summarised in a narrative form along with a 
narrative synthesis of the results from studies for 
which quantitative synthesis is not possible. All 
results will also be tabulated.
Evaluation of genetic tests
Various authors have raised issues concerning the 
methods for assessing diagnostic tests and there 
is a consensus that explicit frameworks should be 
developed analogous to those used in studies of 
clinical effectiveness.84,85 The ACCE model has 
been developed by the Office of Genomics and 
Disease Prevention (Center for Disease Control, 
Atlanta, USA), working with the Foundation for 
Blood Research, to evaluate DNA-based genetic 
tests.53 This model takes its name from the four 
components of the evaluation: Analytic validity, 
Clinical validity, Clinical utility and associated 
Ethical, legal and social issues. This model is still in DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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its development stage; however, it provides a useful 
framework to inform the evaluation of genetic tests. 
Analytical validity is the ability of the test to 
accurately and reliably measure the genotype 
of interest and is concerned with assessing test 
performance in the laboratory and is closely related 
to quality assurance of the laboratory processes 
surrounding the test. Clinical validity is defined 
as the ability of the test to detect or predict the 
phenotype (disorder) of interest. Elements of 
clinical validity include clinical sensitivity, clinical 
specificity, and positive and negative predictive 
values of the test (Table 29). The clinical sensitivity 
measures the proportion of individuals with the 
defined disorder, or who will get the disorder in the 
future, and whose test results are positive, whereas 
clinical specificity measures the proportion of 
individuals who do not have the defined clinical 
disorder and whose test results are negative. 
Clinical utility is defined as the likelihood that 
the test will lead to an improved outcome, and 
incorporates assessment of the risk and benefits 
of genetic testing, as well as economic evaluation. 
This is perhaps the most important aspect of the 
evaluation in that it assesses whether testing will 
alter clinical management, benefit those tested and 
at what cost. 
Of particular relevance to this project are questions 
of clinical validity and clinical utility. Additionally, 
the last component of the ACCE framework will 
be covered by considering psychosocial aspects 
of using genetic testing for HHC in terms of 
psychological issues, quality of life, discrimination 
and stigmatisation and legal implications. 
Methods for economic evaluation 
A comparison of the costs and consequences of the 
diagnostic testing strategies with and without DNA 
testing will be made using decision-analytic models. 
These will be populated with data from systematic 
reviews and systematic searches of the literature 
and, when necessary, using guidelines and expert 
opinion. Costs will be derived from primary data 
from previous studies and from national and local 
NHS unit costs. The outcome will be reported as 
cost per case detected.
The structure and data inputs of all of the decision 
trees will be informed by systematic literature 
reviews and the results of systematic searches and 
by discussion with experts. 
TABLE 29  Calculation of components of clinical validity
Test
Participants
Total With disease Without disease
Positive a b a+b
Negative c d c+d
Total a+c b+d a+b+c+d
Sensitivity = a/a+c.
Specificity = d/b+d.
Positive predictive value (PPV) = a/a+ b.
Negative predictive value (NPV) = d/c+d.
PPV and NPV vary with disease prevalence but are useful clinically for ruling the condition in or out.
The ideal study to determine these parameters in the case of HHC is a population-based genotyped cohort of young adults 
followed through life; as this is not possible, a pragmatic approach is to use controlled cohort studies.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Appendix 2  
Sources of information, including 
databases searched and search terms
The following databases were searched for published studies and ongoing research. Searches were 
restricted to the English language and human studies. Bibliographies of related papers were assessed for 
relevant studies.
Databases searched Issues or dates searched
Cochrane Library (Database of Systematic Reviews and 
Controlled Trials Register)
Issue 2, 19 April 2007
MEDLINE (Ovid) 1966–2007 (19 April 2007)
EMBASE (Ovid) 1980–2007 (19 April 2007)
ISI Proceedings 2003–7 (23 April 2007)
NHS Economic Evaluations Database (NHS CRD databases) 23 April 2007
NHS HTA database (NHS CRD databases) 23 April 2007
NHS DARE database (NHS CRD databases) 23 April 2007
ISI Science Citation Index 1970–2007 (23 April 2007)
BIOSIS Previews (EDINA) meeting abstracts 2003–7 (23 April 2007)
HuGeNeT 23 April 2007
EconLit 23 April 2007
MEDION 23 April 2007
National Guidelines Clearinghouse 23 April 2007
UK National Screening Committee 23 April 2007
PsycINFO (OVID) 1985–2007 (23 April 2007)
CINAHL (OVID) 1982–2007 (23 April 2007)
NRR (National Research Register) 23 April 2007Appendix 2
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Search terms used for the diagnosis of 
haemochromatosis were as follows in MEDLINE 
(Ovid): 
1.  Hemochromatosis/
2.  (HHC or HH).ti,ab. 
3.  Metal Metabolism, Inborn Errors/
4.  (hemochromatosis or haemochromatosis).ti,ab.
5.  (hemochromotosis or haemochromotosis).ti,ab. 
6.  (hemachromatosis or haemachromatosis).ti,ab. 
7.  4 or 5 or 6 
8.  hereditary.ti,ab. 
9.  7 and 8 (1328)
10. 1 or 2 or 3 or 9 
11. Ferritin/an, bl, du [Analysis, Blood, Diagnostic 
Use] 
12. Transferrin/an, du, bl 
13. serum iron.ti,ab. 
14. serum ferritin.ti,ab. 
15. transferrin saturat$.ti,ab. 
16. (iron adj3 (overload$or excess$or accumulat$or 
build?up or bind$)).ti,ab. 
17. Iron Overload/di 
18. ((biochem$or liver or blood) adj3 (test$or 
screen$or biopsy or detect$)).ti,ab. 
19. Biopsy/
20. “Serologic Tests”/
21. Blood Chemical Analysis/
22. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 
19 or 20 or 21 
23. exp HLA Antigens/ge, an, bl, du [Genetics, 
Analysis, Blood, Diagnostic Use] 
24. ((family or relat$or parent$or sibling$or 
mother$or father$or brother$or sister$) adj5 
(screen$or test$or detect$or cascad$)).ti,ab. 
25. 23 or 24 
26. (HFE adj5 gene).ti,ab. 
27. (C282Y or H63D).ti,ab. 
28. ((DNA or genetic or gene) adj3 (test$or 
screen$or detect$)).ti,ab. 
29. Homozygote/
30. Genetic Screening/
31. 26 or 27 or 28 or 29 or 30 
32. limit 31 to yr=“1996 – 2006” 
33. 32 or 25 
34. 22 or 33 
35. “Sensitivity and Specificity”/
36. predictive value of tests/
37. false positive reactions/
38. False Negative Reactions/
39. ROC curve/
40. Diagnosis, Differential/
41. Reference Values/
42. (diagnos$adj3 (efficen$or efficac$or 
effectiv$or accuracy or correct or reliab$or 
error$or mistake$or inaccura$or incorrect or 
unreliable)).ti,ab. 
43. (sensitivity adj3 (test or tests)).ti,ab. 
44. (specificity adj3 (test or tests)).ti,ab. 
45. (screen$or test$).mp. 
46. ((detect$or identif$) and (C282Y or H63D or 
HLA-H)).ti,ab. 
47. 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 
43 or 44 or 45 or 46 
48. animal/
49. human/
50. 48 not (48 and 49) 
51. 10 and 34 and 47 
52. 51 not 50 
53. limit 52 to english language 
Search terms for psychosocial aspects were as 
follows in MEDLINE (Ovid):
1.  Hemochromatosis/
2.  (hemochromatosis or haemochromatosis).ti,ab. 
3.  (hemochromotosis or haemochromotosis).ti,ab. 
4.  (hemachromatosis or haemachromatosis).ti,ab. 
5.  2 or 3 or 4 
6.  hereditary.ti,ab. 
7.  5 and 6 
8.  1 or 7 
9.  ((family or relat$or parent$or sibling$or 
mother$or father$or brother$or sister$) adj5 
(screen$or test$or detect$or cascad$)).ti,ab. 
10. (HFE adj5 gene).ti,ab.
11. (C282Y or H63D).ti,ab. 
12. ((DNA or genetic or gene) adj3 (test$or 
screen$or detect$)).ti,ab. 
13. Genetic Screening/
14. (screen$or test$).mp. 
15. 10 or 11 
16. 14 and 15 
17. 9 or 12 or 13 or 14 or 16
18. exp Psychology/
19. psychosocial.mp. 
20. “Patient Acceptance of Health Care”/
21. (accept$or fear$or worr$or perception or 
attitude$or concern$).ti,ab.
22. 18 or 19 or 20 or 21 
23. 17 and 22 and 8 
24. limit 23 to (humans and english language) 
Search terms for epidemiological studies in 
MEDLINE (Ovid) were as follows:
1.  (hemochromatosis or haemochromatosis).ti,ab. 
2.  (hemochromotosis or haemochromotosis).ti,ab. 
3.  (hemachromatosis or haemachromatosis).ti,ab. 
4.  1 or 2 or 3
5.  hereditary.ti,ab. DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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6.  4 and 5 
7.  Hemochromatosis/ep, et [Epidemiology, 
Etiology] 
8.  incidence.ti. 
9.  prevalence.ti. 
10. *incidence/
11. *Prevalence/
12. *Risk Factors/
13. *Time Factors/
14. epidemiol.ti. 
15. etiolog$.ti.
16. aetiolog$.ti. 
17. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16
18. 7 or 6 
19. 17 and 18 
20. limit 19 to (humans and english language) 
Search terms for liver biopsy complications in 
MEDLINE (Ovid) were as follows:
1.  Hemochromatosis/
2.  Liver/
3.  Biopsy/ae, mo, co 
4.  (1 or 2) and 3
5.  (liver biopsy adj5 (complication$or adverse$or 
safety or death)).mp. 
6.  4 or 5
7.  limit 6 to (humans and english language) 
Primary search terms for economic searches in 
MEDLINE (Ovid) were as follows: 
1.  Hemochromatosis/
2.  (HHC or HH).ti,ab. 
3.  Metal Metabolism, Inborn Errors/
4.  (hemochromatosis or haemochromatosis).ti,ab. 
5.  (hemochromotosis or haemochromotosis).ti,ab. 
6.  (hemachromatosis or haemachromatosis).ti,ab. 
7.  4 or 5 or 6 
8.  hereditary.ti,ab.
9.  7 and 8 
10. 1 or 2 or 3 or 9 
55. exp ECONOMICS/
56. exp ECONOMICS, HOSPITAL/
57. exp ECONOMICS, PHARMACEUTICAL/
58. exp ECONOMICS, NURSING/
59. exp ECONOMICS, DENTAL/
60. exp ECONOMICS, MEDICAL/
61. exp “Costs and Cost Analysis”/
62. VALUE OF LIFE/
63. exp MODELS, ECONOMIC/
64. exp FEES/and CHARGES/
65. exp BUDGETS/
66. (economic$or price$or pricing or 
pharmacoeconomic$or pharma economic$).tw. 
67. (cost$or costly or costing$or costed).tw. 
68. (cost$adj2 (benefit$or utilit$or minim$)).tw. 
69. (expenditure$not energy).tw. 
70. (value adj2 (money or monetary)).tw. 
71. budget$.tw. 
72. (economic adj2 burden).tw.
73. “resource use”.ti,ab. 
74. or/55–73 
75. letter.pt. 
76. editorial.pt. 
77. comment.pt.
78. or/75–77 
79. 74 not 78 
80. 10 and 79 
81. limit 80 to (humans and english language) 
The search strategies were translated to run in the 
databases listed above. Full search strategies are 
available upon request.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Appendix 3  
List of excluded studies 
Cadet E, Capron D, Perez AS, Crepin SN, Arlot S, 
Ducroix JP, et al. A targeted approach significantly 
increases the identification rate of patients with 
undiagnosed haemochromatosis. J Intern Med 
2003;253:217–24. (No strategy comparison.)
Cavanaugh JA, Wilson SR, Bassett ML. Genetic testing 
for HFE hemochromatosis in Australia: the value of 
testing relatives of simple heterozygotes. J Gastroenterol 
Hepatol 2002;17:800–3. (Location Australia and no 
control group.)
Datz C, Lalloz MRA, Vogel W, Graziadei I, Hackl 
F, Vautier G, et al. Predominance of the HLA-H 
Cys282Tyr mutation in Austrian patients with genetic 
haemochromatosis. J Hepatol 1997;27:773–9. (Location 
Austria.)
Emery J, Rose P, Harcourt J, Livesey K, Merryweather-
Clarke A, Pointon JJ, et al. Pilot study of early diagnosis 
of hereditary haemochromatosis through systematic case 
finding in primary care. Community Genet 2002;5:262–5. 
(No control group and unclear case definition.)
Gleeson F, Ryan E, Barrett S, Crowe J. Clinical 
expression of haemochromatosis in Irish C282Y 
homozygotes identified through family screening. Eur J 
Gastroenterol Hepatol 2004;16:859–63. (No control group, 
no strategy comparison)
Guttridge MG, Carter K, Worwood M, Darke C. 
Population screening for hemochromatosis by PCR using 
sequence-specific primers. Genet Test 2000;4:111–14. (No 
control group and no strategy comparison.)
Hannuksela J, Niemela O, Leppilampi M, Parkkila 
AK, Koistinen P, Nieminen P, et al. Clinical utility and 
outcome of HFE-genotyping in the search for hereditary 
hemochromatosis. Clin Chim Acta 2003;331:61–7. (No 
control group and no strategy comparison.)
Jackson HA, Bowen DJ, Worwood M. Rapid genetic 
screening for haemochromatosis using heteroduplex 
technology. Br J Haematol 1997;98:856–9. (No control 
group and no strategy comparison.)
Jezequel P, Bargain M, Lellouche F, Geffroy F, Dorval I. 
Allele frequencies of hereditary hemochromatosis gene 
mutations in a local population of west Brittany. Hum 
Genet 1998;102:332–3. (No defined HHC group and no 
strategy comparison.)
Jorquera F, Dominguez A, az-Golpe V, Espinel J, Munoz 
F, Herrera A, et al. C282Y and H63D mutations of the 
Clinical validity and utility
Adams PC, Chakrabarti S. Genotypic/phenotypic 
correlations in genetic hemochromatosis: evolution of 
diagnostic criteria. Gastroenterology 1998;114:319–23. 
(Location Canada.)
Adams PC. Implications of genotyping of spouses to limit 
investigation of children in genetic hemochromatosis. 
Clin Genet 1998;53:176–8. (Location Canada: included 
under cost-effectiveness studies.)
Adams PC, Kertesz AE, McLaren CE, Barr R, 
Bamford A, Chakrabarti S. Population screening for 
hemochromatosis: a comparison of unbound iron-
binding capacity, transferrin saturation, and C282Y 
genotyping in 5,211 voluntary blood donors. Hepatology 
2000;31:1160–4. (Location Canada.) 
Asberg A, Hveem K, Thorstensen K, Ellekjter E, 
Kannelonning K, Fjosne U, et al. Screening for 
hemochromatosis: high prevalence and low morbidity 
in an unselected population of 65,238 persons. Scand J 
Gastroenterol 2001;36:1108–15. (No control group and no 
strategy comparison.)
Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. 
HFE genotype in patients with hemochromatosis and 
other liver diseases. Ann Intern Med 1999;130:953–62. 
(Location USA.)
Bartolo C, McAndrew PE, Sosolik RC, Cawley KA, 
Balcerzak SP, Brandt JT, et al. Differential diagnosis of 
hereditary hemochromatosis from other liver disorders 
by genetic analysis: gene mutation analysis of patients 
previously diagnosed with hemochromatosis by liver 
biopsy. Arch Pathol Lab Med 1998;122:633–7. (Location 
USA.)
Benn HP, Nielsen P, Fischer R, Schwarz D, Engelhardt R, 
Darda C, et al. Screening for hereditary hemochromatosis 
in prospective blood donors. Beitr Infusionsther 
Transfusionsmed 1994;32:314–6. (No control group and 
no strategy comparison.)
Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE 
genotypes on measurements of iron overload in patients 
attending a health appraisal clinic. Ann Intern Med 
2000;133:329–37. (Location USA.)
Cadet E, Capron D, Gallet M, Omanga-Leke ML, 
Boutignon H, Julier C, et al. Reverse cascade screening 
of newborns for hereditary haemochromatosis: a model 
for other late onset diseases? J Med Genet 2005;42:390–5. 
(No control group and no strategy comparison.)Appendix 3
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haemochromatosis gene in patients with iron overload. 
Rev Esp Enferm Dig 2001;93:298–302. (Location Spain; 
excludes southern Europeans.)
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Appendix 4  
Ongoing studies identified from the 
National Research Register
UK Women’s Cohort 
Study phase 2 
NRR data provider: Leeds Teaching Hospitals 
NHS Trust.
Region: Northern/Yorkshire Regional Office.
Project number: N0436165676.
Principal research question: To determine the 
relationship between iron intake, iron status 
and the risk of iron overload in subjects who are 
heterozygous (and homozygous) for two genetic 
mutations (C282Y and H63D) associated with 
haemochromatosis compared with subjects without 
these mutations.
Lead centre name: University of Leeds.
Start date: 1 May 2000.
End date: 30 December 2007 [ongoing at time of 
writing].
Project status: Ongoing.
Funding organisation name: Food Standards 
Agency.
Funding amount: £250,000.
Funding organisation name: NHS R&D Support 
Funding.
Funding reference number: 2007/08.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Appendix 5  
Quality assessment of experimental studies
Quality assessment of clinical validity studiesa
Item Judgementb
1.  Were selection criteria for eligibility of patients objective and clearly described to allow replication?
2.  Is the definition of iron overload likely to correctly classify HHC? 
3.  Did the study use proper sampling so that all patients were equally likely to enter the study?
4.  Was the control population appropriate and clearly described?
5.  Did the study use proper sampling so that all control subjects were equally likely to enter the 
study? 
6.  Was the DNA test method described in sufficient detail to permit replication?
7.  Was the execution of biochemical methods described in sufficient detail to permit replication? 
8.  Were groups under comparison comparable in terms of age, sex and race?
9.  Was there any mention of missing data?
10. Was the sample of patients representative of the patients who will receive the test in practice, i.e. 
are results generalisable? 
a  Modified from QUADAS80 and Spitzer et al.81
b  Given as yes, no or unclear.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Appendix 6  
Quality assessment of observational studies
A
n assessment was used for included studies 
that were not RCTs. These quality criteria 
were adapted from Spitzer and colleagues.81 The 
original checklist was modified to include items 
of particular relevance to assessing observational 
studies.
1.  Does the trial use proper random assignment? 
A study with proper random assignment would 
include multiple conditions with random 
assignment and would use an appropriate 
method for the assignment (e.g. random 
numbers table, computer generated, etc.) with 
allocation concealment. 
2.  Did the study use proper sampling? A study 
with proper sampling would allow for all 
patients to be equally likely to enter the 
study (e.g. patients selected consecutively or 
randomly sampled).
3.  Was the sample size adequate? A proper sample 
size enables adequately precise estimates 
of priority variables found to be significant 
(e.g. can compute confidence intervals within 
relatively small range or relatively small SEM).
4.  Were the criteria for definition or measurement 
of outcomes objective or verifiable? Good 
outcome measures would be defined by 
clear methods for measuring outcomes (i.e. 
an operational definition) that are public, 
verifiable and repeatable.
5.  Were outcomes measured with blind 
assessment? In studies with blind assessment 
those evaluating outcomes are unaware of the 
treatment status of those being evaluated. 
6.  Were objective criteria used for the eligibility 
of subjects? Good eligibility criteria would use 
clear, public, verifiable characteristics, which 
are applied for inclusion and exclusion. 
7.  Were attrition rates (%) provided? A study 
should report the number of patients who 
could not be contacted for outcome measures 
or later, e.g. dropouts or withdrawals because 
of treatment toxicity.
8.  Were groups under comparison comparable? 
Comparable groups show similar results across 
a reasonable range of baseline characteristics 
that could be expected to affect results.
9.  Are the results generalisable? Generalisable 
results come from a sample population that 
is representative of the population to which 
results would be applied.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Appendix 7  
Data extraction of clinical validity studies
Reference and design Intervention Participants Outcome measures
Author: Cardoso et al.87
Year: 1998
Country: Sweden
Study design: Cohort 
with control
Number of centres: One
Funding: Swedish 
Medical Research 
Council, Swedish Society 
of Medicine, Ruth and 
Richard Julins Foundation 
and the Karolinska 
Institute
Tests: DNA 
tests (C282Y 
and H63D) 
Number of participants: Intervention: 87 with HHC; 
control: 117 random healthy Swedish subjects
Sample attrition/dropout: None
Inclusion criteria for study entry: High transferrin 
saturation (> 60% in men and > 50% in women) 
and increased ferritin levels > 300 mg/l and a liver 
biopsy with typical iron staining indicating primary 
HHC
Exclusion criteria for study entry: Siblings of patients 
with HHC in the study were excluded
Characteristics of participants: 67 men with mean 
age of 47 (range 20–73) years and 20 women with 
mean age of 49 years (range 25–72)
Primary outcome: 
Frequency of C282Y and 
H63D mutations
Secondary outcomes:
Method of assessing 
outcomes: Molecular 
genetic analyses of the 
HFE gene (PCR followed 
by enzyme restriction) 
were performed in 
genomic DNA from 
unrelated patients and in 
healthy subjects
Adverse symptoms: n/a
Length of follow-up: n/a
Recruitment dates: Not 
stated
Results
Primary outcome  Intervention HHC Control p-value
C282Y 164 9 < 0.001
H63D 6 29 < 0.01
Other 4 196
Comments
C282Y homozygosity 
Iron overload population 
(defined) Control population  Total 
Yes, DNA test positive a 80 b 0 a+b 80
No, DNA test negative c 7 d 117 c+d 124
Total a+c 87 b+d 117 a+b+c+d 204
Calculate clinical sensitivity, specificity, PPV and NPV if possible and note whether this agrees with any of these values that are 
reported in the text of the paper:
Clinical sensitivity = a/a + c = 80/87 × 100 = 92%
Clinical specificity = d/b + d = 117/117 × 100 = 100%
PPV = a/a + b = 80/80 × 100 = 100%
NPV = d/c + d = 117/124 × 100 = 94.4%
Comments: Of the patients, 92% were homozygous and 4.5% were heterozygous for the C282Y mutationAppendix 7
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Quality assessment by modified QUADAS80 and Spitzer et al.81
Item Judgementa
1. Were selection criteria for eligibility of patients objective and clearly described? Y
2. Is the definition of iron overload likely to correctly classify HHC? Y
3. Did the study use proper sampling so that all patients were equally likely to enter the study? U
4. Was the control population appropriate? U
5. Did the study use proper sampling so that all control subjects were equally likely to enter the 
study?
Y
6. Was the DNA test described in sufficient detail to permit replication? Y
7. Was the execution of the biochemical methods described in sufficient detail to permit 
replication?
N (no details)
8. Were the groups under comparison comparable in terms of age, sex and race? U
9. Was there any mention of missing data? N
10. Was the sample of patients representative of the patients who will receive the test in 
practice, i.e. are the results generalisable?
Y
a  Y, yes; N, no; U, unclear.
Reference 
and design Intervention Participants Outcome measures
Author: 
Hellerbrand et 
al.88
Year: 2001
Country: 
Germany
Study design: 
Cohort with 
control
Number of 
centres: One
Funding: None 
stated
Tests: DNA tests (C282Y 
and H63D)
Number of participants: Intervention: 36 unrelated 
HHC patients; control: 126 healthy hospital 
employees
Sample attrition/dropout: None
Sample crossovers: n/a
Inclusion criteria for study entry: The diagnosis of 
haemochromatosis was based on clinical history 
and exclusion of other causes of iron overload. 
Criteria for HHC: (1) increased transferrin 
saturation (repeatedly > 50%) and elevated serum 
ferritin levels, (2) hepatocellular haemosiderin 
deposits of grade III–IV, (3) hepatic iron index (HII) 
> 1.9 and/or total amount of iron removed (IR) 
> 5 g in men (> 3 g in women)
Exclusion criteria for study entry: Chronic viral 
hepatitis infection
Characteristics of participants: 10 women and 26 
men with a mean age of 56 ± 13 years. All patients 
were Caucasian and their geographical origin was 
southern Germany
Primary outcomes: 
Frequency of C282Y 
and H63D mutations
Secondary outcomes: 
None
Method of assessing 
outcomes: Mutations 
detected using single-
stranded conformation 
polymorphism 
analysis for capillary 
electrophoresis and 
restriction length 
polymorphism
Adverse symptoms: 
None
Length of follow-up: n/a
Recruitment dates: n/aDOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Results
Primary outcomes 
Intervention, n Control, n p-value C282Y  H63D
+/+  –/– 26 0
+/–  +/– 3 0
+/–  –/– 2 6
–/–  –/– 2 88
–/–  +/– 2 29
–/–  +/– 1 3
Comments:
C28Y homozygosity 
Iron overload population 
(defined) Control population  Total 
Yes, DNA test positive a 26 b 0 a+b 26
No, DNA test negative c 10 d 126 c+d 136
Total a+c 36 b+d 126 a+b+c+d 162
Calculate clinical sensitivity, specificity, PPV and NPV if possible and note whether this agrees with any of these values that are 
reported in the text of the paper:
Clinical sensitivity = a/a + c = 26/36 × 100 = 72.2%
Clinical specificity = d/b + d = 126/126 × 100 = 100%
PPV = a/a + b = 26/26 × 100 = 100%
NPV = d/c + d = 126/136 × 100 = 92.7%
Comments: 72.2% were homozygous for the C282Y mutation.
Quality assessment by modified QUADAS80 and Spitzer et al.81
Item Judgementa
1. Were selection criteria for eligibility of patients objective and clearly described? Y
2. Is the definition of iron overload likely to correctly classify HHC? Y
3. Did the study use proper sampling so that all patients were equally likely to enter the study? U
4. Was the control population appropriate? N
5. Did the study use proper sampling so that all control subjects were equally likely to enter the 
study?
U
6. Was the DNA test described in sufficient detail to permit replication? Y
7. Was the execution of the biochemical methods described in sufficient detail to permit 
replication?
N
8. Were the groups under comparison comparable in terms of age, sex and race? U
9. Was there any mention of missing data? N
10. Was the sample of patients representative of the patients who will receive the test in 
practice, i.e. are the results generalisable?
Y
a  Y, yes; N, no; U, unclear.Appendix 7
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Reference 
and design Intervention Participants Outcome measures
Author: 
Holmstrom 
et al.89
Year: 2002
Country: 
Sweden
Study design: 
Controlled 
cohort study
Number of 
centres: One
Funding: 
Swedish 
Medical 
Research 
Council, 
Swedish 
Society of 
Medicine, 
Nanna Svartz 
Foundation, 
Ragnhild 
and Einar 
Lundstroms 
Memory 
Foundation
Tests: DNA 
tests (C282Y, 
H63D and 
S65C); 
serum levels 
of ferritin, 
transferrin 
and iron; total 
haemoglobin; 
iron staining of 
liver biopsies 
(if performed) 
and 
phlebotomy 
treatment 
details 
extracted from 
files for 231 of 
296 patients
Number of participants:
Iron overload cohort: 296
Control cohort: 250
Sample attrition/dropout:
Iron overload cohort: In 78 cases the 
exact serum ferritin value at the time of 
diagnosis could not be found and in 90 
patients data on transferrin saturation 
were missing
Control cohort: Not reported
Sample crossovers: Not applicable
Inclusion criteria for study entry:
Iron overload cohort: Participants were 
selected from those genotyped for HFE 
mutations at the study hospital from 1 
October 1997 to 19 September 2000. All 
had either (1) serum ferritin > 300 mg/l 
(men) or > 200 mg/l (women) or (2) 
transferrin saturation > 50% (men) or 
> 45% (women). Patients with hepatic 
iron staining of grade 1 or more or who 
had been treated with phlebotomies 
were classified as having iron overload
Control cohort: Not specified but were 
recruited from hospital staff, students, 
and their relatives and none had a history 
of liver disease or had received multiple 
blood transfusions
Exclusion criteria for study entry:
Iron overload cohort: Those patients 
found by family screening or those 
related to another subject in the study. 
A further 17 patients were excluded 
who had hyperferritinaemia because 
of acute hepatitis, acute liver failure, 
hepatocellular carcinoma, thyrotoxicosis, 
acute leukaemia or myelodysplastic 
syndrome
Control cohort: None specified 
Characteristics of participants: 
Iron overload cohort: Mean age: 54.5 
(SD 14.8) years; female: 39%
Control cohort: Mean age: 47.7 (SD 
17.9) years; female: 64%
Primary outcome: Frequencies of C282Y, H63D 
and S65C HFE genotypes in patient and control 
cohorts
Secondary outcomes: Iron overload in relation 
to genotype; biochemical iron parameters and 
clinical data in relation to S65C mutation; HFE 
mutations and biochemical iron parameters in 
members of one family
Method of assessing outcomes: 
(1) Mutation analysis: human genomic DNA was 
extracted from peripheral blood leucocytes
Iron overload cohort: Identification of mutations 
in the HFE gene by automatic DNA sequence 
determination, corresponding to the first half 
of exon 2 and the whole of exon 4. The ABI 
Prism Big Dye Primer Cycle Sequencing Kit on 
an ABI Prism 377 DNA Sequencer (PE Applied 
Biosystems) was used
Control cohort: Identification of mutations 
in the HFE gene carried out by restriction 
fragment length polymorphism (RFLP). 
Following electrophoresis on precast 
polyacrylamide gels bands were visualised 
by silver staining using the PlusOne DNA 
Silver Staining kit (Pharmacia Biotech AB). All 
substitutions detected by RFLP were confirmed, 
either by repeating RFLP testing (C282Y) or by 
automatic sequence analysis (H63D, S65C)
(2) Biochemical analysis: serum levels of 
ferritin, transferrin and iron determined by 
automated turbidimetry/nephelometry or 
spectrophototometry. Transferrin saturation 
calculated according to the formula 4(p – 
iron/p – transferrin). Total haemoglobin value 
determined on whole blood samples
Iron overload cohort: Values for serum ferritin 
and/or transferrin saturation and haemoglobin 
count collected retrospectively from patient 
files from the time of diagnosis (before initiation 
of phlebotomy treatment)
Control cohort: Serum ferritin, transferrin 
saturation and haemoglobin count analysed 
from blood samples collected from each 
participant
Adverse symptoms: None reported
Length of follow-up: No follow-up
Recruitment dates: Not reportedDOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Results
Primary outcomes 
Iron overload cohort 
(n = 296), n (%)
Control cohort 
(n = 250), n (%) p-value
C282Y, C282Y 84 (28.4) 1 (0.4) <0.001
C282Y, wt* 30 (10.1) 27 (10.8) <0.001
C282Y, H63D 21 (7.1) 2 (0.8)
H63D, H63D 7 (2.4) 7 (2.8)
H63D, wt* 52 (17.6) 41 (16.4)
wt, wt* 102 (34.5) 172 (68.8)
Comments: Original results table included separate results for the S65C mutation in combination with C282Y, H63D or wt. 
Results above marked with * calculated by reviewer by combining the S65C results with those for C282Y and H63D and wt
The paper also reports that the TfR2 Y205X mutation could not be detected in any of the 44 patients in whom this was 
investigated
C28Y homozygosity 
Iron overload population 
(defined) (n = 296)
Control population 
(n = 250) Total 
Yes, DNA test positive a 84 b 1 a+b 85
No, DNA test negative c 212 d 249 c+d 461
Total a+c 296 b+d 250 a+b+c+d 546
Calculate clinical sensitivity, specificity, PPV and NPV if possible and note whether this agrees with any of these values that are 
reported in the text of the paper:
Clinical sensitivity = a/a + c = 84/296 × 100 = 28.4%
Clinical specificity = d/b + d = 249/250 × 100 = 99.6%
PPV = a/a + b = 84/85 × 100 = 98.8%
NPV = d/c + d = 249/461 × 100 = 54.0%
Comments: 
Quality assessment by modified QUADAS80 and Spitzer et al.81
Item Judgementa
1. Were selection criteria for eligibility of patients objective and clearly described? Y
2. Is the definition of iron overload likely to correctly classify HHC? U
3. Did the study use proper sampling so that all patients were equally likely to enter the study? U
4. Was the control population appropriate? N
5. Did the study use proper sampling so that all control subjects were equally likely to enter the 
study?
U
6. Was the DNA test described in sufficient detail to permit replication? Y
7. Was the execution of the biochemical methods described in sufficient detail to permit 
replication?
U
8. Were the groups under comparison comparable in terms of age, sex and race? N
9. Was there any mention of missing data? Y
10. Was the sample of patients representative of the patients who will receive the test in 
practice, i.e. are the results generalisable?
U
a  Y, yes; N, no; U, unclear.Appendix 7
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Reference 
and design Intervention Participants Outcome measures
Author: 
Jouanolle et 
al.90
Year: 1997
Country: 
France
Study design: 
Controlled 
cohort study
Number of 
centres: Not 
stated
Funding: In 
part by the 
Association 
Francaise 
Contre les 
Myopathies 
and the 
Fondation 
Langlois
Tests: DNA tests (C282Y 
and H63D)
Other interventions 
used: Haplotype analysis
Number of participants: Genetic 
haemochromatosis cohort: 132; random control 
cohort: 139; first-degree relatives: 30
Sample attrition/dropout: Not reported
Sample crossovers: Not applicable
Inclusion criteria for study entry: 
Genetic haemochromatosis cohort: Participants had 
been diagnosed with genetic haemochromatosis 
during the period 1968–89. Diagnosis was based 
on clinical and biological signs in the absence 
of any cause of secondary iron overload with 
at least one of (1) increased stainable iron in 
at least 75% of hepatocytes, (2) hepatic iron 
concentration > 100 mmol/g dry weight, (3) hepatic 
iron index > 2 and (4) > 5 g of iron removed by 
weekly phlebotomy. Most of the patients were 
clinically affected and/or had a family history of 
haemochromatosis
Random control cohort: Not specified but came 
from the general population
First-degree relatives: Spouses or siblings of the 
haemochromatosis patients described above. These 
participants had (1) no sign of iron overload and 
(2) each of his/her haplotype recognised in at least 
one other relative sharing one haplotype with the 
proband without any evidence of iron overload
Exclusion criteria for study entry: None specified 
for any group of participants
Characteristics of participants: Not described for 
any group of participants
Primary outcome: 
Frequencies of C282Y 
and H63D HFE genotypes 
in patient and control 
cohorts, and in first-
degree relatives
Secondary outcomes: 
Haplotype analysis
Method of assessing 
outcomes: Mutation 
analysis: DNA was 
prepared from whole 
blood; C282Y and H63D 
loci were analysed in 
control and patient groups 
by fluorescent sequencing 
and the C282Y and H63D 
mutations were then 
screened using enzymatic 
digestion of PCR products 
(RFLP analysis); five 
microsatellite markers, 
D6S510, HLA-F, MOG, 
D6S105 and D6S1260, 
were analysed by PCR
Adverse symptoms: None 
reported
Length of follow-up: No 
follow-up
Recruitment dates: Not 
reported
Results
Primary outcomes 
Iron overload cohort 
(n = 132), n (%)
Control cohort 
(n = 139), n (%)
First-degree relatives 
cohort (n=30), n (%)
C282Y, C282Y 122 (92.4) 0 (0) 0 (0)
C282Y, wt* 3 (2.3) 5 (3.6) 0 (0)
C282Y, H63D 3 (2.3) 3 (2.2) 0 (0)
H63D, H63D 2 (1.5) 5 (3.6) 0 (0)
H63D, wt* 2 (1.5) 33 (23.7) 9 (30)
wt, wt* 0 (0) 93 (66.9) 21 (70)
Comments: The paper does not report on statistical differences between groups and no p-values are presentedDOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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C28Y homozygosity 
Iron overload population 
(defined) (n = 132) Control population (n = 139) Total 
Yes, DNA test positive a 122 b 0 a+b 122
No, DNA test negative c 10 d 139 c+d 149
Total a+c 132 b+d 139 a+b+c+d 271
Calculate clinical sensitivity, specificity, PPV and NPV if possible and note whether this agrees with any of these values that are 
reported in the text of the paper:
Clinical sensitivity = a/a + c = 122/132 × 100 = 92.4%
Clinical specificity = d/b + d = 139/139 × 100 = 100%
PPV = a/a + b = 122/122 ×100 = 100%
NPV = d/c + d = 139/149 × 100 = 93.3%
Comments: 
Quality assessment by modified QUADAS80 and Spitzer et al.81
Item Judgementa
1. Were selection criteria for eligibility of patients objective and clearly described? Y
2. Is the definition of iron overload likely to correctly classify HHC? Y
3. Did the study use proper sampling so that all patients were equally likely to enter the study? U
4. Was the control population appropriate? N (no information)
5. Did the study use proper sampling so that all control subjects were equally likely to enter the 
study?
Y
6. Was the DNA test described in sufficient detail to permit replication? Y
7. Was the execution of the biochemical methods described in sufficient detail to permit 
replication?
n/a
8. Were the groups under comparison comparable in terms of age, sex and race? U
9. Was there any mention of missing data? N
10. Was the sample of patients representative of the patients who will receive the test in practice, 
i.e. are the results generalisable?
Y
a  Y, yes; N, no; U, unclear; n/a, not applicable.Appendix 7
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Reference 
and design Intervention Participants Outcome measures
Author: 
Mura et al.91
Year: 2005
Country: 
France
Study 
design: 
Controlled 
cohort study
Number of 
centres: Not 
stated
Funding: 
Institut 
National 
de la Santé 
et de la 
Recherche 
Médicale
Tests: DNA tests (C282Y, 
H63D and S65C); iron 
status based on transferrin 
saturation, ferritin 
concentration and serum 
iron concentration
Other interventions used: 
None reported
Number of participants: Haemochromatosis 
cohort: 478; control cohort: 410; other 
patients: 3047
Sample attrition/dropout: Not reported
Sample crossovers: Not applicable
Inclusion criteria for study entry: 
Haemochromatosis cohort: This cohort 
included people diagnosed before and after 
the HFE gene was cloned in 1996. Before 
the HFE gene was cloned clinical diagnosis of 
haemochromatosis was based on classic signs 
and symptoms of the disease: (1) elevated 
transferrin saturation and/or serum ferritin 
concentration, (2) hepatic symptoms, such as 
unexplained elevation of serum liver enzymes, 
cirrhosis, liver failure, or diabetes mellitus and 
(3) non-specific compatible symptoms: fatigue, 
abdominal pain, joint pain, cardiac arrhythmia 
and hyperpigmentation. DNA testing was 
performed retrospectively in this group. 
Since the discovery of the HFE gene, patients 
have undergone DNA testing prospectively 
because of iron parameters elevated above the 
normal values [transferrin saturation > 45%, 
serum ferritin > 400 mg/l (men) or > 300 mg/l 
(women)], whether associated or not with 
other symptom(s) that could suggest HHC, or 
on cascade family testing
Control cohort: Randomly selected but no 
further information is provided
Other patients: This group included people 
who had an incidental finding of an elevated 
serum iron parameter and/or a family history of 
haemochromatosis
Exclusion criteria for study entry:
Characteristics of participants: All participants 
were from Brittany and of Caucasian origin. No 
other characteristics are reported
Primary outcome: 
Frequencies of C282Y, H63D 
and S65C HFE genotypes in 
patient and control cohorts
Secondary outcomes: 
Comparison of age and 
serum iron parameters 
displayed at diagnosis by 
patients clinically diagnosed 
before HFE gene test 
availability with those 
subjected to a prospective 
HFE gene test
DNA analysis: DNA 
extracted from peripheral 
blood leukocytes; HFE 
mutations C282Y, H63D and 
S65C analysed by an RFLP 
method described in earlier 
papers. Part of exon 2 or 4 
was amplified by PCR and 
the PCR products were then 
enzymatically digested
Iron status:
Haemochromatosis cohort: 
Transferrin saturation, ferritin 
concentration and serum 
iron concentration was 
determined before the start 
of therapeutic phlebotomies
Adverse symptoms: None 
reported
Length of follow-up: No 
follow-up
Recruitment dates: Other 
patients were included over 
a 5-year period (from 1997 
to mid-2002) and tested 
prospectively
Results
Primary outcomes 
Haemochromatosis cohort 
(n = 478), n (%)
Control cohort 
(n = 410), n (%)
Other patients 
(n = 3047)
C282Y, C282Y 388 (81.17) 2 (0.49) 561 (18.41)
C282Y, wt* 22 (4.60) 50 (12.20) 656 (21.53)
C282Y, H63D 32 (6.69) 9 (2.20) 311 (10.21)
H63D, H63D 6 (1.26) 3 (0.73) 106 (3.48)
H63D, wt* 11 (2.30) 100 (24.39) 486 (15.95)
wt, wt* 19 (3.97) 246 (60.00) 927 (30.42)DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
95
Comments: Original results table included separate results for the S65C mutation in combination with C282Y, H63D or wt. 
Results above marked with * calculated by reviewer by combining the S65C results with those for C282Y and H63D and wt. 
Results for other patients were divided into five time bands; these have been merged by the reviewer to give the results for 
the group over the whole time period. All percentage values also calculated by reviewer
Original results also present calculated expected genotype frequencies with confidence intervals, calculated from the observed 
allele frequencies
The paper does not report on statistical differences between groups and no p-values are presented
C28Y homozygosity 
Iron overload population 
(defined) Control population  Total 
Yes, DNA test positive a 388 b 2 a+b 390
No, DNA test negative c 90 d 408 c+d 498
Total a+c 478 b+d 410 a+b+c+d 888
Calculate clinical sensitivity, specificity, PPV and NPV if possible and note whether this agrees with any of these values that are 
reported in the text of the paper:
Clinical sensitivity = a/a + c = 388/478 × 100 = 81.2%
Clinical specificity = d/b + d = 408/410 × 100 = 99.5%
PPV = a/a + b = 388/390 × 100 = 99.5%
NPV = d/c + d = 408/498 × 100 = 81.9%
Comments: 
Quality assessment by modified QUADAS80 and Spitzer et al.81
Item Judgementa
1. Were selection criteria for eligibility of patients objective and clearly described? U
2. Is the definition of iron overload likely to correctly classify HHC? U
3. Did the study use proper sampling so that all patients were equally likely to enter the study? U
4. Was the control population appropriate? Y
5. Did the study use proper sampling so that all control subjects were equally likely to enter the 
study?
Y
6. Was the DNA test described in sufficient detail to permit replication? Y
7. Was the execution of the biochemical methods described in sufficient detail to permit 
replication?
N
8. Were the groups under comparison comparable in terms of age, sex and race? U
9. Was there any mention of missing data? N
10. Was the sample of patients representative of the patients who will receive the test in practice, 
i.e. are the results generalisable?
U
a  Y, yes; N, no; U, unclear.Appendix 7
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Reference 
and design Intervention Participants Outcome measures
Author: 
Murphy et 
al.62
Year: 1998
Country: 
Ireland
Study design: 
Controlled 
cohort study
Number of 
centres: Not 
reported 
Funding: Not 
reported
Tests: DNA tests (C282Y 
and H63D)
Other interventions used: 
Control cohort: all HLA 
typed at the HLA-A, 
HLA-B and HLA DR loci
Number of participants: 
Haemochromatosis cohort: 30; 
control cohort: 404 
Sample attrition/dropout: Not 
reported
Sample crossovers: Not applicable
Inclusion criteria for study entry:
Haemochromatosis cohort: Clinically 
assessed and pathologically diagnosed 
by liver biopsy as having primary 
haemochromatosis
Control cohort: Not specified but 
were all volunteers from a bone 
marrow registry
Exclusion criteria for study entry: Not 
reported
Characteristics of participants: Not 
reported
Primary outcome: Prevalence of 
C282Y and H63D HFE genotypes in 
patient and control cohorts
Secondary outcomes: Linkage 
disequilibrium analysis of HFE gene 
mutations with the HLA-A, HLA-B and 
HLA-DR loci in the control cohort
Method of assessing outcomes: 
Chromosomal DNA extracted from 
peripheral blood followed by PCR 
amplification of a 2224 base pair 
region of the HFE gene containing the 
positions where the mutations occur. 
Specificity of the reaction checked 
by sequencing PCR products derived 
from a number of samples. Mutation 
analysis carried out by immobilising 
PCR products on replicate nylon 
membranes and independently 
hybridising these with four digoxigenin-
labelled oligonucleotide probes 
specific for the normal and mutant 
versions of the HFE sequence. Alkaline 
phosphatase-labelled antidigoxigenin 
antibody used to detect bound 
digoxigenin probes and reaction 
visualised by chemiluminescent 
detection, using CSPD substrate 
(Boehringer Mannheim). Samples of 
known HFE genotype always included 
to control and confirm the specificity 
of the probes used. HLA typing at 
the HLA-A and HLA-B locus using a 
medium PCR-SSOP typing scheme 
(reference given) and at the HLA-DR 
locus using a low resolution PCR-SSOP 
typing scheme (reference given) down 
to the allele or broad allele group
Adverse symptoms: None reported
Length of follow-up: No follow-up
Recruitment dates: Not reported
Results
Primary outcomes 
Haemochromatosis cohort 
(n = 30), n (%) Control cohort (n = 404), n (%)
C282Y, C282Y 27 (90.0) 5 (1.24)
C282Y, wt  1 (3.3) 60 (14.85)
C282Y, H63D 0 (0) 10 (2.48)
H63D, H63D 1 (3.3) 6 (1.49)
H63D, wt 0 (0) 92 (22.77)
wt, wt  1 (3.3) 231 (57.18)DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Comments: Original results also present 95% confidence intervals. The paper does not report on statistical differences 
between groups and no p-values are presented
C28Y homozygosity 
Iron overload population 
(defined) Control population  Total 
Yes, DNA test positive a 27 b 5 a+b 32
No, DNA test negative c 3 d 399 c+d 402
Total a+c 30 b+d 404 a+b+c+d 434
Calculate clinical sensitivity, specificity, PPV and NPV if possible and note whether this agrees with any of these values that are 
reported in the text of the paper:
Clinical sensitivity = a/a + c = 27/30 × 100 = 90.0%
Clinical specificity = d/b + d = 399/404 × 100 = 98.8%
PPV = a/a + b = 27/32 × 100 = 84.4%
NPV = d/c + d = 399/402 × 100 = 99.3%
Comments: 
Quality assessment by modified QUADAS80 and Spitzer et al.81
Item Judgementa
1. Were selection criteria for eligibility of patients objective and clearly described? U
2. Is the definition of iron overload likely to correctly classify HHC? U
3. Did the study use proper sampling so that all patients were equally likely to enter the study? U
4. Was the control population appropriate? N (no information)
5. Did the study use proper sampling so that all control subjects were equally likely to enter 
the study?
N
6. Was the DNA test described in sufficient detail to permit replication? Y
7. Was the execution of the biochemical methods described in sufficient detail to permit 
replication?
n/a
8. Were the groups under comparison comparable in terms of age, sex and race? U
9. Was there any mention of missing data? N
10. Was the sample of patients representative of the patients who will receive the test in 
practice, i.e. are the results generalisable?
U
a  Y, yes; N, no; U, unclear; n/a, not applicable.Appendix 7
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Reference 
and design Intervention Participants Outcome measures
Author: 
Neilsen et 
al.92 
Year: 1998 
Country: 
Germany
Study 
design: 
Cohort with 
control 
Number 
of centres: 
One
Funding: 
Not stated 
Tests: DNA tests (C282Y 
and H63D); serum iron 
to give serum ferritin 
(SF; mg/l), transferrin 
saturation (TS; %) and 
liver iron content (LIC)
Number of participants: HHC patients: 92 
(unrelated); healthy volunteer control subjects: 
157 (unrelated) (family members of patients: 
34 – not reported here). All patients and control 
subjects of German ancestry (at least three 
generations)
Sample attrition/dropout: None
Sample crossovers: n/a
Inclusion criteria for study entry: 
HHC patients: Presence of at least three of the 
following criteria: TS > 62%; SF > 300 mg/l; LIC 
> 2000 mgFe/g wet weight; hepatic iron index 
(HII) [HI (mg/year) = (LIC/age)] > 30; grade III or 
IV stainable iron in liver; > 4 g of iron removed by 
phlebotomy
Family members: All relatives available
Controls subjects: Unrelated healthy volunteers 
Exclusion criteria for study entry: None stated
Characteristics of participants:*
HHC patients: 92 (59 men, 33 women). Total: age 
49.1 ± 12.5, SF 1.087 (2.858–413), TS 90 ± 11, LIC 
2.16 (3.51–1.33). Men: age 48.7 ± 12.6, SF 1451 
(3.471–607), TS 96 ± 11, LIC 2.22 (3.73–1.32). 
Women: age 49.6 ± 12.6, SF 701 (1.721–286), TS 
88 ± 10, LIC 2.08 (3.21–1.35)
Control subjects: 157 (80 men, 77 women). 
Total: age 42.3 ± 17.1, SF 49 (138–17), TS 31 ± 13, 
LIC not detected. Men: age 42.8 ± 16.3, SF 75 
(183–31), TS 33 ± 11, LIC not detected. Women: 
age 41.8 ± 17.8, SF 33 (90–12), TS 29 ± 14, LIC not 
detected
*Results for SF and LIC are geometric mean and 
asymmetric widths
Primary outcomes: 
Frequency of C282Y and 
H63D
Secondary outcomes: 
Parameters of iron 
metabolism
Method of assessing 
outcomes: Genomic 
DNA isolated from EDTA 
blood samples using 
QIAamp Blood Kit. PCR 
using primers for C282Y 
and H63D mutations. 
Amplified products digested 
with SnaBI for C282Y 
mutation and BclI for 
H63D mutation. SF, TS and 
total iron-binding capacity 
using routine methods. 
Liver iron measured non-
invasively using SQUID 
biomagnetometer
Adverse symptoms: n/a
Length of follow-up: n/a
Recruitment dates: 1993–7
Results 
Genotypes  Patients (n=92)
Family members 
(n=34)
Control subjects 
(n=157) p-value
Homozygosity C282Y 87 9 0
Composite 
heterozygosity
4 3 NR
Heterozygosity C282Y 1 18 15
Homozygosity H63D 0 0 2
Heterozygosity H63D 0 1 37
No mutation 0 3 NR
Comments: Unclear reporting in paper makes calculations for composite heterozygosity difficultDOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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C28Y homozygosity 
Iron overload population 
(defined) Control population  Total 
Yes, DNA test positive  a 87 b 0 a+b 87
No, DNA test negative c  5 d 157 c+d 162
Total a+c  92 b+d  157 a+b+c+d 249
Calculate clinical sensitivity, specificity, PPV and NPV if possible and note whether this agrees with any of these values that are 
reported in the text of the paper:
Clinical sensitivity = a/a + c = 87/92 × 100 = 94.6%
Clinical specificity = d/b + d = 157/157 × 100 = 100%
PPV = a/a + b = 87/87 × 100 = 100%
NPV = d/c + d = 157/162 × 100 = 96.9%
Comments: Reported that 96.4% of patients were homozygous and 4.3% were heterozygous for C282Y
Quality assessment by modified QUADAS80 and Spitzer et al.81
Item Judgementa
1. Were selection criteria for eligibility of patients objective and clearly described? Y
2. Is the definition of iron overload likely to correctly classify HHC? Y
3. Did the study use proper sampling so that all patients were equally likely to enter the study? U
4. Was the control population appropriate? N
5. Did the study use proper sampling so that all control subjects were equally likely to enter the 
study?
N
6. Was the DNA test described in sufficient detail to permit replication? Y
7. Was the execution of the biochemical methods described in sufficient detail to permit 
replication?
N
8. Were the groups under comparison comparable in terms of age, sex and race? U
9. Was there any mention of missing data? N
10. Was the sample of patients representative of the patients who will receive the test in practice, 
i.e. are the results generalisable?
Y
a  Y, yes; N, no; U, unclear.Appendix 7
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Reference 
and design Intervention Participants Outcome measures
Author: Ryan 
et al93
Year: 1998 
Country: 
Ireland
Study design: 
Cohort with 
control 
Number of 
centres: One
Funding: Not 
stated 
Tests: DNA tests 
(C282Y and H63D)
Number of participants: (1) HHC patients: 60 
(unrelated); (2) HHC patients: 18 (lower iron overload); 
(3) unrelated controls: 109
Sample attrition/dropout: None
Sample crossovers: n/a
Inclusion criteria for study entry: (1) For HHC 
patients diagnosis on basis of clinical history, physical 
examination, persistently raised transferrin saturation 
and serum ferritin and > 3+ hepatic iron deposition; 
(2) HHC with persistently raised iron indices but < 3+ 
hepatic iron deposition on liver biopsy; (3) control group 
of randomly selected individuals from hospital staff
Exclusion criteria for study entry: None stated
Characteristics of participants: Not stated
Primary outcome: 
Frequency of C282Y 
and H63D
Secondary outcomes: 
Parameters of iron 
metabolism
Method of assessing 
outcomes: DNA 
extracted from 10 ml 
blood collected in 
EDTA tubes or from 
Guthrie cards using 
Chelex resin. Primers 
used to amplify 
fragments of C282Y 
and H63D included 
internal restriction 
enzyme control sites. 
Following amplification 
the PCR product was 
digested with RsaI 
for C282Y mutation 
and MboI for H63D 
mutation. No details of 
biochemical tests
Adverse symptoms: n/a
Length of follow-up: n/a
Recruitment dates: Not 
stated
Results
Genotypes Group 1: HII > 3+, n Group 2: HII < 3+, n Group 3: Control group, n
Homozygosity C282Y 56 14 0
Composite 
heterozygosity
1 2
Heterozygosity C282Y 1 1 31
Homozygosity H63D ND 4
Heterozygosity H63D ND 1 27
No mutation 2 0 47
Comments: ND, not determined because of complete linkage disequilibrium
C28Y homozygosity 
Iron overload population 
(defined): Group 1: HII 
> 3+ Control population Total
Yes, DNA test positive a 56 b 0 a+b 56
No, DNA test negative c 4 d 109 c+d 113
Total a+c 60 b+d 109 a+b+c+d 169DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Calculate clinical sensitivity, specificity, PPV and NPV if possible and note whether this agrees with any of these values that are 
reported in the text of the paper:
Clinical sensitivity = a/a + c = 56/60 × 100 = 93.3%
Clinical specificity = d/b + d = 109/109 × 100 = 100%
PPV = a/a + b = 56/56 × 100 = 100%
NPV = d/c + d = 109/113 × 100 = 96.5%
Comments: Reported that 93% of HHC patients fulfilling standard diagnostic criteria are homozygous for C282Y 
C28Y homozygosity 
Iron overload population 
(defined): Group 2: HII 
< 3+ Control population  Total 
Yes, DNA test positive a 14 b 0 a+b 14
No, DNA test negative c  4 d 109 c+d 113
Total a+c  18 b+d  109 a+b+c+d 127
Calculate clinical sensitivity, specificity, PPV and NPV if possible and note whether this agrees with any of these values that are 
reported in the text of the paper:
Clinical sensitivity = a/a + c = 14/18 × 100 = 77.8%
Clinical specificity = d/b + d = 109/109 × 100 = 100%
PPV = a/a + b = 14/14 × 100 = 100%
NPV = d/c + d = 109/113 × 100 = 96.5%
Comments: Reported that 77% of patients with provisional diagnoses of HHC but who do not fulfil standard diagnostic 
criteria are homozygous for C282Y mutation
Quality assessment by modified QUADAS80 and Spitzer et al.81
Item Judgementa
1. Were selection criteria for eligibility of patients objective and clearly described? U
2. Is the definition of iron overload likely to correctly classify HHC? U
3. Did the study use proper sampling so that all patients were equally likely to enter the study? U
4. Was the control population appropriate? N
5. Did the study use proper sampling so that all control subjects were equally likely to enter the 
study?
Y
6. Was the DNA test described in sufficient detail to permit replication? Y
7. Was the execution of the biochemical methods described in sufficient detail to permit replication? N
8. Were the groups under comparison comparable in terms of age, sex and race? U
9. Was there any mention of missing data? N
10. Was the sample of patients representative of the patients who will receive the test in practice, i.e. 
are the results generalisable?
U
a  Y, yes; N, no; U, unclear.Appendix 7
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Reference and design Intervention Participants Outcome measures
Author: UK Haemochromatosis 
Consortium38
Year: 1997
Country: UK
Study design: Cohort with 
control 
Number of centres: Four
Funding: NE Thames Regional 
Health Authority, Peter Samuel 
Charitable Trust, Nuffield 
Foundation
Tests: DNA tests 
(C282Y and 
H63D)
Number of participants: 115 well-
characterised patients with HHC; control 
group: 101 healthy blood donors
Sample attrition/dropout: None
Sample crossovers: n/a
Inclusion criteria for study entry: 
Diagnosis of HHC on the basis of 
hepatic iron index > 1.9 or greater 
than 5 g mobilisable iron by quantitative 
phlebotomy. Control samples were 
obtained from healthy blood donors
Exclusion criteria for study entry: None 
stated
Characteristics of participants: Not stated
Primary outcome: 
Frequency of C282Y and 
H63D
Secondary outcomes: 
Method of assessing 
outcomes: The 
prevalence of the C282Y 
and H63D mutations 
was determined by 
PCR amplification and 
restriction enzyme 
digestion
Adverse symptoms: n/a
Length of follow-up: n/a 
Recruitment dates: Not 
stated
Results
Primary outcomes  Intervention group, n Control group, n
HH/YY 105 1 Homozygous
HH/CC 5 65 Wild type
HD/CC 0 22
HD/CY 3 4
HH/CY 1 6
DD/CC 1 3
Comments: 
C28Y homozygosity 
Iron overload 
population (defined) Control population  Total 
Yes, DNA test positive a 105 b 1 a+b 106
No, DNA test negative c 10 d 100 c+d 110
Total a+c 115 b+d 101 a+b+c+d 216
Calculate clinical sensitivity, specificity, PPV and NPV if possible and note whether this agrees with any of these values that are 
reported in the text of the paper:
Clinical sensitivity = a/a + c = 105/115 × 100 = 91.3%
Clinical specificity = d/b + d = 100/101 × 100 = 99.0%
PPV = a/a + b = 105/106 × 100 = 99.0%
NPV = d/c + d = 100/110 × 100 = 91.0%
Comments: Reported that 91% of patients with HHC were homozygous for the C282Y mutationDOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
103
Quality assessment by modified QUADAS80 and Spitzer et al.81
Item Judgementa
1. Were selection criteria for eligibility of patients objective and clearly described? Y
2. Is the definition of iron overload likely to correctly classify HHC? Y
3. Did the study use proper sampling so that all patients were equally likely to enter 
the study?
U
4. Was the control population appropriate? U
5. Did the study use proper sampling so that all control subjects were equally likely 
to enter the study?
U
6. Was the DNA test described in sufficient detail to permit replication? Y
7. Was the execution of the biochemical methods described in sufficient detail to 
permit replication?
N
8. Were the groups under comparison comparable in terms of age, sex and race? U
9. Was there any mention of missing data? N
10. Was the sample of patients representative of the patients who will receive the test 
in practice, i.e. are the results generalisable?
Y
a  Y, yes; N, no; U, unclear.
Reference and design Intervention Participants Outcome measures
Author: Vantyghem et 
al.94
Year: 2006 
Country: France
Study design: Cohort 
with control 
Number of centres: 
One
Funding: Not stated 
Tests: DNA tests 
(C282Y and H63D)
Number of participants: I group patients: 156 
recruited at endocrinology department; C 
group control subjects: 106
Sample attrition/dropout: None
Sample crossovers: n/a
Inclusion criteria for study entry: 
I group: Abnormal iron markers, serum 
ferritin (SF) > 300 ng/ml or transferrin 
saturation (TS) > 45%. Tests performed 
because of general symptoms (fatigue, 
weight loss, arthralgia), diabetes, 
hepatomegaly, disturbed liver enzymes or 
hypogonadism
C group: Healthy Caucasian subjects without 
family history of diabetes or iron overload
Exclusion criteria for study entry: None 
stated
Characteristics of participants:*
I group: 68% men, age 52 ± 17 years, 
body mass index 27 ± 6 kg/m2, blood iron 
level 145 ± 56 mg/dl, SF 910 ± 1304 ng/
ml, TS 58 ± 28%. Clinical symptoms: 
11% melanodermic, 51% diabetic, 24% 
admitted excessive alcohol intake, 26% had 
hepatomegaly, 10% complained of arthralgia, 
10% suffered from heart disease
C group: No details given
* Data are mean ± SD
Primary outcome: 
Frequency of C282Y and 
H63D
Secondary outcomes: 
Parameters of iron 
metabolism
Method of assessing 
outcomes: DNA extracted 
from whole blood samples. 
HFE mutations were 
detected with PCR assays 
followed by restriction 
enzyme digestion with Rsa1 
for C282Y and Bcl1 for 
H63D. Blood samples for 
iron parameters collected 
from fasting patients. 
Serum iron levels were 
measured using standard 
colorimetric method, and 
serum transferrin levels 
were determined by rate 
immunoturidimetry on an 
automated analyser. Serum 
TS values were calculated 
as follows: [(serum 
iron/2) x SF)] × 100. SF 
levels were measured 
by chemiluminescence 
immunoassay
Adverse symptoms: n/a
Length of follow-up: n/a
Recruitment dates: Not 
statedAppendix 7
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Results
Genotypes
Group I (abnormal 
iron parameters) 
(n = 156), n (%)
Group C (control) 
(n = 106), n (%)
χ2 p-value < 0.001, 
I vs C
Homozygosity C282Y 33 (21) 0
Composite heterozygosity 10 (6.4) 2 (1.8)
Heterozygosity C282Y 34 (21) 14 (13.2)
Homozygosity H63D 5 (3.2) 7 (6.6)
Heterozygosity H63D 33 (21) 23 (21.6)
No mutation 41 (26) 60 (57)
C28Y homozygosity 
Iron overload 
population (defined): 
Group I Group C (control) Total
Yes, DNA test positive a 33 b 0 a+b 33
No, DNA test negative c 123 d 106 c+d 229
Total a+c 156 b+d 106 a+b+c+d 262
Calculate clinical sensitivity, specificity, PPV and NPV if possible and note whether this agrees with any of these values that are 
reported in the text of the paper:
Clinical sensitivity = a/a + c = 33/156 × 100 = 21.2%
Clinical specificity = d/b + d = 106/106 × 100 = 100%
PPV = a/a + b = 33/33 × 100 = 100%
NPV = d/c + d = 106/229 × 100 = 46.3%
Comments:
Quality assessment by modified QUADAS80 and Spitzer et al.81
Item Judgementa
1. Were selection criteria for eligibility of patients objective and clearly described? Y
2. Is the definition of iron overload likely to correctly classify HHC? U
3. Did the study use proper sampling so that all patients were equally likely to enter the 
study?
U
4. Was the control population appropriate? Y
5. Did the study use proper sampling so that all control subjects were equally likely to 
enter the study?
U
6. Was the DNA test described in sufficient detail to permit replication? N
7. Was the execution of the biochemical methods described in sufficient detail to permit 
replication?
U
8. Were the groups under comparison comparable in terms of age, sex and race? U
9. Was there any mention of missing data? N
10. Was the sample of patients representative of the patients who will receive the test in 
practice, i.e. are the results generalisable?
U
a  Y, yes; N, no; U, unclear.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Reference and 
design Intervention Participants Outcome measures
Author: Willis et al.95
Year: 1997 
Country: UK
Study design: Cohort 
with control 
Number of centres: 
One
Funding: Not stated 
Tests: DNA tests 
(C282Y and H63D)
Number of participants: Patients: 18; control 
subjects: 200
Sample attrition/dropout: None
Sample crossovers: n/a
Inclusion criteria for study entry: 
Patients being treated for HHC by phlebotomy. 
Criteria were fasting transferrin saturation 
> 60% in two samples and hepatic iron index 
> 2 where appropriate
Control subjects were patients referred to 
hospital for reasons unrelated to known 
manifestations of HHC representative of 
hospital population; different patient groups 
were included 
Exclusion criteria for study entry: None stated
Characteristics of participants: Not stated
Primary outcome: 
Frequency of mutant alleles, 
845A (C282Y) and 187G 
(H63D)
Secondary outcomes:
Method of assessing 
outcomes: DNA was 
extracted by standard 
methods from blood 
and amplified in PCR 
reactions. PCR products 
underwent allelle-specific 
oligonucleotide hybridisation 
for wild type and mutant 
nucleotide 845 alleles. For 
nucleotide 187 alleles PCR 
product restriction digestion 
with Bcl1 was performed 
(full details given)
Adverse symptoms: n/a
Length of follow-up: n/a
Recruitment dates: Not 
stated
Results
Genotypes Patients (n = 18) Controls (n = 200)
Homozygosity C282Y 18 1
Composite heterozygosity
Heterozygosity C282Y 32
Homozygosity H63D
Heterozygosity H63D
Normal homozygous H63D 18
No mutation
Comment: Full results not reported
C28Y homozygosity 
Iron overload 
population (defined) 
(n = 18) Control population (n = 200) Total
Yes, DNA test positive a 18 b 1 a+b 19
No, DNA test negative c 0 d 199 c+d 199
Total a+c 18 b+d 200 a+b+c+d 218
Calculate clinical sensitivity, specificity, PPV and NPV if possible and note whether this agrees with any of these values that are 
reported in the text of the paper:
Clinical sensitivity = a/a + c = 18/18 × 100 = 100%
Clinical specificity = d/b + d = 199/200 × 100 = 99.5%
PPV = a/a + b = 18/19 × 100 = 94.7%
NPV = d/c + d = 199/199 × 100 = 100%
Comments: Appendix 7
106
Quality assessment by modified QUADAS80 and Spitzer et al.81
Item Judgementa
1. Were selection criteria for eligibility of patients objective and clearly described? Y
2. Is the definition of iron overload likely to correctly classify HHC? Y
3. Did the study use proper sampling so that all patients were equally likely to enter the 
study?
U
4. Was the control population appropriate? N
5. Did the study use proper sampling so that all control subjects were equally likely to 
enter the study?
U
6. Was the DNA test described in sufficient detail to permit replication? Y
7. Was the execution of the biochemical methods described in sufficient detail to permit 
replication?
n/a
8. Were the groups under comparison comparable in terms of age, sex and race? U
9. Was there any mention of missing data? N
10. Was the sample of patients representative of the patients who will receive the test in 
practice, i.e. are the results generalisable?
Y
a  Y, yes; N, no; U, unclear; n/a, not applicable.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Appendix 8  
Data extraction of psychosocial studies
Reference 
and design Intervention Participants Outcome measures
Author: 
Hicken et 
al.96
Year: 2004
Country: 
USA
Study 
design: 
Cohort with 
control
Number 
of centres: 
One
Funding: 
Not 
reported
Haemochromatosis 
cohort: 
Haemochromatosis 
interview with 
additional questions
Control cohort: 
Haemochromatosis 
interview
Other interventions 
used: None
Number of participants: Haemochromatosis cohort: 
87; control cohort: 50
Sample attrition/dropout: Interviews with 10 patients 
were pilot data and were included only in analyses of 
outcomes and attitudes about genetic testing
Sample crossovers: None
Inclusion criteria for study entry: 
Haemochromatosis cohort: (1) Caucasians aged > 18 
years; (2) had haemochromatosis; (3) underwent 
phlebotomy to reduce or maintain ferritin levels 
between January 1990 and May 2000; (4) underwent 
HFE genotyping at least 1 year before chart review
Control cohort: People with hypertension enrolled in a 
trial of an antihypertensive medication. Eligible control 
subjects: (1) were Caucasians aged > 18 years; (2) 
reported that they did not have haemochromatosis; 
(3) had not undergone HFE genotyping
Exclusion criteria for study entry: None reported
Characteristics of participants: 
Haemochromatosis cohort: Age (mean ± SD) 
53.9 ± 12.5 years (range 25–82); years between HFE 
genotyping and study 2.7 ± 1.7 (1.7–4.9); male–female 
55%:45%; married 82%, single/divorced/widowed 
18%; employed 59%, unemployed/retired 41%; 
annual income US$0–50,000 47%, US$50,001–75,000 
46%, income data missing 7%; education < high 
school 8%, high-school graduate 22%, post high 
school 61%, education data missing 9%; health 
insurance 98%, no health insurance 2%
Control cohort: Age (mean ± SD) 58.5 ± 13.7 years 
(range 31–80); years between HFE genotyping and 
study n/a; male–female 56%:44%; married 58%, 
single/divorced/widowed 42%; employed 50%, 
unemployed/retired 50%; annual income US$0–
50,000 62%, US$50,001–75,000 36%, income data 
missing 2%; education < high school 12%, high-
school graduate 22%, post high school 66%, health 
insurance 82%, no health insurance 14%, missing/
don’t know 4%
Primary outcome: 
Knowledge questions 
answered correctly
Secondary outcomes: 
Attitudes about 
genetic testing; 
psychosocial outcomes 
of genetic testing. For 
haemochromatosis cohort 
only, compliance with 
treatment, understanding 
of haemochromatosis and 
treatment, psychosocial 
outcomes of HFE 
genotyping
Method of assessing 
outcomes: Two 
independent raters 
categorised short-answer 
questions using a reliable 
coding system, discussed 
discrepant rating and 
agreed upon a code that 
matched the response. 
Short-answer knowledge 
questions were scored as 
either correct or incorrect. 
Summary scores for 
outcomes of genetic testing 
were created by summing 
positive outcomes (score 
range 4–16) and negative 
outcomes (score range 
8–32) of genetic testing
Adverse symptoms: n/a
Length of follow-up: n/a
Recruitment dates: n/aAppendix 8
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Results
Outcome 
Haemochromatosis 
cohort (n = 57)
Control cohort 
(n = 50) p-value
HFE genotyping beneficial 12.44 13.14 > 0.05
HFE genotyping detrimental 17.56 13.39 < 0.0001
Comments: 34% of patients (n = 30) did not recall undergoing HFE genotyping and were not included in the analyses
Control subjects expected more anxiety (p < 0.0001), sadness (p < 0.0001) and anger (p < 0.005), and to have more difficulty 
paying for genetic testing (p < 0.0001) than was reported by patients (results reported in bar chart)
Summary scores for positive outcomes range from 4 to16 and for negative outcomes from 8 to 32
Outcome: Compliance with treatment
Haemochromatosis 
cohort (n = 87)
Control cohort 
(n = 50) p-value
Achieved iron depletion 99% n/a
Adherence to maintenance therapy in first year 94% n/a
Few difficulties obtaining annual serum ferritin measurements 81% n/a
Comments: Adherence to maintenance therapy declined by 8% annually after the first year. Demographic factors, barriers and 
knowledge were not associated with adherence to maintenance (p > 0.05)
Outcome 
Haemochromatosis 
cohort (n = 57)
Control cohort 
(n = 50) p-value
Satisfied with information received before genotyping 
(mean ± SD)
3.39 ± 0.59 (range 
2–4)
Test determines presence of HFE mutation 46%
Test confirms diagnosis of haemochromatosis 11%
Do not recall 18%
Wanted to receive the test (mean ± SD) 3.38 ± 0.56 (range 
2–4)
Understood the rationale for the testing (mean ± SD) 3.38 ± 0.59 (range 
2–4)
Questions
Individual knowledge questions
Patients (n = 87), 
correct recall (%)
Control subjects 
(n = 50), correct 
recall (%) p-value
Overall recall 65 ± 26 59 ± 30 > 0.05
Define genetic test 48 56
Interpret positive HFE genotype 59 62
Immutability of genetic test result 65 64
Phlebotomy changes iron levels 81 86
Test predicts symptoms 51 42
Test indicates current illness 45 36
Test predicts when symptoms begin 75 76
Children and siblings will have same mutation 49 52DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
109
Short-answer questions % Patients with correct answer
Purpose of phlebotomy 85
Purpose of annual serum ferritin measurement 79
Definition of genetic 90
Difference between HFE genotyping and transferrin saturation test 25
True–false questions % Patients with correct answer
In haemochromatosis the body tends to store too much iron 98
No effective treatment for haemochromatosis 92
Haemochromatosis treated by drawing blood to lower iron levels 98
Not necessary to treat haemochromatosis unless the person has organ damage 96
Possible to have haemochromatosis and not know it 99
About 1 out of every 200 people has haemochromatosis 60
People with haemochromatosis get sick because too much iron damages organs 97
Untreated haemochromatosis may lead to early death 97
No cure for haemochromatosis 86
Haemochromatosis is less common in women 42
Perceived benefits (haemochromatosis cohort n=57)
Improved health and prevention of future health problems 40%
Learning risk to self and family 19%
Improved understanding of health 11%
Improved psychological well-being 12%
No benefits from HFE genotyping identified 19% (n = 11)
Problems from genetic testing (haemochromatosis cohort n=57)
No problems identified 88% (n = 49)
Decreased psychological well-being 2% (n = 1)
Denied health insurance 2% (n = 1)
Comments:
Methodological comments 
Allocation to treatment groups: 
Blinding: Not reported
Comparability of treatment groups: Some significant differences with respect to marital status and health insurance
Method of data analysis: 
Sample size/power calculation: Not reported
Attrition/dropout: Well reported
General comments
Generalisability: 
Outcome measures: 
Intercentre variability: Not applicable
Conflict of interests: Not reportedAppendix 8
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Quality assessment
Yes U/I/Sa No DK/NRb n/ac Comments
Proper random assignment n/a
Proper sampling NR
Adequate sample size NR
Objective outcomes Y
Blind assessment NR
Objective eligibility criteria Y
Reported attrition Y
Comparability of groups N
Generalisability U
a  U/I/S, uncertain/incomplete/substandard.
b  DK/NR, don’t know/not reported.
c  n/a, not applicable.
Quality criteria for assessment of observational studies revised from Spitzer et al.81DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Reference and design Intervention Participants Outcome measures
Author: Meiser et al.97
Year: 2005
Country: Australia
Study design: Cohort 
without control
Number of centres: One
Funding: Author 
supported by National 
Health and Medical 
Research Council of 
Australia
Self administered 
questionnaires: genetics 
of haemochromatosis 
knowledge (at 2 
weeks and 12 months 
post consultation); 
understanding of test 
result (at 2 weeks post 
consultation only); 7-item 
intrusion subscale of the 
Impact of Event Scale 
(IES) (at 2 weeks post 
consultation only); 6-item 
short version of the state 
component of the State–
Trait Anxiety Inventory 
(STAI-State); Medical 
Outcomes Study 36-
item Short-Form Health 
Survey (SF-36)
Other interventions 
used: None
Number of participants: 
Haemochromatosis cohort: 101
Sample attrition/dropout: Participants 
were lost to follow-up: 74 (73.3%) 
and 62 (61.4%) completed the 2-week 
and 12-month post-consultation 
questionnaires respectively. There are 
four, five or six missing baseline data 
points for each of the reported clinical 
variables
Sample crossovers: None
Inclusion criteria for study entry: 
Recruited through a haemochromatosis 
clinic at a major teaching hospital. 
Participants referred for diagnostic 
evaluation of symptoms, genetic 
testing for HHC, advice regarding early 
detection and preventative strategies 
and/or standardised patient education 
tailored to individual needs
Exclusion criteria for study entry: Unable 
to give informed consent or had limited 
literacy in English
Characteristics of participants, n (%): 
Age < 30 years 16 (15.8), 30–39 years 
17 (16.8), 40–49 years 22 (21.8), 50–59 
years 37 (36.6), 60+ years 9 (8.9), mean 
age 45 years (range 18–69); male 63 
(62.4), female 38 (37.6); married 73 
(72.3), not married 28 (27.7); biological 
children 72 (71.3), no biological children 
29 (28.7); post-school qualifications 77 
(65.3), no post-school qualifications 24 
(23.8); clinically unaffected 66 (68.8), 
clinically affected 30 (31.3); ferritin 
level low 13 (13.7), ferritin level high 82 
(86.3); mutation status – homozygous 
for C282Y 43 (45.3), homozygous 
for H63D 11 (11.6), compound 
heterozygote (C282Y/H63D) 20 
(21.1), heterozygote C282Y 13 (13.7), 
heterozygote H63D 8 (8.4); family 
history of haemochromatosis 48 (47.5), 
no family history 49 (48.5)
Primary outcomes: 
Psychological distress 
levels (IES, STAI-State and 
SF-36)
Secondary outcomes: 
Knowledge about genetics 
of haemochromatosis 
and understanding of test 
results
Method of assessing 
outcomes: Intrusion 
subscale of the IES: scale 
ranges from ‘not at all’ to 
‘often’. STAI-State scale 
ranges from ‘not at all’ to 
‘very much’, scores range 
from 20 to 80. SF-36 
provides indicators across 
eight dimensions, scores 
for each range from 0 to 
100, with higher scores 
indicating better health 
or well-being. There are 
two summary indices, 
the physical component 
summary (PCS) and 
the mental component 
summary (MCS). General 
US population averages 
are exactly 50 for both SF-
36 component summaries, 
the standard deviation is 
10 for both the PCS and 
the MCS
Adverse symptoms: N/A
Length of follow-up: 12 
months.
Recruitment dates: 
February 2001–May 2003Appendix 8
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Results
Outcome 
Unaffected, 
mean (SD)
Affected, 
mean (SD)
Total, mean 
(SD) p-value
STAI-State short version intrusion subscale baseline 45.8 (7.6), 
n = 59
45.5 (8.6), 
n = 26
45.8 (7.7), 
n = 89
0.89
STAI-State intrusion subscale 2 weeks post 
consultation
44.6 (7.1), 
n = 38
46.5 (7.1), 
n = 18
45.1 (7.0), 
n = 58
0.37
STAI-State intrusion subscale 12 months post 
consultation
43.2 (5.9), 
n = 21
44.6 (5.1), 
n = 16
43.8 (5.6), 
n = 37
0.45
Comments: p-value refers to a statistical comparison between mean scores of clinically affected and unaffected participants. 
Changes across time points for the STAI-State for both clinically unaffected and affected participants combined were not 
suggested by the data and this was confirmed by statistical analyses. There were no statistically significant associations between 
baseline generalised anxiety and age, sex, educational level, marital status or ferritin levels
IES 2 weeks post consultation 4.0 (5.8), n = 44 5.6 (6.8), 
n = 21
4.6 (6.2), n = 68 0.48
Comments: p-value refers to a statistical comparison between mean scores of clinically affected and unaffected participants. 
One participant scored over 20 on the intrusion subscale of the IES. A score of 20 or higher on the intrusion subscale of the IES 
is considered to be strongly predictive of a significant stress response syndrome
PCS of SF-36 baseline 49.0 (7.7), 
n = 59
42.9 (10.7), 
n = 28
46.9 (9.4), 
n = 91
0.02*
PCS of SF-36 2 weeks post consultation 47.8 (9.4), 
n = 42
43.6 (10.0), 
n = 20
46.4 (9.7), 
n = 65
0.06
PCS of SF-36 12 months post consultation 45.1 (11.5), 
n = 23
41.1 (14.0), 
n = 17
43.4 (12.6), 
n = 40
0.50
MCS of SF-36 baseline 46.7 (9.7), 
n = 59
42.3 (10.5), 
n = 28
45.3 (10.0), 
n = 91
0.06
MCS of SF-36 2 weeks post consultation 47.2 (9.8), 
n = 42
42.5 (12.0), 
n = 20
45.6 (10.6), 
n = 65
0.17
MCS of SF-36 12 months post consultation 51.0 (8.5), 
n = 23
45.7 (9.6), 
n = 17
48.7 (9.3), 
n = 40
0.08
Comments: p-value refers to a statistical comparison between mean scores of clinically affected and unaffected participants. 
*Significant at p < 0.05. Changes across time points for the PCS for both clinically unaffected and affected participants 
combined were not suggested by the data and this was confirmed by statistical analyses. Paper states that a statistically 
significant increase in the MCS score (i.e. better mental health) was observed at the 12-month follow-up compared with 
baseline (no p-value reported)
For all indices of the SF-36 subscales clinically unaffected individuals had higher scores than affected individuals and these 
differences were statistically significant for most subscales: role–physical (p < 0.001), bodily pain (p = 0.039), general health 
(p = 0.01), vitality (p = 0.01), social functioning (p = 0.017) and mental health (p = 0.02). A trend for differences between 
clinically unaffected and affected participants was observed for role–emotional (p = 0.092), and no statistically significant 
differences were found for physical functioning (p = 0.02). There were no statistically significant associations between baseline 
PCS or baseline MCS and age, sex, educational level, marital status or ferritin levels
Participants (n = 101) correctly answering:
2-week follow-up 
(**estimated from 
figure)
12-month follow-up (all 
estimated values)
Regular removal of blood will avoid or reduce many of the 
symptoms of haemochromatosis (True)
93.2% 98.7%
A person who has two copies of the gene change for 
haemochromatosis is likely to develop haemochromatosis (True)
87.3% 87.2%
Hereditary haemochromatosis is uncommon (False) 85.3%** 75.6%
A person who has just one copy of the gene change for 
haemochromatosis usually will be perfectly healthy (True)
76.1% 70.5%
To be at risk of developing haemochromatosis you need to inherit 
one copy of the gene change from each of your parents (True)
71.2%** 69.9%DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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If a person carried two copies of the haemochromatosis gene 
change they have a 100% change of passing on the two gene 
changes to a son or daughter (False)
54.5%** 67.9%
The gene change C282Y is found in most people with 
haemochromatosis (True)
45.2% 59.6%
Understanding of gene changes
Participants 
(n=42) 
homozygous 
for C282Y or 
H63D, n (%)
Participants (n=19) 
heterozygous for 
C282Y or H63D, n 
(%)
Participants (n=16) 
compound heterozygotes, 
n (%)
One gene change 7 (16.7) 12 (63.2) 4 (23.5)
Two gene changes 28 (66.7) 3 (15.8) 10 (58.8)
Unable to remember 7 (16.7) 4 (21.1) 2 (17.6)
Iron studies
Uptake of iron studies 96% of participants for whom iron studies were recommended reported 
having had iron studies in the past year at the 12-month follow up
Venesection 62% of participants who had increased serum ferritin at baseline reported 
ever having had a venesection; 57% reported having undergone a 
venesection in the past year
Methodological comments 
Allocation to treatment groups: n/a 
Blinding: Not reported
Comparability of treatment groups: n/a
Method of data analysis: 
Sample size/power calculation: Not reported
Attrition/dropout: Data is missing from some tables but this is not commented on by the authors. Loss to follow-up at 2 weeks 
and 12 months is reported with some information about the characteristics of the missing participants
General comments
Generalisability: Uncertain
Outcome measures: Used validated instruments
Intercentre variability: n/a
Conflict of interests: Not reportedAppendix 8
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Quality assessment
Yes U/I/Sa No DK/NRb n/ac Comments
Proper random assignment n/a
Proper sampling NR
Adequate sample size NR
Objective outcomes Y
Blind assessment NR
Objective eligibility criteria U
Reported attrition I
Comparability of groups n/a
Generalisability U
a  U/I/S, uncertain/incomplete/substandard.
b  DK/NR, don’t know/not reported.
c  n/a, not applicable.
Quality criteria for assessment of observational studies revised from Spitzer et al.81
Reference and 
design Intervention Participants Outcome measures
Author: Power 
and Adams98
Year: 2001
Country: Canada
Study design: 
Observational 
before and after
Number of 
centres: One
Funding: Medical 
Research Council 
of Canada
Intervention: Genetic 
test; no control group
Other interventions 
used: None
Number of participants: Participants drawn from 
two sources: (1) referred group: 117 patients 
being assessed for haemochromatosis – includes 
those suspected clinically and family members; 
(2) screened group: 25 homozygotes identified 
through a screening study – they were not aware 
of result. Control: n/a
Sample attrition/dropout: Not reported although 
data does not appear to be complete in some 
analyses
Sample crossovers: None
Inclusion criteria for study entry: (1) Referred 
group: referred to clinic with suspicious clinical 
signs and symptoms, raised iron parameters, 
family history; (2) screened group: homozygotes 
identified as part of screening study
Exclusion criteria for study entry: Not reported
Characteristics of participants: 46 participants 
homozygous – 21 men, 25 women; 41 participants 
heterozygous – 18 men 23 women ; remainder 
wild type, gender not reported. Mean age: 
referred group 46 ± 13 years, screened group 
41 ± 12 years. Most of the referred group had 
raised ferritin and some had symptoms of possible 
haemochromatosis. All of the screened group 
were asymptomatic, three had raised ferritin
Primary outcomes: 
STAI-State Anxiety pre 
and post genetic test 
result; SF-36 pre and 
post genetic test result; 
1-year post-genetic 
test result, screened 
group only: feelings 
about test results, 
questions assessing 
specific psychosocial 
outcomes
Method of assessing 
outcomes: Pre test 
and immediately post 
test, standardised 
questionnaires 
administered; 1-year 
post-test structured 
interview (screened 
group only)
Length of follow-up: 
1 year post test for 
screened group only
Recruitment dates: 
Not givenDOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Results 
Primary outcomes  Pre Post p-value
Mean STAI
Overall (n = 142) 39.15 ± 11.45  35.54 ± 11.46 < 0.01
Homozygotes (n = 27) 39.7 34.0* < 0.05*
Heterozygotes (n = 23) 37.2 32.2* < 0.05*
Wild type (n = 35) 40.4 38.8 Not significant
Comments: Values for homozygotes, heterozygotes and wild-type subgroups read from chart. *p-value for comparison with 
pretest value. These results include data from the 25 participants identified by population screening who do not meet the 
inclusion criteria of this review. n in subgroup analyses to not add up to the overall total
SF-36 Overall no change
Vitality Improvement < 0.05
Comments: SF-36 scores reported in chart; too small to enable values to be read with any accuracy
Methodological comments 
Allocation to treatment groups: n/a
Blinding: n/a
Comparability of treatment groups: n/a
Method of data analysis: Seems appropriate
Sample size/power calculation: n/a
Attrition/dropout: Not reported
General comments
Generalisability: Screened population and referred population analysed together but no significant differences between the 
groups 
Outcome measures: Validated standardised measures used
Intercentre variability: n/a
Conflict of interests: None declaredAppendix 8
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Quality assessment
Yes U/I/Sa No DK/NRb n/ac Comments
Proper random assignment n/a
Proper sampling NR
Adequate sample size Sample size to determine if there was 
enough power to detect a difference not 
reported
Objective outcomes Y
Blind assessment NR
Objective eligibility criteria U
Reported attrition NR
Comparability of groups n/a
Generalisability U
a  U/I/S, uncertain/incomplete/substandard.
b  DK/NR, don’t know/not reported.
c  n/a, not applicable.
d  The subgroup of 25 people identified by population screening do not meet the inclusion criteria of the review. Results 
for this group have not been reported on except where it is not possible to separate out these results from those of the 
referred patient group
Quality criteria for assessment of observational studies revised from Spitzer et al.81DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Appendix 9  
Data extraction of cost-effectiveness studies 
Study characteristics
Reference Adams 1998100 El-Serag et al. 200099
Country of origin Canada USA
Base year prices 1997 Studies from 1994 to 1999
Intervention Screening with genetic test for 
haemochromatosis compared with using iron 
studies.
Screening with haemochromatosis-associated 
HFE gene testing compared with iron studies or 
no screening.
Study type Cost-minimisation model Cost-effectiveness decision tree model
Study group Children and spouses of an affected proband 
with HHC; 291 children of 121 homozygotes
Hypothetical cohort of siblings and children of an 
affected proband with HHC
Perspective Not stated (appears to be societal) Societal
Industry role None disclosed Lead author supported by Glaxo Wellcome
Study base-case 
‘headline’ predictions/
findings
Genotyping the spouse of a homozygote is the 
most cost-efficient strategy in pedigree studies
Gene testing is a cost-effective method of 
screening relatives of patients with HHC
Results
Base case The primary outcome was diagnosis of the 
C282Y mutation. Probands and children were 
also tested by phenotyping
Of 121 homozygotes identified by phenotyping, 
116 were homozygous for the C282Y mutation; 
13 children out of 291 investigated were 
found with the C282Y mutation; 116 spouses 
were genotyped and 9 were found to be 
heterozygous for C282Y
The costs incurred in the phenotypic strategy 
are the investigation of 291 children of 
homozygotes (CDN$58,200). The costs 
incurred in the spousal genotyping strategy 
are the investigation of 116 spouses and 22 
subsequent children (CDN$35,600)
The outcome was estimated in life-years saved 
(LYS). The benefits were discounted at an annual 
rate of 3%. The discounted life expectancy was 
39 years for children and 65.5 years for siblings
The strategy of HFE gene testing of the proband, 
followed by testing of a child, was the most 
cost-effective strategy to screen one child at an 
incremental cost-effectiveness ratio (ICER) of 
US$508 per LYS. For screening two or more 
children the strategy of gene testing the spouse 
if the proband was found to be homozygous was 
the most cost-effective. For example, screening 
two children had an ICER of US$3665 per 
additional LYS, whereas screening using serum 
iron studies had an ICER of US$7934 per LYS and 
the strategy in which children were gene tested 
before the proband had an ICER of US$12,277 
per LYS. For siblings, all screening strategies 
were dominant compared with no screening. 
Screening with serum iron studies was the most 
expensive screening strategy throughout. Of the 
two strategies that used HFE gene testing, gene 
testing of the siblings first resulted in lower costs 
when only one sibling was screened; however, 
for two or more siblings, HFE gene testing of the 
proband first was less costly Appendix 9
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Sensitivity analysis None reported One-way and two-way sensitivity analyses 
were performed to measure the effect on the 
ICER, relative to no screening. The cost of gene 
testing was varied between US$191 and US$85. 
The cost of measuring serum iron transferrin 
saturation and serum ferritin was varied from 
US$85 to US$40. The proportion of patients 
with haemochromatosis in whom HFE gene 
testing was positive for the C282Y+/+ mutation 
was varied between 60% and 100%. The 
sensitivity and specificity of iron studies were 
varied between 90% and 100%. The frequency 
of serum iron studies in children was reduced to 
every 10 years. The prevalence of the C282Y+/– 
mutation in the population was varied between 1 
per 1000 persons to 20 per 1000 persons
Conclusions
The genotyping of the spouse eliminated the 
need for the investigation of 269 children and 
resulted in a cost saving of 39%
HFE gene testing for the C282Y mutation was a 
cost-effective method for screening the relatives 
of patients with HHC
Caveats
There is some uncertainty in the reporting; 
13 homozygotes were found amongst the 291 
children but only 10 of these were genotyped. 
All children had normal transferrin saturation 
and ferritin; it is unclear how three of the 
homozygotes were identified
The study assumes that the same number of 
people are diagnosed using either strategy and 
there will be the same benefit in each case. The 
sources of the costs are not reported. The study 
assumed that liver biopsy and venesection costs 
were similar between both strategies
The authors did not present sufficient detail to 
enable the appropriateness of the data sources to 
be discussed. Some of the authors’ assumptions 
were not explicitly justified and no references 
were provided. The impact of some of the 
estimates was investigated by sensitivity analyses, 
but the ranges used were not adequately justified
Internal validity of economic evaluations
Item
Adams 1998100 El Serag et al. 200099
Critical 
appraisal Reviewer comment
Critical 
appraisal Reviewer comment
Is there a well-defined 
question?
 Does genotyping of spouses of 
homozygotes result in fewer 
investigations of children and 
subsequent cost savings?
 To compare the cost-effectiveness 
of no screening with screening 
strategies that incorporate gene 
testing and serum iron studies for 
relatives of patients with confirmed 
HHC
Is there a clear 
description of 
alternatives (i.e. who 
did what to whom, 
where and how 
often)?
 All children of proband tested 
using biochemical and DNA tests 
vs all spouses tested using DNA 
tests and children of spouses, 
who are homozygous tested
 Genotypic vs iron studies vs no 
screening
Has the correct 
patient group/
population of interest 
been clearly stated?
 Children of an affected proband 
with HHC
 Siblings and children of an affected 
proband with HHC
Is the correct 
comparator used?
 DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Is the study type 
reasonable?
? Cost-minimisation. The same 
number of children tested 
positive for C282Y mutation 
using both strategies
? Cost-effectiveness analysis. No 
health-related quality of life values 
included
Is the perspective of 
the analysis clearly 
stated?
?  Societal
Is the perspective 
employed appropriate?
? Unclear how this relates to UK 
NHS
? Unclear how this relates to UK NHS
Is the effectiveness 
of the intervention 
established?
 
Has a lifetime horizon 
been used for analysis 
and if not has a shorter 
time horizon been 
justified?
 ×
Are the costs and 
consequences valued 
credibly? 
? Sources of costs not reported ? The authors seem to have included 
all of the costs relevant to HHC 
and screening. The total costs were 
estimated using a decision model. 
The unit prices were derived from 
published studies and tariffs
Is differential timing 
considered?
 × Costs discounted at 3%
Is incremental analysis 
performed?
 × Cost per life-year saved
Is sensitivity analysis 
undertaken and 
presented clearly? 
× No  Sensitivity analysis presented for 
cost of gene testing and iron studies, 
proportion of patients with HHC 
in whom gene testing was positive, 
sensitivity and specificity of iron 
studies and prevalence of C282 
Y+/+ mutation in the population
External validity of economic studies
Item Adams 1998100 El-Serag et al.200099
1. Patient group – are the patients in the study similar to 
those of interest in England and Wales?
? Patient setting is from 
Canada
? Patient setting is from USA
2. Health-care system/setting – comparability to England 
and Wales; comparability of available alternatives; 
similar levels of resources; institutional arrangements 
comparable?
? Canadian perspective ? US perspective
3. Treatment – comparability with clinical management? ? Treatment in Canada 
although clinical management 
appears similar to that in UK
? Treatment in US although 
clinical management appears 
similar to that in UK
4. Resource costs – comparability between study and 
setting/population of interest?
× Canadian cost data × US cost data
?, unclear or unknown; , item judged suitable to generalise to England and Wales with or without some readjustment; ×, 
item judged not suitable to generalise to England and Wales as either not possible to see how an adjustment could be made 
easily in the short/medium term or relevant data unavailable.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Appendix 10  
Systematic searches
Sensitivity and specificity of biochemical tests
Three studies61,103,111 met the inclusion criteria for the systematic search and the results are reported in 
Table 30.
TABLE 30  Sensitivity and specificity of biochemical tests
Iron measurement Sensitivity Specificity PPV Reference
TS > 45% 94% 94% 6% Olynyk et al. 1999103 
TS > 50% 94% 96% 16% Olynyk et al. 1999103 
TS > 55% 90% Adams and Chakrabarti 1998111
TS > 60% 91% 93% 31.3% Moodie et al. 200261 
SF > 300 mg/l 96% Adams and Chakrabarti 1998111 
(men)
73% 85% 12.9% Moodie et al. 200261
50% 87% 2% Olynyk et al. 1999103
75% 87% 2% Olynyk et al. 1999103
SF > 200 mg/l 97% Adams and Chakrabarti 1998111 
(women)
73% 70% Moodie61
PPV, positive predictive value; SF, serum ferritin; TS, transferrin saturation.
Liver biopsy complications
Two studies124,125 met the inclusion criteria; however, these did not supply all of the data required and so 
the search was extended to include relevant audit studies that reported the necessary data (Table 31).
TABLE 31  Liver biopsy complications
Probability Reference Comment
From randomised controlled trials
Death 0% Lindor et al. 1996124
Bleeding (only bleeding, no mention of 
transfusion)
2.10% Lindor et al. 1996124 With ultrasound
4.40% Lindor et al. 1996124 No ultrasound
3.20% Lindor et al. 1996124 Total
2.40% Papini et al.126 Menghini biopsy
0.60% Papini et al.126 Ultrasound
Extended inclusion criteria to find data for sensitivity analysisAppendix 10
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Probability Reference Comment
Death 0.13–0.33% Gilmore et al. 1995119 UK audit
0–0.6% Stone and Mayberry 1996127 UK audit
Bleeding requiring transfusion  0.7% Gilmore et al. 1995119 UK audit
1.8% Stone and Mayberry 1996127 UK audit
Epidemiology
Results of the searches for epidemiology studies are reported in Chapter 1 (Epidemiology).DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Appendix 11  
Probabilistic sensitivity analysisAppendix 11
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Parameters used for the probabilistic sensitivity analysis
Parameter name Mean Distribution Alpha Beta
Diagnostic pathway
HHC prevalence 0.038 Beta  11 278.2
TS sensitivity  0.94 Triangle  0.75 0.99
TS specificity  0.94 Triangle  0.75 0.99
SF sensitivity  0.73 Triangle 0.5 0.99
SF specificity  0.85 Triangle  0.75 0.99
HHC DNA YY 0.913 Triangle  0.9 1
Proportion raised SF > 1000 mg/l
DNA positive  0.39 Beta 11.9 18.7
DNA negative  0.24 Beta  26 82.4
Family testing, sibling
Risk  0.25 Fixed
Penetrance  0.76 Beta  20 6.3
SF > 200 mg/l, SF sensitivity 0.73 Triangle  0.5 0.99
SF > 200 mg/l, SF specificity  0.7 Triangle  0.5 0.99
Family testing, child
Risk 0.05 Fixed
Initial proportion with iron overload 0.2 Beta  12.1 48.4
Costs (£)
DNA laboratory 100 Gamma  96.04 1.04
Nurse 8.75 Gamma  96.04 0.09
Consultant 39 Gamma  96.04 0.4
Liver biopsy 388.05 Gamma  96.04 4.04
Iron laboratory 23.40 Gamma  96.04 0.24
Venesection 8.75 Gamma 96.04 0.09
Number of monitors child 5 Gamma 24.01 0.2
Number of treatments 20 Gamma 61.46 0.32
SF, serum ferritin; TS, transferrin saturation; YY, homozygous C282Y/C282Y.DOI: 10.3310/hta13230  Health Technology Assessment 2009; Vol. 13: No. 23
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Results from the probabilistic sensitivity analysis
Cost per case detected (£)
Diagnostic testing Family testing, sibling  Family testing, offspring 
First quartile 97 –234 7323
Second quartile 139 –189 8311
Third quartile 187 –145 9458
Fourth quartile 691 23 18,196
FIGURE 7  Probabilistic sensitivity analysis results for cases detected and total costs saved for diagnostic testing decision tree.
FIGURE 8  Probabilistic sensitivity analysis results for cases detected and total costs saved for sibling family testing decision tree.
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